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Chapter 1
THE ANNEXINS
The annexins (from the Greek annex - “bring/hold together”) are a 
family of more than 160 membrane-binding proteins that share structural 
properties and biological activities associated with membrane-related 
processes [1;2]. Annexin proteins are expressed in more than 65 different 
groups of organisms ranging from fungi and protists to plants and higher 
vertebrates [1;3]. In humans (the annexin A group), 12 annexins have 
been identified (i.e., Annexin A1 (ANXA1) - ANXA11 and ANXA13). The 
members of the annexin family have two important common criteria. First, 
annexin proteins share a highly homologous core domain, comprising four 
so-called annexin repeats of approximately 70 amino acids long (with 
the exception of ANXA6, which consists of 8 annexin repeats), packed 
into an α-helical disk [1]. The ability of annexins to bind to negatively 
charged phospholipids in a Ca2+-dependent manner is the second common 
characteristic of proteins within the annexin family. Annexin proteins 
participate in a variety of membrane-related processes, both inside the cell 
(e.g., signal transduction, endocytosis, cytoskeleton organization, cellular 
proliferation, differentiation) and in the extracellular environment (e.g., 
receptors for serum proteases, blood coagulation, inhibitors of neutrophil 
migration) [2]. However, their physiological function remains largely 
unknown. In 1999, Jacob H. Rand introduced the term “annexinopathies” 
[4]. It has been shown that the abnormalities in the expression levels of two 
annexins contribute to pathogenesis of human diseases: overexpression 
of ANXA2 on leukocytes is associated with increased fibrinolysis and 
bleeding in acute promyelocytic leukemia [5]; reduced expression of 
ANXA5 on placental syncytiotrophoblasts and endothelial cells is linked to 
pregnancy loss and to thrombosis in the antiphospholipid syndrome [6-8].
This thesis focuses on ANXA5, the most abundant protein of the annexin 
family and a physiological anticoagulant protein. Two main aspects were 
of interest. First, the mode of action of ANXA5-based anticoagulation on 
cell surfaces exposing negatively charged phospholipids. The second aspect 
of our interest was the associations between genetic variations in the 
ANXA5 gene and diseases related to thrombosis and inflammation. This 
general introduction starts with an overview of hemostasis linked to our 
first question. In regard to the second aspect of this thesis, the information 
about the structure of the ANXA5 gene and ANXA5 polymorphic variations 
will be presented later in the introduction chapter. 
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GENERAL OVERVIEW OF HEMOSTASIS 
The hemostatic system is a highly complex process that maintains blood 
in a fluid state under physiological conditions and even after the vascular 
injury [9;10]. The interactions between the endothelial cells lining the vessel 
wall, blood flow and blood coagulability (i.e. procoagulant and anticoagulant 
factors, fibrinolysis) play an important role in the hemostatic balance. An 
impaired equilibrium between the components of the hemostatic system may 
result in either thrombotic complications or a bleeding tendency. Knowledge 
of the hemostatic system is important for a better understanding of disease 
states associated with thrombosis (i.e., the formation of a clot within a 
blood vessel), such as venous thromboembolism and atherothrombosis 
(thrombosis triggered by plaque rupture, leading to myocardial infarction 
and stroke) [9;11;12].
Hemostasis can be divided into primary hemostasis (the formation of the 
platelet plug), secondary hemostasis (coagulation) and tertiary hemostasis 
(fibrinolysis). Upon vascular damage, the contraction of the vessel wall 
occurs to reduce blood flow through the vessel wall rupture. Platelets adhere 
to the subendothelial matrix, become activated, and form the primary 
hemostatic plug [13]. Plasma factor (F) VII/VIIa binds to extravascular 
tissue factor (TF), initiating thereby the coagulation protease cascade that 
in turn leads to the formation of thrombin. Activation of platelets results 
in the translocation of phosphatidylserine (PS) from the inner leaflet of 
the plasma membrane to the outer leaflet [14] that also promotes the 
enzymatic reactions of the coagulation cascade. Thrombin, the key enzyme 
in hemostasis, activates platelets, FV and FVIII, FXI, FXIII, TAFI (thrombin 
activatable fibrinolysis inhibitor) and cleaves plasma fibrinogen into fibrin. 
The fibrin network stabilizes the plug formed by aggregated platelets. Once 
the vessel wall is repaired, the fibrin platelet clot will be lysed (fibrinolysis) 
in order to restore the normal blood flow.        
Blood coagulation  (Figure 1) as a cascade or waterfall of consecutive 
enzymatic reactions (a cascade model) has been described 51 years ago 
[15;16]. According to that model, clotting factors, which are present in blood 
as zymogens, are converted into active enzymes via either the extrinsic or 
intrinsic pathways. The extrinsic pathway of blood coagulation is initiated 
by TF present on the surface of perivascular tissue, which binds circulating 
FVII/activated FVII (FVIIa). The TF/FVIIa complex is the physiological 
activator of the coagulation reactions [2], and this complex can activate FIX 
and FX. FXa assembled with the non-enzymatic cofactor FVa on an anionic 
phospholipid surface in the presence of Ca2+-ions (prothrombinase complex) 
leads to the formation of a small amount of thrombin. An alternative way of 
thrombin generation occurs via the intrinsic pathway or contact activation 
pathway when blood is exposed to an exogenous negatively charged surface 
(collagen, glass, kaolin). Contact activation leads to autoactivation of FXII, 
which in turn activates FXI. Thereafter, FXIa activates FIX. FIXa associates 
with the non-enzymatic protein FVIIIa on a negatively charged phospholipid 
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surface in the presence of Ca2+-ions to form the tenase complex. The 
tenase complex activates FX, which in turn rapidly converts prothrombin 
into thrombin. A secondary burst (propagation) of thrombin formation 
necessary for an adequate hemostatic response is provided by the activation 
of FXI by thrombin (the positive feedback in the coagulation cascade) [17]. 
Platelets play a critical role in the amplification of the coagulation cascade by 
providing a catalytic surface [10;18]. Thrombin cleaves soluble fibrinogen 
into insoluble fibrin polymers, which stabilize the platelet plug. 
In the late 1990s, a revised model of blood coagulation was postulated in 
which there is no distinction between the extrinsic and intrinsic pathways 
[19]. Coagulation reactions occur on a phospholipid surface containing 
anionic phospholipids, especially PS, often provided by activated platelets, 
activated endothelial cells or microparticles derived from these cells [20]. 
Besides the cascade model of blood coagulation, a cell-based model of 
coagulation has been proposed too [18]. According to this model, hemostasis 
in vivo occurs in three overlapping phases: initiation of coagulation on 
TF-bearing cells; amplification of the coagulant response on the surface 
of activated platelets; and propagation, in which hemostatic amounts of 
thrombin are generated on the platelet surface [18].
The coagulation cascade is a tightly regulated process with many positive but 
also negative feedback loops. Tissue factor pathway inhibitor (TFPI) inhibits 
the initiation of blood coagulation at the level of TF/FVIIa. Antithrombin 
inactivates almost all coagulation enzymes. Activated protein C (APC) 
inactivates cofactors FVIIIa and FVa thereby dampening the prothrombinase 
and tenase complexes. Protein S, a cofactor of protein C, also has an APC 
independent anticoagulant effect by direct inhibition of the formation of 
prothrombinase and tenase complexes on a phospholipid surface. The most 
recently described component of the anticoagulant system is the protein 
Z/Z-dependent protease inhibitor system that inhibits FXa, FXIa and FIXa 
by different mechanisms [21]. 
Fibrinolysis is the physiological mechanism that dissolves the fibrin clot 
in order to restore the blood flow. The key enzyme in this process is 
plasmin, which is formed by the activation of plasminogen in the presence 
of its activators (tissue type-plasminogen-activator, t-PA and urinary-type 
plasminogen activator, u-PA). Plasmin cleaves fibrin into small soluble 
fragments. Fibrinolysis is inhibited by plasminogen activator inhibitors 
(PAI-1 and PAI-2) as well as by plasmin inhibitors (α2-antiplasmin, α2-
macroglobulin, α1-antitrypsin) [22]. TAFI, which is activated only by high 
thrombin concentrations, inhibits fibrinolysis through inhibition of the 
binding of plasminogen to fibrin [17]. FXIIIa stabilizes the fibrin clot by the 
formation of cross-links between the various fibrin chains.     
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ANNEXIN A5
Localization and exocytosis of Annexin A5                                                                                                 
Annexin A5 (ANXA5), also known as placental protein 4 [23], vascular 
anticoagulant protein α [24]), calphobindin I [25], endonexin II [26], 
placental anticoagulant protein I [27], lipocortin V [28] and 35 γ-calcimedin 
[29] is the most abundant protein of the annexin family [1]. The history of 
ANXA5 started about 36 years ago with its isolation from placental tissues 
by Bohn and colleagues [30]. Thereafter, ANXA5 was isolated from different 
tissues: arteries of the umbilical cord, bovine aorta, human placenta, human 
and bovine lung, human and rat liver, rat heart and kidney as well as from 
skin, heart, spleen, uterus, skeletal muscle of a human source [24;27;31-
34]. 
The protein is widely distributed in human tissues. ANXA5 is especially 
highly expressed by cells that serve a barrier function, including placental 
trophoblasts, vascular endothelium and endothelial cells of the choroid 
plexus of the brain [35-38]. The placenta is the richest source of ANXA5 in 
humans, where ANXA5 is expressed by trophoblasts, a layer of epithelial 
cells covering all villous trees and separating the villous interior from the 
maternal blood [39]. The human placental trophoblasts have a two-layered 
structure consisting of the underlying layer of progenitor mononucleated 
cytotrophoblasts and the outer layer of syncytiotrophoblasts formed by 
fusion of cytotrophoblasts. ANXA5 localizes within the cytosol of placental 
syncytio- and cytotrophoblasts [38] and is also present on the apical 
membranes of syncytiotrophoblasts, where it is bound to the anionic 
phospholipid phosphatidylserine (PS) externalized during trophoblast 
differentiation and fusion [36;40;41]. It has been suggested that ANXA5 
could serve as a local antithrombotic protein in the maintenance of blood 
fluidity in the placenta [42;43]. Furthermore, ANXA5 is present in large 
amounts in cultured human umbilical vein endothelial cells (HUVEC; 3.6 
x 10-12 g/cell) (35). ANXA5 is also found inside blood cells: leukocytes 
(2.8 x 10-14 g/cell), platelets (4.5 x 10-16 g/cell) and erythrocytes (2.3 x 
10-16 g/cell) [35]. However, stimulation of platelets with strong agonists 
(e.g., thrombin, ADP, collagen) does not result in release of ANXA5 from 
platelets, suggesting that ANXA5 could not function as a natural systemic 
anticoagulant [35]. ANXA5 is also strongly expressed in tissues involved in 
secretory processes (prostate, testis and the islets of Langerhans) [37]. In 
pathological specimens, the abundant presence of ANXA5 has been found 
in atherosclerotic lesions of the coronary arteries [37;44]. 
As other annexins, ANXA5 is mainly an intracellular protein because it lacks 
a signal peptide required for the classical endoplasmic reticulum - Golgi 
secretion pathway. In mammals, there are more than 20 polypeptides 
(e.g., fibroblast growth factor, interleukin 1β, platelet-derived growth factor 
etc.), which lack the signal peptide [45;46]. Nevertheless, proteins lacking 
the typical signal peptide could reach the extracellular environment through 
onclassical secretion pathways (i.e., independent of the endoplasmic 
15
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reticulum and Golgi apparatus). Recent evidence indicates that members of 
the annexin family can also be released into the extracellular environment 
by nonclassical exocytosis pathways. Annexin A1 is actively secreted into 
human seminal plasma [47], and the glucocorticoid-induced externalization 
of Annexin A1 from folliculo-stellate cells has been proposed to be mediated 
by the ATP-binding cassette transporters [48]. Annexin A2 translocates 
from the cytoplasm to the cell surface in response to a brief period of 
temperature stress both in vitro and in vivo [46]. Up to now, the mechanisms 
by which ANXA5 is externalized from cells are still unknown. It is known 
that ANXA5 could be released nonspecifically from injured or dying cells 
[49;50]. ANXA5 has been found in extracellular fluids like blood plasma, 
cerebrospinal fluid, amniotic fluid and urine [35;49-52]. However, ANXA5 
levels present in extracellular fluids are considerably lower compared to its 
intracellular levels. Plasma levels of ANXA5 measured in EDTA plasma of 
healthy controls are in the range 0 - 5 ng/ml [35].       
Figure 2. A model of the Annexin A5 2D crystallization. A, A schematic 
representation of the Annexin A5 molecule bound to a negatively charged phospholipid 
membrane in the presence of Ca2+-ions. B, Upon binding to a PS-exposing surface, 
monomeric Annexin A5 forms trimers, which associate into 2D crystal forms. Adapted 
from Oling et al., 2001 [63]
Annexin A5: structure and phospholipid-binding properties    
ANXA5 is a non-glycosylated single chain protein of 320 amino acids with 
a molecular weight of 35.7 kDa. The primary structure of its polypeptide is 
organized in a short N-terminal tail and a conserved C-terminal core, which 
comprises four repeats (Figure 2). The repeats are homologous sequences 
of approximately 65-70 amino acids, and each repeat contains the area 
known as the ‘endonexin loop’ (~17 amino acids long) for the calcium 
binding sites [53]. The tertiary structure of an ANXA5 molecule was resolved 
by Huber and colleagues in 1990 [54]. X-ray crystallography revealed that 
the polypeptide chain of ANXA5 is folded into four domains. Each domain 
comprises five alpha-helices wound into a right-handed superhelix. The 
domains are tightly associated to form two modules (domains I, IV) and 
16
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(domains II, III). The interaction between domain I and IV is mediated in 
a non-covalent manner by the amino-terminal tail. Domain II and III are 
linked via a short interhelical turn. The ANXA5 molecule is slightly bent, with 
both a convex and a concave face [54;55]. A short amino-terminal tail is 
located at the concave surface, and the calcium- and phospholipid-binding 
sites - on the convex, membrane-facing side of the ANXA5 molecule. The 
Ca2+-binding sites are suited as protruding loops; three of them are located 
in homologous conserved segments (Met/Leu)-Lys-Gly-(Ala/Leu)-Gly-Thr 
within the “endonexin loop” in domains I, II, IV [56;57]. In the presence 
of a high Ca2+ concentration (10-60 mM), structural changes in domain III 
lead to the formation of a new calcium site. Sopkova et al. showed that the 
formation of this new calcium site causes the displacement of a Tryptophan 
residue at position 187 from a buried to an exposed conformation on the 
one hand and results in the loss of two calcium sites in domains II and IV 
on the other hand [58].
ANXA5 binds in a Ca2+-dependent manner to phospholipids, with a preference 
for negatively charged phospholipids such as phosphatidylserine (PS) [59]. 
Ellipsometric experiments showed that half-maximal binding of ANXA5 to 
phospholipid bilayers consisting of 5 mol% PS/95 mol% Phosphatidylcholine 
(PC) and 20 mol% PS/80 mol% PC is reached at the millimolar Ca2+ levels 
of 1.5 mmol/L and 0.22 mmol/L, respectively [59]. ANXA5 binds with high 
affinity to a 20% PS/80% PC surface (dissociation constant [Kd] <1-2 x 
10-10 mol/L) [59;60]. Besides its binding to model membranes, ANXA5 also 
binds to PS-exposing cell membranes of stimulated, apoptotic and necrotic 
cells [61;62]. Based on its capacity to bind PS-exposing membranes with 
high affinity, ANXA5 is widely used for visualization of cell death, both in 
vitro and in vivo, in animal models and in patients [64]. Furthermore, the 
ANXA5 affinity assay, which comprises the incubation of cells with labelled 
ANXA5 and the vital dye propidium iodide, allows us to discriminate between 
living cells and cells with the apoptotic or necrotic phenotypes [62].
ANXA5 molecules exist in two forms: a water-soluble and membrane-
bound form. Cryo-electron microscopy and X-ray crystallography studies 
demonstrated that the structure of water-soluble ANXA5 is almost identical 
to that of its membrane-bound form [57;65;66]. This means that upon 
binding to a phospholipid membrane, ANXA5 maintains its convex-concave 
shape, does not become flat and does not undergo significant structural 
changes [6]). This also indicates that Ca2+-binding loops are located at the 
different distances from the membrane surface. In this context, domain III 
is the most distinct from the membrane surface and domain II is the closest 
as shown by X-ray crystallography and atomic force microscopy [66;67]. 
In solution, ANXA5 molecules are monomers and do not assemble into 
crystal lattices. At phospholipid surfaces containing negatively charged 
phospholipids (e.g., planar phospholipid monolayers, vesicles, phospholipid 
bilayers), ANXA5 self-assembles into two-dimensional (2D) ordered crystal 
structures [63;65;67;68]. Brisson and colleagues showed by electron 
17
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microscopy and atomic force microscopy that upon binding to PS, ANXA5 
forms trimers, which are the basic building blocks of a 2D crystal lattice, 
and these trimers associate via protein-protein interactions into four 2D 
crystal forms (basic P6 crystal; crystal form-1, -2 and -3) [63] (Figure 2). 
The type of a 2D crystal depends on PS content and Ca2+ concentration. 
The low-density honeycomb-like P6 crystals, which are commonly found, 
are formed at low-to-medium PS content (5 to 20%). The high-density 
P3 crystals are found at high PS content (above 40%) and could also be 
formed from the P6 form as a result of a crystal phase transition [63;69]. It 
should be noted that the basic ANXA5 P6 crystals are open lattices with the 
presence of large protein-free spaces (~ 9 nm in diameter) around the six-
fold symmetry centres [63;70]. It has been suggested that other annexins 
or proteins could be integrated within the ANXA5 2D arrays and that such 
assemblies could be of physiological importance [70-72], for example, in 
cell membrane repair [73]. It has recently been demonstrated that ANXA5 
also trimerizes at the surface of apoptotic Jurkat cells [74]. Ungethüm 
and colleagues were the first to show by using a FRET (Fluorescence 
Resonance Energy Transfer) approach combined with transmission electron 
microscopy that ANXA5 forms trimers and these trimers assembles into 
2D ordered crystals on a cellular membrane [74]. Not only ANXA5 but also 
other annexins form 2D crystals of the trimers on the surface of artificial 
membranes. Trimerization has been observed for ANXA4 [75], ANXA6 
[76;77] and ANXB12 (from hydra) [71].
Annexin A5 biological activities      
ANXA5 exhibits a variety of biological activities inside the cell and in the 
extracellular environment as well. 
Annexin A5 as an anticoagulant and antithrombotic protein 
The first observed in vitro activity of ANXA5 was its anticoagulant activity 
[24;31]. ANXA5 is supposed to belong to the physiological anticoagulants. 
As mentioned above, the physiological anticoagulant system includes 
inhibitors of the serine proteases (antithrombin, heparin cofactor II, α2-
antiplasmin, α2-macroglobulin, α1-antitrypsin), inhibitor of TF (TFPI) and 
inhibitors of the nonenzymatic cofactors FVa/FVIIIa (protein C/protein S 
system in combination with either Thrombomodulin or endothelial protein C 
receptors (EPCRs)). The mechanism of ANXA5-based anticoagulation differs 
from that of other known physiological anticoagulants. It has been shown 
that ANXA5 interferes in the complicated process of blood coagulation 
through nonenzymatic interactions with negatively charged phospholipids 
and does not anticoagulate through proteolysis or direct/indirect inhibition 
of enzymes [31;78]. That means that ANXA5 interference occurs indirectly 
and thus, there is no direct interaction between ANXA5 and coagulation 
factors. Data from fluorescence correlation spectroscopy experiments on 
supported artificial membranes showed that ANXA5 and FVIIIa do not 
interact directly [79]. ANXA5 anticoagulant activity is based on its high 
affinity binding to anionic phospholipids, especially PS (dissociation constant 
[Kd] less than 0.2 nM) [59] and reducing the availability of PS for other 
ligands by shielding PS lipids upon binding [78;79]. ANXA5 competes with 
18
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coagulation factors for the same phospholipid-binding sites on the plasma 
membrane and displaces coagulation factors from procoagulant surfaces, 
thereby impairing their complex formation. 
ANXA5 is widely known as a strong inhibitor of blood coagulation 
[27;31;80;81]. In vitro studies have shown that ANXA5 inhibits the 
assembly of coagulation enzyme-substrate complexes on artificial and 
cellular membranes [31;61;78]. In a human ex vivo thrombosis model, in 
which nonanticoagulated blood was perfused over the extracellular matrix of 
tumor necrosis factor-stimulated endothelial cells, ANXA5 has been shown 
to prevent thrombus formation [82]. Under low shear rates conditions 
reflecting blood flow in small veins, ANXA5 inhibited both platelet adhesion 
and fibrin deposition. At higher shear rates (i.e., comparable with those in 
medium-sized arteries), ANXA5 impaired platelet aggregation but had no 
inhibitory effects on platelet adhesion [82]. In vitro perfusion experiments 
demonstrated that the ANXA5 inhibitory potential on platelet thrombus 
formation was comparable with that of a direct thrombin inhibitor, hirudin, 
or an antibody against TF [83]. ANXA5 interferes in the coagulation cascade 
at a triple level – inhibiting prothrombinase, factor Xase and also interfering 
with the action of FVIIa-TF complex [83]. It has been proposed that it could 
be the explanation for the powerful inhibitory effects of ANXA5 [83]. 
In in vivo animal models, ANXA5 is an effective inhibitor of thrombus 
formation in a laser- and photochemically-induced venous thrombus model 
in rats [84]. Furthermore, ANXA5 accumulates at the site of injured jugular 
veins in rabbits and decreases fibrin deposition [85]. ANXA5 is also an 
effective inhibitor of arterial thrombosis in a rabbit carotid artery injury 
model by reducing thrombus weight in a dose-dependent manner, inhibiting 
fibrin deposition and reducing platelet accumulation at the site of arterial 
injury [86]. More importantly, in an arterial thrombus model, the inhibitory 
effects of ANXA5 were not associated with bleeding tendency, even at 
supraclinical ANXA5 concentrations (i.e., greater than that required to 
induce an antithrombotic effect), whereas the therapy with heparin induced 
bleeding at extravascular sites [86].     
Recombinant fusion proteins that have been constructed based on the 
structure of the native ANXA5 molecule exhibit stronger anticoagulant and 
antithrombotic activities both in vitro and in vivo compared to those of the 
native ANXA5. An example of these proteins is a two-domain recombinant 
fusion protein consisting of a human ANXA5 domain and a Kunitz protease 
inhibitor domain (i.e., serine protease inhibitor) [13;87]. These fusion 
proteins bind to PS-exposing membranes (sites of thrombogenesis) via the 
ANXA5 domain that greatly facilitates the binding of the Kunitz protease 
inhibitor domain to the active site of the membrane-associated enzyme/
cofactor assemblies. It has been demonstrated that fusion proteins are 
powerful inhibitors of coagulation reactions in an in vitro TF-initiated clotting 
assay and they have higher antithrombotic activities in a mouse arterial 
thrombosis model in vivo compared to those of the native ANXA5 [13]. 
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One of these fusion proteins, ANXA5-6L15 (an aprotinin mutant) efficiently 
inhibits the TF-FVIIa complex on the PS/PE-exposing membranes in an in 
vitro clotting assay and has potent cardioprotective features in a rat cardiac 
ischemia-reperfusion injury model [87]. More importantly, ANXA5-6L15 
does not induce a bleeding tendency and is more effective as a cardiprotector 
than a direct thrombin inhibitor, hirudin. It has been suggested that ANXA5-
6L15 could be a promising drug candidate for cardioprotection against 
myocardial ischemia-reperfusion injury [87]. 
Another example of fusion proteins with potent antithrombotic properties 
is Diannexin A5, a homodimer of ANXA5 [88;89]. The designed 14 amino 
acid peptide that links the monomer ANXA5 molecules in Diannexin allows 
the dimer to bind PS with ~10-fold higher affinity compared to the native 
ANXA5 monomer (Kd 0.6 nM versus 5.1 nM) [89]. In comparison with the 
native ANXA5, Diannexin A5 is more effective in inhibition of platelet-fibrin 
clot formation both in vitro and in a mouse laser-induced arterial thrombosis 
model in vivo [89]. Diannexin A5 is also highly efficient in inhibition of 
venous thrombosis in a rat venous thrombosis model [88].
It is generally assumed that the anticoagulant mechanism of ANXA5 could 
be explained by displacement of coagulation factors from procoagulant 
surfaces and thus, inhibiting their complex formation [78;90]. However, 
the mechanism of ANXA5-based anticoagulation is more complex than just 
the displacement concept. In 1992, Andree and colleagues demonstrated 
incomplete displacement of FXa, FVa and prothrombin from the phospholipid 
surface by ANXA5 [78]. It has been proposed that the formation of rigid 
clusters of ANXA5 may explain its anticoagulant effect and that ANXA5 
arrays do not completely block binding of coagulation factors but reduce the 
lateral mobility of membrane-bound coagulation factors preventing thereby 
their complex formation [78]. The complexity of the ANXA5 anticoagulant 
mechanism on a cellular surface has further been supported by data of 
Ravassa et al., who showed that ANXA5 that self-assembles into 2D arrays at 
the cell membrane down-regulates the expression of the procoagulant tissue 
factor by inducing its internalization [91]. To date, there is no experimental 
data regarding the effect of ANXA5 lattice formation on the lateral mobility 
and complex formation of coagulation factors. Thus, the mechanism of 
ANXA5-based anticoagulation is still not completely understood.          
Annexin A5 anti-inflammatory-related activities    
ANXA5 possesses anti-inflammatory-related activities, such as inhibition of 
phospholipase A2 activity, inhibition of pro-inflammatory effects of oxidized 
low-density lipoproteins (LDLs) and regulation of interferon-gamma (IFN-γ) 
receptor signaling.
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The activity of ANXA5 as an inhibitor of phospholipase A2 is also based 
on its property to shield negatively charged phospholipids, substrates for 
phospholipase A2. Phospholipase A2 hydrolyses membrane phospholipids 
releasing a fatty acid and a lysophospholipid. The free fatty acid in the 
form of arachidonic acid is subsequently converted into prostaglandins and 
leukotrienes, which are pro-inflammatory mediators [92]. Studies with 
artificial membranes and HL-60 cells have demonstrated that ANXA5 inhibits 
the phospholipase A2-mediated hydrolysis of membrane phospholipids in a 
calcium-dependent manner [93-95] and that mutations in the Ca2+-binding 
sites of ANXA5 could modify its inhibitory effect [94]. However, inhibition of 
cytosolic phospholipase A2 activity by ANXA5 was shown to be much smaller 
and less specific than that by ANXA1 [96]. Thus, ANXA1 but not ANXA5 is 
thought to be an endogenous negative regulator of cytosolic phospholipase 
A2 [96].       
The next property of ANXA5, which could contribute to its anti-inflammatory 
effects, is an association of ANXA5 with LDL isolated from human 
plasma. It has been reported that ANXA5 binds specifically to oxidized 
phosphatidylcholine present in oxidized LDL but not to native LDL [97]. 
Oxidized phospholipids generated during oxidative modification of LDL 
possess a variety of atherogenic and pro-inflammatory effects [97;98]. 
A recent report demonstrated inhibitory capacities of ANXA5 on pro-
inflammatory effects of oxidized LDL and lysophosphatidylcholine in vitro 
and in a mouse intra-peritoneal recruitment model in vivo [99]. Whether 
ANXA5 influences binding and uptake of oxidized LDL by macrophages is 
not completely understood. One study reported that ANXA5 binding to 
oxidized LDL did not influence binding of oxidized LDL to monocytic U937 
cells and subsequently, had no effect on LDL uptake by these cells [97]. 
In a recent study, inhibitory effects of ANXA5 on oxidized LDL binding and 
uptake by macrophages have been reported [99]. It should be noted that 
enhanced uptake of oxidized phospholipids by macrophages might promote 
the formation of foam cells, which play a key role in atherogenesis, and 
therefore, accelerate atherosclerosis [97;99]. Whether ANXA5 really inhibits 
uptake of oxidized LDL by macrophages deserves further investigation.  
ANXA5 is also able to interact with the intracellular domain of the R2 subunit 
of the human interferon-gamma (IFN-γ) receptor to form a stable complex 
and to negatively regulate IFN-γ signalling [100]. 
Annexin A5 anti-apoptotic activities     
Cells undergoing apoptosis (programmed cell death) and necrotic cells 
are characterized by externalization of PS, one of the “eat me” signals for 
phagocytosis by macrophages. ANXA5, which binds with high affinity to PS, 
influences membrane dynamics of the PS-expressing cell surfaces. ANXA5 
inhibits phagocytosis of the apoptotic Jurkat cells by J774 macrophages and 
that inhibition of phagocytosis requires high ANXA5 concentrations (about 
20 µg/ml or 560 nM) [101]. The inhibitory action of ANXA5 is based not only 
on PS shielding but also on the internalization of receptors/ligands that are 
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in the proximity of PS (101). Besides its inhibitory effects on phagocytosis, 
ANXA5 has been reported to influence the apoptotic cell death program 
after binding to CEM human T-lymphoma cells by delaying the activation 
of caspase-3 processing [102]. On the other hand, ANXA5 binding to Fas-
stimulated human Jurkat T-lymphoma cells shows no effect on progression 
of apoptosis [103].     
ANXA5 has also been proposed to be an important modulator of the immune 
response against tumor cells as well as that against dying and dead cells in 
mouse models in vivo by inhibiting cell uptake by macrophages [104;105]. 
Munoz et al. showed that necrotic human T cells introduced into the 
circulation of wild-type mice cause a strong delayed-type hypersensitivity 
reaction (DHT; i.e., the reaction that characterized by an induction of a 
specific T cell response), whereas ANXA5 deficient mice (i.e., lacking 
endogenous ANXA5) showed almost no DHT reaction after immunization 
with necrotic cells [104].
Other Annexin A5 activities        
In the intracellular environment, ANXA5 has been suggested to be involved 
in signal transduction pathways. As an example, ANXA5 inhibits the 
activity of protein kinase C isoforms with a Ca2+/phospholipid-binding C2 
domain [106;107]. The data from in vitro studies indicate that ANXA5 
inhibits the activity of protein kinase C via a mechanism of phospholipid 
sequestration and the Ca2+-binding site located in domain 1 of ANXA5 plays 
a crucial role in protein kinase C inhibition [107]. It has also been shown 
that ANXA5 could function as a signalling protein for vascular endothelial 
growth factor receptor by directly interacting with the intracellular domain of 
the receptor and could be involved in the regulation of vascular endothelial 
cell proliferation [108].
ANXA5 as well as ANXA6 and ANXA7 are able to form voltage-dependent 
calcium channels within artificial lipid bilayers [55;109]. Two main models 
were proposed to explain the ion channel activity of ANXA5: one involves 
a hydrophilic pore, which lies at the centre of the ANXA5 molecule and 
forms a prominent ion channel; the second model involves the penetration 
of ANXA5 into the membrane [55]. Data of Isas and colleagues support 
the hypothesis that ANXA5 could insert into the lipid bilayer at mild acidic 
conditions (pH 5-6) [110]. However, it is still not clear if there is any 
relevance of the ion channel activity of ANXA5. 
Recently, a few new activities of ANXA5 were described. Brisson and colleagues 
reported that ANXA5, a protein that self-assembles into two dimensional 
(2D) arrays on the cell membrane, promotes membrane repair [73]. 
ANXA5 molecules bind to PS exposed at ruptured membrane edges and 
form 2D arrays, which stabilize the membrane, prevent wound expansion 
and promote membrane resealing. In contrast, an ANXA5 mutant that lacks 
the ability of forming 2D arrays and ANXA5-null mouse perivascular cells 
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were unable to promote membrane repair, showing a severe membrane 
defect. In this context, the capacity of ANXA5 to promote membrane repair 
is of vital importance for cells as failure to reseal membranes leads to cell 
death or may contribute to the development of degenerative diseases. It 
has been suggested that ANXA5 may be of therapeutic value in pathologies 
associated with defects in the membrane repair machinery [73]. 
Another ANXA5 activity is based on its binding to intact lipopolysaccha-
ride (LPS) expressed in the outer membrane of Gram-negative bacteria 
and to the lipid A domain of LPS, which is mainly responsible for the 
endotoxin effect of LPS [111]. It has been shown that ANXA5 inhibits LPS-
induced production of proinflammatory cytokines such as TNF-α in vitro and 
in mice in vivo. Therefore, it has been proposed that ANXA5 could play a 
role in host defense against Gram-negative endotoxemia by reducing LPS 
effects in vivo and may protect against attack induced by LPS [111].
ANNEXINOPATHIES 
General overview of annexinopathies                                                                                                        
The idea that annexins and ANXA5 particularly could be of biological im-
portance is based on their wide distribution in tissues and their membrane-
related biological activities. Although the gene knock-out models at the 
cellular and the animal levels have provided some evidence for the possible 
biological roles of annexins, the precise function of the annexin family as 
a whole and that of individual annexins still remains to be proven. It has 
been shown that the ANXA1 knock-out mouse has changes in the inflamma-
tory response, supporting thereby the role of ANXA1 in inflammation [112]. 
Examination of the ANXA2 knock-out mice demonstrated the involvement 
of ANXA2 in the regulation of fibrinolysis and neovascularization [113]. Mice 
lacking ANXA5 are viable, fertile and do not show a thrombotic phenotype 
[114]. Later, it has been demonstrated that loss of maternal ANXA5 is asso-
ciated with reduction in litter size and foetal weight as well as with placental 
thrombosis, providing thereby evidence that the maternal ANXA5 acts as 
an antithrombotic protein [115]. In the case of the ANXA5 knock-out mouse 
model or in some other cases, it is important to keep in mind that changes 
in expression levels of one individual annexin could affect the expression of 
other members of the annexin family and that the deficiency of one could 
lead to compensatory upregulation of another [114;116;117]. It has also 
been proposed that similar changes in expression levels of annexins can 
occur in disease states in humans [117]. 
The term “annexinopathy” introduced by Jacob H. Rand in 1999 links 
abnormalities in annexin expression levels, which could be of genetic 
or acquired origin, to disease conditions [4]. The ANXA5-related 
annexinopathy, one of the first described annexinopathies, is associated 
with the antiphospholipid syndrome (APS). The APS manifests as vascular 
thrombosis and/or recurrent pregnancy loss in patients with the persistent 
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presence of antiphospholipid antibodies (APLs) in plasma. A decreased ANXA5 
expression has been reported on placental villi of women with APS [118] as 
well as on cultured placental trophoblasts and endothelial cells exposed to 
IgG fractions from APS patients [6]. APL-mediated reduced expression of 
ANXA5 on placental syncytiotrophoblasts and on endothelial cells was shown 
to explain recurrent pregnancy loss and vascular thrombosis in APS [6]. The 
deficiency of ANXA5 on cell surfaces is associated with acceleration of plasma 
coagulation as well as with an increased procoagulant activity of cultured 
trophoblasts/endothelial cells in vitro [6;119] and placental thrombosis 
in an animal model in vivo [43]. One of the mechanisms responsible for 
APL-mediated acceleration of blood coagulation is the disruption of the 
protective antithrombotic shield of ANXA5 on the cell surfaces by APLs. 
Evidence for that came from atomic force microscopy experiments showing 
varying degrees of disruption of the ANXA5 2D ordered crystallization on 
the phospholipid bilayers in the presence of monoclonal human APL and 
ß2-glycoprotein I (the major APL co-factor) [120]. It is known that APLs 
are a heterogeneous population of auto-antibodies. In this respect, another 
human monoclonal antibody (i.e., CIC15) was unable to disrupt the 2D 
ordered arrays of ANXA5 [70].      
The list of annexinopathies is still not complete. Modern genetic approaches 
allow us to identify new mutations and/or polymorphic variations within the 
annexin genes, which through dysregulation of annexin expression levels 
could contribute to disease states. We believe that future research will re-
veal a new class of annexin genetic disorders, which in turn may lead to 
unravelling of the exact biological functions of annexins.     
Annexin A5 gene; Annexin A5 genetic variations in disease states 
The gene encoding ANXA5 protein consists of an untranslated exon 1 and 
12 coding exons that span approximately 29 kb on the human chromosome 
4q27 [121-123] (Figure 3). The human ANXA5 promoter lacks a TATA box 
and contains three transcription start sites (tsp) [122]. Basal transcription 
has been shown to be controlled by the two SP1 (specificity protein 1 
transcription factor) sites, which are located in the CpG-island with an 
average 75% G+C nucleotide content [123]. The SP1 transcription factor 
binds directly to the GC-rich motifs of DNA and enhances gene transcription. 
The human ANXA5 gene also contains an upstream endogenous retroviral 
long terminal repeat (437 bp), which has impact on the regulation of ANXA5 
transcription. The region downstream of the tsp1 in exon 1 (from +31 to 
+79) was found to be absolutely essential for the ANXA5 transcriptional 
activity [123]. In this segment (called an alternative promoter), two main 
elements were identified: DNA motif A (GCGTTT) with a binding site for 
c-MYB (transcriptional activator Myb) and DNA motif B (GCAGCTGC) 
containing an AP4 (activating enhancer-binding protein 4) site. The MED-
1 element (Multiple start site Element Downstream) (GCTCCG), which is 
an extension of the motif B, has been proposed to be relevant in gene 
transcriptional regulation. However, its role in transcriptional control needs 
to be clarified [123].    
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Figure 3. The human Annexin A5 gene and Annexin A5 promoter variations. 
A, A schematic representation of the Annexin A5 gene displays the upstream non-
transcribed region (NTR) and 13 exons. The untranslated exons are depicted in grey, 
coding exons – in white. The promoter region is in black. Adapted from Carcedo et al., 
2001 (123). B, Polymorphic variations in the 496-bp promoter region of the Annexin 
A5 gene and three common promoter haplotypes, according to Bogdanova et al., 2007 
(126). Nucleotide numbering is from the first transcription start point (tsp1). Minor 
alleles are in bold and underlined. The ATG codon means the translation initiation 
codon. 
It is known that gene expression is regulated at various levels, including 
1) transcription, 2) regulation at the level of RNA (processing, transport, 
translation and degradation of the mature mRNAs) and 3) protein processing 
and degradation. It is generally assumed that functional genetic variations 
could influence gene expression. A decreased or an increased mRNA or 
protein expression as a consequence of an affected gene expression might 
be associated with some disease features. If ANXA5 variations affect ANXA5 
expression within the vascular wall or in placental trophoblasts where large 
amounts of ANXA5 are present, it is expected to be associated with some 
clinical outcomes, such as an increased or decreased risk of placental or 
vascular thrombosis.
To date, our knowledge about the regulation of ANXA5 gene expression is 
insufficient. In 2002, Gonzales-Conejero et al. showed for the first time 
that the single nucleotide polymorphism (SNP) rs1131239, which is located 
one nucleotide upstream of the ATG (AUG in the mRNA) initiation codon in 
exon 2 of the ANXA5 gene, affects ANXA5 translation efficiency resulting in 
higher plasma ANXA5 levels in minor rs1131239T-allele carriers [124]. The 
authors suggested a protective role of increased plasma ANXA5 levels in the 
occurrence of arterial thrombosis as the presence of the minor rs1131239T-
allele was associated with a decreased risk of myocardial infarction [124] 
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and a lower risk of developing new thrombotic events during 36 months 
follow-up [125]. The above mentioned SNP rs1131239 is located in the 
Kozak consensus sequence (i.e. GCCRCCaugG (R = purine)), which plays a 
crucial role in the initiation of translation in humans [127;128]. Mutagenesis 
experiments showed that some nucleotides within the Kozak motif are more 
important than the others [128]. The nucleotides A or G at position -3 (i.e. 
upstream from the AUG codon) as well as G at positions +4 (i.e. downstream 
from the AUG codon) and -6 appeared to have the biggest contribution 
to the translation process whereas the contribution of the nucleotides CC 
at positions -1 and -2 was shown to be small (128;129). It has also been 
shown that only in the absence of -3R (i.e., A or G) and +4G mutations at 
positions -1 and -2 do exert some influence on translation [129]. Subsequent 
studies have confirmed the Kozak’s experimental data demonstrating the 
lack of association between SNP rs1131239 and plasma ANXA5 levels in 
healthy persons [130;131]. Several research groups have investigated the 
clinical relevance of SNP rs1131239. The minor rs1131239T-allele was not 
associated with a decreased risk of myocardial infarction in the Dutch and 
Finnish male patients [132;133], nor was it associated with ischemic stroke 
[134], preeclampsia [135] and vascular thrombosis in the antiphospholipid 
syndrome [136].  
In 2007, Bogdanova and colleagues reported four ANXA5 promoter 
polymorphisms [126] (Figure 3). SNP rs112782763 (g. -19G>A, upstream 
from tsp 1), which is located in the gGCCc sequence, affects the zinc 
finger binding of the MTF-1 (metal-regulatory) transcription factor [137]. 
Substitution at rs28717001 (g. +1A>C) changes the tsp1 itself. The third 
SNP rs28651243 (g. +27T>C, downstream from the tsp1) disrupts a SP1 
consensus sequences. Finally, SNP rs113588187 (g. +76G>A, downstream 
from the tsp1) destroys a BamHI restriction site in close proximity of an AP-4 
(motif B)/MED-1 consensus, which in turn is essential for the full ANXA5 
promoter activity [123;126]. Bogdanova and colleagues also showed that the 
expression of the ANXA5 gene could be influenced by two ANXA5 promoter 
haplotypes [126]. The ANXA5 promoter activity (luciferase reporter gene 
assay) was reduced in the M1 haplotype comprising minor alleles of two 
SNPs (rs28717001, rs28651243) and in the M2 haplotype consisting of four 
SNPs (rs112782763, rs28717001, rs28651243, rs113588187) to 57-62% 
and 37-42% activity of the wild-type haplotype (100%), respectively [126]. 
Later, the M2 ANXA5 allele was linked to reduced ANXA5 mRNA levels in 
placental tissues compared to the wild-type allele [138].
The idea that the hypofunctional ANXA5 M2 allele may promote a 
procoagulant state in placentas has initially been proposed by Bogdanova 
and colleagues. They reported that the presence of this haplotype is 
associated with a 2.4-fold increased risk of pregnancy loss in German 
females [126]. An association of the ANXA5 M2 haplotype with recurrent 
pregnancy loss was further confirmed in Italian [139], Japanese [140] and 
Bulgarian women [141], but not in subjects from East China [142] and also 
not in a second cohort of Japanese women [143]. The presence of the M2 
haplotype is also related to the risk factor of recurrent pregnancy loss in 
26
Chapter 1
polycystic ovarian syndrome [144]. Recently, it has been proposed that in 
patients with obstetric APS, a reduced ANXA5 expression at the placental 
villi through carriage of the ANXA5 M2 haplotype may be an explanation for 
pregnancy loss as well as a predisposing factor for the development of APLs 
(so-called “genetic” revised model of APS) [145], though data confirming 
this idea are still not available.       
An association of the ANXA5 M2 haplotype with deep venous thrombosis 
(DVT) was also assessed. However, the contribution of the M2 haplotype 
to thrombotic risk remains debatable. In two Italian studies, it was shown 
that the presence of the M2 haplotype is associated with an increased risk 
of DVT in pregnancy/postpartum period as well as in the general population 
[146;147]. On the other hand, in a Spanish study, the minor rs1131239T-
allele, which is located in the ANXA5 Kozak sequence and completely linked 
to SNPs rs112782763 and rs113588187 specific for the M2 haplotype 
[131;140], was not associated with a first episode of DVT [124].     
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OUTLINE OF THE THESIS 
The aim of this thesis was two-fold: 1) to extend our knowledge on the role 
of ANXA5 two-dimensional lattices in ANXA5-based anticoagulation; 2) to 
study whether ANXA5 genetic variations contribute to the pathogenesis of 
thrombosis- or inflammation-related diseases in order to get more insight 
into the biological significance of endogenous ANXA5 in humans.
Chapter 2 addresses the ANXA5 self-association on PS-exposing cell 
surfaces and the role of ANXA5 lattices in PS-depending coagulation 
reactions. The flow cytometric and microscopic Fluorescence Resonance 
Energy Transfer (FRET) approach was used to visualize both ANXA5 
interactions and interactions between FIX and FVIII of the intrinsic pathway 
of blood coagulation on PS-exposing cell surfaces.
In Chapter 3 we described the four common ANXA5 haplotypes within 
the ANXA5 gene upstream region in healthy controls. Furthermore, we 
demonstrated the variability of plasma ANXA5 levels regarding to ANXA5 
haplotypes. 
In Chapter 4 we investigated whether ANXA5 variations and/or plasma 
ANXA5 levels exerted an influence on carotid atherosclerosis progression by 
evaluating carotid IMT (intima-media thickness, a marker of atherosclerosis) 
as well as contributed to cardiovascular disease (CVD) risk in patients with 
familial hypercholesterolemia (FH). To achieve this goal, two large cohorts 
of FH patients were investigated: the ASAP (Atorvastatin versus Simvastatin 
on Atherosclerosis Progression) and GIRaFH (Genetic Identification of Risk 
factors in Familial Hypercholesterolemia). 
In Chapter 5 we aimed to evaluate whether ANXA5 promoter SNPs and/
or common haplotypes are associated with deep venous thrombosis (DVT) 
in the Dutch general population. For this study, we used a case-control 
study on risk factors for DVT, the Amsterdam Case-control Thrombophilia 
(ACT) study, and a large group of population controls (Nijmegen Biomedical 
Study, NBS). 
In Chapter 6 we studied an association of ANXA5 common haplotypes 
with thrombosis (either arterial or venous) and pregnancy morbidity in APS 
(antiphospholipid syndrome) patients. 
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ABSTRACT 
Background: Annexin A5 (ANXA5) anticoagulant activity is based on its 
high affinity for negatively charged phospholipids. The formation of ANXA5 
two-dimensional (2D) lattices has been proposed to be relevant for ANXA5-
mediated anticoagulant effects.
Objectives: To get more insight into the role of ANXA5 lattices in 
phosphatidylserine (PS)-depending coagulation processes on the cell surface.
Methods and Results: We used a flow cytometric and confocal Fluorescence 
Resonance Energy Transfer (FRET) approach to visualize FIX-FVIII 
interactions. Upon binding to ionomycin-activated COS1 cells, coagulation 
factors FIX and FVIII interact with each other forming the tenase complex 
(fluorescence FRET signal 49.1±10.6%). The interactions between FIX 
and FVIII were inhibited by pre-assembled ANXA5 at 5 nM (FRET signal 
4.1±1.1%). ANXA1, which binds to PS without forming 2D lattices, reduced 
FIX-FVIII interactions to a lesser extent under the same conditions (FRET 
signal 23.1±1.0%). Higher ANXA5 concentrations were required to block the 
binding of FIX and FVIII to activated cells. Using the same FRET approach, 
we observed that ANXA5 assembles into 2D tightly-packed lattices on 
artificial membranes and PS-exposing cells such as ionomycin-activated 
platelets and COS1 cells. ANXA1 showed hardly any FRET upon binding 
to ionomycin-activated platelets or stimulated COS1 cells, an indicator of 
membrane-bound unstructured clusters.  
Conclusions: Our observations suggest that ANXA5 lattice formation on 
PS-exposing cell surfaces contributes to ANXA5 anticoagulant properties. 
We assume that ANXA5 lattices inhibit tenase complex formation not only 
by shielding of PS but also by reducing the lateral mobility of PS-bound 
coagulation factors.
FRET studies of Annexin A5 lattice formation
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INTRODUCTION 
Thrombosis is a leading cause of morbidity and mortality in the developed 
world [1,2]. Many genetic and acquired risk factors affecting the hemostatic 
balance could contribute to the formation of a clot within a blood vessel 
[2,3]. 
Annexin A5 (ANXA5), a Ca2+-dependent phospholipid-binding protein of the 
annexin family, is involved in the pathogenesis of thrombotic disorders [4]. 
This protein possesses strong anticoagulant and antithrombotic properties, 
both in vitro and in vivo [5-9], which are based on its binding to anionic 
phospholipids exposed by apoptotic or activated cells and on shielding of 
thrombogenic cell surfaces from availability for coagulation reactions. The 
ANXA5 antithrombotic shield on endothelial cells as well as on placental 
trophoblasts may be disrupted by antiphospholipid antibodies that results 
in vascular thrombosis and recurrent pregnancy loss in the antiphospholipid 
syndrome [4,10]. Decreased ANXA5 placental expression through 
carriage of the M2/ANXA5 haplotype has recently been proposed to be a 
predisposing factor for thrombophilia-related obstetric complications [11]. 
In addition, reduced binding of ANXA5 to endothelial cells is associated with 
atherosclerotic changes and is a potential mechanism for atherothrombosis 
in systemic lupus erythematosus patients [12]. 
ANXA5 anticoagulant properties have been thoroughly examined. In vitro 
studies have shown that ANXA5 targeting the anionic phospholipids inhibits 
the assembly of coagulation enzyme-substrate complexes on artificial and 
cellular membranes: a) prothrombinase (activated factor V (FVa)+FXa); 
b) intrinsic tenase (FVIIIa+FIXa); c) tissue factor+FVIIa [5-7]. ANXA5 
additionally blocks fusion of activated platelets with tissue factor-bearing 
microvesicles [13]. However, the anticoagulant mechanism of ANXA5 seems 
to be more complex than just displacement of coagulation factors from 
procoagulant membranes. It has been demonstrated that, upon binding 
to anionic phospholipids, ANXA5 self-assembles into two-dimensional 
(2D) trimer-based lattices on synthetic as well as on cellular membranes 
[14-16]. Andree and colleagues were the first to suggest that ANXA5 
anticoagulant activity may be explained by the reduced lateral mobility of 
coagulation factors in rigid sheets of clustered ANXA5 molecules covering 
the model membrane [6]. In addition, ANXA5 appears to down-regulate the 
expression of the procoagulant tissue factor by inducing its internalization, 
supporting the complexity of the anticoagulant mechanism of ANXA5 [17]. 
The present study was performed in order to get more insight into the role 
of ANXA5 lattices on PS-exposing cell surfaces in coagulation reactions. 
We visualized interactions of coagulation factors of the tenase complex 
(i.e. FIX-FVIII interactions) as well as ANXA5-ANXA5 interactions on cell 
surfaces using a FRET (Fluorescence Resonance Energy Transfer) approach. 
FRET measures the energy transfer of an excited donor fluorophore to an 
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acceptor fluorophore in a dipole-dipole interaction, resulting in the quenching 
of the donor’s fluorescence intensity and an increase (sensitization) in the 
acceptor’s emission intensity [18,19]. This mechanism requires resonance 
interaction between donor and acceptor over distances of 2-10 nm and 
spectral overlap between the donor’s emission spectrum and the acceptor’s 
excitation spectrum. Using a flow cytometric (FCM) and confocal acceptor-
sensitized emission FRET approach, we determined ANXA5 self-association 
on model membranes as well as on PS-exposing cells. The same approach 
was also applied to assess an effect of ANXA5 membrane-bound assemblies 
on FIX-FVIII interactions on the surface of ionomycin-activated COS1 cells. 
MATERIALS AND METHODS 
Preparation of recombinant human ANXA5   
Recombinant human ANXA5 was prepared as described [20]. ANXA5 was 
purified using a DEAE (Amersham Biosciences) and Resource Q column 
(Pharmacia) installed at a fast protein liquid chromatography apparatus 
(Pharmacia). The protein appeared to be free of contaminants as determined 
by SDS-PAGE and Surface-Enhanced Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (SELDI-TOF MS; Bio-Rad). ANXA5 concentrations 
were measured using a Zymutest ANXA5 ELISA kit (Hyphen Biomed).
Labeling and separation of labeled ANXA5                    
ANXA5 was labeled with Alexa Fluor 488 (A488), A546 or A647 monosuc-
cinimidyl-esters (Molecular Probes, Invitrogen) according to the manufac-
turer’s instructions. Alexa labeled ANXA5 molecules with different stoichio-
metries were separated by FPLC (Pharmacia) using a Resource Q column. 
The dye to protein ratios were checked by SELDI-TOF MS. For that, labeled 
ANXA5 was spotted onto a normal phase protein chip (NP20; Bio-Rad). 
Sinapinic acid (Bio-Rad) prepared in 50% acetonitrile/0.1% trifluoroacetic 
acid was applied twice (1 µl each time and 2 minutes apart) and the chip 
was allowed to air-dry prior to reading on a SELDI-TOF MS. ANXA5 concen-
trations were determined by a Zymutest ANXA5 ELISA (Hyphen Biomed). 
For FCM and microscopic FRET experiments, we only used labeled ANXA5 
with 1:1 stoichiometry.
Labeling of coagulation factors and ANXA1    
For FCM and imaging experiments, recombinant human FIX (nonacog alfa; 
Wyeth Pharma S.A.) and FVIII (octocog alfa; Baxter S.A.) were labeled with 
Cy3 and Cy5 monoreactive sulfoindocyanine N-hydroxysuccinimidyl esters 
(Amersham Biosciences, Europe) following the manufacturer’s instructions. 
The Cy3 dye to FIX labeling ratio (i.e. molecules of dye per molecule of 
protein) determined by absorbance (Nanodrop ND-1000 spectrophotometer, 
Isogen Life Science) at 280 nm and 550 nm was 2.5:1. The degree of Cy5-
labeled FVIII was determined by absorbance at 280 and 650 nm and the 
dye/protein labeling ratio constituted 4.5:1. Recombinant mouse ANXA1, 
kindly provided by dr. B. Brachvogel (University of Cologne, Germany), 
was labeled with A546 or A647 monosuccinimidyl-esters (Molecular Probes, 
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Invitrogen) according to the manufacturer’s protocol. The A546 and 
A647 dye to ANXA1 labeling ratios determined by the Nanodrop ND-1000 
spectrophotometer and SELDI-TOF MS were 2.5:1 and 3.5:1, respectively.
Preparation of multilamellar lipid vesicles     
Phosphatidylserine (PS), phosphatidylethanolamine (PE) and phosphatidyl-
choline (PC) were from Avanti Polar Lipids (USA). 20 mol% PS, 20 mol% 
PE and 60 mol% PC were mixed in a glass tube under nitrogen conditions, 
dried with nitrogen and resuspended in Tris-buffered saline (TBS: 50 mM 
Tris-HCl (pH 7.4), 150 mM NaCl). A phospholipid solution was vortexed to 
give a suspension of multilamellar lipid vesicles (MLVs). MLVs were used at 
5 µM final concentration.   
Preparation of quiescent and ionomycin-activated platelets  
Citrate (3.8 %) venous blood from healthy volunteers was collected with a 
19-gauge needle. The citrated blood was centrifuged at 150 g without brake 
at RT for 15 minutes. Platelet rich plasma was acidified by addition of 1/10 
volume acid-citrate-dextrose buffer (ACD: 85 mM trisodium citrate, 71.4 
mM citric acid • H2O, 111 mM glucose). Platelets were concentrated by an 
additional centrifugation step at 330 g without brake for 15 minutes. The 
pellet was resuspended twice in Hepes-Tyrodes buffer (HT: 145 mM NaCl, 5 
mM KCl, 0.5 mM Na2HPO4 • 2 H2O, 1 mM MgSO4  • 7 H2O, 10 mM HEPES, 
5.5 mM glucose, pH 6.5 and 7.25) containing prostaglandin I2 (10 ng mL
-1) 
(Cayman Chemical, USA). Washed platelets (100 × 109 L-1) were activated 
by using 7 µM ionomycin (Sigma Aldrich) and 2.5 mM CaCl2 at RT for 15 
minutes. For FCM experiments, 0.5-1.0 × 106 activated platelets mL-1 were 
incubated with labeled ANXA5 (20 nM) or ANXA1 (40 nM) in the presence of 
2.5 mM CaCl2 at RT for 10-15 minutes.  
Cell preparation       
COS1 cells (monkey kidney cells) were maintained in IMDM (Invitrogen) 
supplemented with 10% heat-inactivated fetal calf serum (FCS; Invitrogen) 
and 1% antibiotics (penicillin/streptomycin; ICN Biomedicals). For imaging 
experiments, cells were cultured in glass bottomed (0.17 mm) WillCo-dishes 
(WillCo Wells BV, the Netherlands) at 37°C for 24 hours. Before imaging, 
cells were washed with HEPES-buffered saline (HBS: 25 mM HEPES, pH 7.4, 
135 mM NaCl, 5 mM KCl, 5 mM glucose) and stimulated with ionomycin 
(4 µM) in the presence of 2.5 mM CaCl2. Confocal FRET experiments were 
performed with labeled ANXA5 or ANXA1 as well as with FIX-Cy3/FVIII-Cy5 
under conditions described below. For FCM measurements, COS1 cells were 
trypsinized and washed in HBS followed by activation with 2 µM ionomycin 
at RT for 10-15 minutes. Activated COS1 cells (1.0-1.5 × 105 cells mL-1) 
were incubated with Cy3- and/or Cy5-labeled coagulation factors in the 
presence of 2.5 mM CaCl2 at RT for 15 minutes. To study an effect of pre-
bound ANXA5 or ANXA1 on FIX-FVIII interactions, activated cells were 
pretreated with unlabeled ANXA5 or ANXA1 (5-100 nM). 
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THP-1 monocytic cells were cultured in RPMI 1640 with glutamax-I and 
HEPES (Invitrogen) supplemented with 10% FCS and 1% penicillin/
streptomycin. To obtain nucleated cells that express anionic phospholipids, 
THP-1 cells were treated with 5 µM ionomycin at 37°C for 20 hours. A 
necrotic phenotype of THP-1 cells was obtained by performing twice a 
freeze-thawing procedure. FCM FRET experiments were performed with 
1.5-2.0 × 105 cells mL-1 cells incubated with labeled ANXA5 (60 nM) and 
2.5 mM CaCl2. 7-Amino-actinomycin D (7-AAD; Sigma Aldrich) (1µg mL
-1) 
was used to check the apoptotic and necrotic phenotype of the THP-1 cells. 
Flow cytometric FRET measurements     
To study ANXA5-ANXA5 as well as FIX-FVIII interactions on physiological 
cell membranes, we performed FRET experiments using an Epics Elite ESP 
(Beckman Coulter) equipped with a 488 nm Argon laser, a 532 nm solid-
state laser and a 633 nm HeNe laser. ANXA5-A546 or FIX-Cy3 (donor) was 
excited with the 532 nm laser and the emitted signal was measured in 
the FL2 channel with a 575/29 nm band pass (BP) filter. ANXA5-A647 or 
FVIII-Cy5 (acceptor) was excited with the 633 nm laser and emission was 
sampled in the FL3 channel with a 675/45 nm BP filter and a 625 DLP 
filter. A FRET signal was obtained by excitation of the donor with the 532 
nm laser and the emitted signal of the acceptor was used as readout. An 
average FRET efficiency was calculated by quenching of the donor [21]. 
The energy transfer efficiencies of FIX-FVIII interactions were corrected for 
the labeling ratios of donor and acceptor as previously described [21,22]. 
All equations are depicted in Supplemental Materials. Control experiments 
were performed with labeled ANXA1 as ANXA1 does not form a 2D network 
on model membranes [23,24]. 
Two-step FRET experiments were performed according the following 
scheme: the first step – FRET between ANXA5-A488 (donor 1) & 
ANXA5-A546 (acceptor 1), the second step – FRET between ANXA5-A546 
(acceptor 1=donor 2) & ANXA5-A647 (acceptor 2) [25]. The emitted signal 
of ANXA5-A488 was measured in the FL1 channel with a 525/39 BP filter, 
ANXA5-A546 - in FL2 with a 575/29 BP filter and ANXA5-A647 - in FL3 with 
a 675/45 BP filter. Different combinations of labels were tested to optimize 
the detector and compensation settings, as the combination (ANXA5-
A488+ANXA5-A647) should not give FRET and both ANXA5-A546 and 
ANXA5-A647 should not be excited by the 488 nm laser. A FRET signal was 
measured upon excitation of ANXA5-A488 (donor 1) with the 488 nm laser 
and the emitted signal of ANXA5-A647 (acceptor 2) was used as readout. 
To prevent calcium phosphate crystal formation in the flow cell, we used 
TBS buffer. Data analysis was performed using CXP analysis version 2.2 
software (Beckman Coulter). 
Confocal FRET experiments      
FRET experiments were performed with the A546/A647 and Cy3/Cy5 pairs 
of fluorophores on a LSM 510 Meta confocal laser-scanning microscope 
(CLSM) (Carl Zeiss GmbH, Jena, Germany) with a Plan-Apochromat 63X/1.4 
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oil immersion objective at RT (21°C). The donor A546 (or Cy3) and the 
acceptor A647 (or Cy5) were excited with the HeNe 543 nm and HeNe 
633 nm laser line and emission was sampled with a 565-615 nm and 650-
710 nm BP filters, respectively. FRET channel images were obtained by 
excitation of the donor with the 543 nm laser and collection of emission at 
650-710 nm. Images were acquired in multi track configuration mode as 
8-bit images of 512×512 pixel sizes. Four time-scan averages were used to 
increase the signal to noise ratio. Each channel had the same optical slice 
(1 μm thick). During all acquisition sessions, the same microscope settings 
were used. The images were analyzed using ImageJ version 1.43n software 
(U.S. National Institutes of Health, Bethesda, Maryland, USA, http://rsb.
info.nih.gov/ij/) containing the “FRET and colocalization Analyzer” plug-
in [26]. The “FRET index” images were generated using the equation of 
Youvan D.C. et al. (1997) and the mean bleed through coefficients. After 
thresholding (i.e. pixel intensities below a threshold value equal to 35), 
mean FRET efficiency values of the whole surface delimited by the cell 
contour were determined. The distribution of FRET pixels intensities on the 
cell membrane was presented as a surface plot.  
Production of ANXA5-A647 labeled beads    
MagnaBind Amine Derivatized Beads (Pierce) were labeled with ANXA5-A647 
in the presence of the BS3 cross-linker solution following the manufacturer’s 
instructions. In short, beads were washed three times with PBS (Braun) 
using a magnetic separation unit. To 5 µl washed beads, 1 ml ANXA5-A647 
(50 µg mL-1 in PBS) and 1 M cross-linker suspension (BS3) were added. 
After incubation for 30 minutes, the remaining free amine groups were 
blocked with 50 µl of 1 M Tris. 
Effects of unlabeled ANXA5 on the binding and on membrane-bound 
lattices of labeled ANXA5       
To study an effect of unlabeled ANXA5 on the binding of labeled ANXA5 to 
ionomycin-activated platelets, unlabeled ANXA5 (20-100 nM) and 20 nM 
ANXA5-A546 were added simultaneously to activated cells (0.5-1.0 × 106 
mL-1) prior to the addition of calcium (2.5 mM). In binding experiments, 
ANXA5-A546 was excited by the 532 nm laser. To determine an effect of un-
labeled ANXA5 on the ANXA5 lattice formation, activated platelets (0.5-1.0 
× 106  mL-1) were preincubated with labeled ANXA5 (ANXA5-A546+ANXA5-
A647) and 2.5 mM CaCl2. Subsequently, platelets were checked for FRET 
prior to addition of unlabeled ANXA5 (20-100 nM). In FRET experiments, 
the emitted signal of the acceptor (ANXA5-A647) is shown upon excitation 
of the donor (ANXA5-A546) with the 532 nm laser.  
Data analysis        
Data are shown as mean±SD. The differences between two groups were 
tested by unpaired t-test (GraphPad Prism version 5.03 software). Two-
sided p-values <0.05 were considered statistically significant.   
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RESULTS
FIX+FVIII complex formation on PS-exposing cells determined by 
FRET measurements        
Upon binding to PS-exposing cell surfaces, coagulation factors FIX and FVIII 
interact with each other forming thereby a tenase complex [27,28]. We 
visualized FIX-FVIII interactions on the surface of ionomycin-activated COS1 
cells using a flow cytometric (FCM) FRET approach. Activated COS1 cells 
were incubated with both Cy3-labeled FIX (donor) (Figure 1A1) and Cy5-
labeled FVIII (acceptor) (Figure 1A2) in the presence of 2.5 mM calcium. 
Excitation of FIX-Cy3 by the 532 nm laser showed the emitted signal of 
FVIII-Cy5 (Figure 1A3) and decreased mean fluorescence intensity (MFI) 
of the donor (Figure 1A4). That indicates FRET from FIX-Cy3 to FVIII-
Cy5 (fluorescence FRET signal 49.1±10.6%). The average FRET efficiency 
values corrected for the labeling ratios of donor and acceptor were equal to 
0.25±0.07.         
The existence of FIX-FVIII interactions was also confirmed by confocal 
FRET measurements (Figure 1B and Figure S1). Representative images 
illustrate the binding and co-localization of labeled coagulation factors on 
the surface of ionomycin-activated COS1 cells (Figure 1B). After correction 
for spectral bleed through, mean FRET values of FIX-FVIII interactions were 
equal to 45.4±4.8. Control experiments performed in the presence of the 
Ca2+-chelating agent EDTA (10 mм) showed abolished binding of FIX-Cy3 
and thus FRET (Figure 1B). The results of FRET experiments demonstrate 
that coagulation factors FIX and FVIII form complexes on the surface of 
ionomycin-activated COS1 cells.
ANXA5 but not ANXA1 efficiently inhibits FIX-FVIII interactions    
To obtain more insight into the mechanism of ANXA5 anticoagulant proper-
ties, we tested an effect of unlabeled ANXA5 pre-bound on the surface of 
ionomycin-activated COS1 cells on FIX-FVIII interactions as well as on FIX, 
FVIII binding individually (Figure 2). ANXA5 effects were compared with 
those of ANXA1, which is also known to shield anionic phospholipids. FCM 
FRET experiments demonstrated that FIX-FVIII interactions were already 
inhibited by pre-bound ANXA5 at low concentrations (5 nM) (fluorescen-
ce FRET signal 4.1±1.1% versus 49.1±10.6% in the absence of ANXA5; 
p<0.01). At a saturating concentration (20 nM), ANXA5 completely blocked 
the interaction between FIX and FVIII (Figure 2A and Figure S2). By con-
trast, pre-assembled ANXA1 at 5 nM and 20 nM partly affected FIX-FVIII 
interactions, reducing FRET signal from 49.1±10.6% to 23.0±1.0% and 
20.7±7.7%, respectively. FIX-FVIII interactions were strongly inhibited at 
high ANXA1 concentrations (100 nM) (Figure 2A and Figure S2). 
Pre-bound ANXA5 shielding PS reduced the binding of FIX and FVIII to 
ionomycin-activated COS1 cells in a concentration-dependent manner (Figure 
2B and Figure S2). In comparison with its effect on FIX-FVIII interactions, 
higher ANXA5 concentrations were required to inhibit the binding of FIX and 
FVIII to the cell surface. At saturating ANXA5 concentrations (20 nM), the 
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Figure 1. FIX-FVIII interactions on the surface of ionomycin-activated 
COS1 cells. A, For FCM measurements, activated cells were incubated with FIX-Cy3 
(220 nM) and/or FVIII-Cy5 (39 nM) in the presence of 2.5 mM calcium for 15 min. 
Dot plots show FIX (A1) and FVIII (A2) binding to activated cells upon excitation with 
the 532 nm and 633 nm laser, respectively. Tenase complex formation is illustrated 
by energy transfer from the excited FIX-Cy3 to FVIII-Cy5 upon excitation with the 
532 nm laser (A3) and decreased MFI of the donor (A4; white histogram). The black 
histogram represents the MFI of the FIX-Cy3 alone in the donor channel. B, Confocal 
images are shown of FIX-Cy3 (150 nM; green) and FVIII-Cy5 (19.5 nM; red) fluores-
cence intensities with the donor channel and acceptor channel setting, respectively 
as indicated in Materials and Methods. The uncorrected FRET signal (yellow) illus-
trates the emitted signal of FVIII-Cy5 upon excitation with the laser of the donor. 
The “Colocalization diagram” indicates co-localization of coagulation factors on the 
membrane of COS1 cells and the mean of FRET indices. Control experiments were 
performed in the presence of the Ca2+-chelating agent EDTA (bottom panel). Scale 
bar 20 µm.
binding of coagulation factors was still partly reduced. Pre-bound ANXA1 
(5-100 nM), even at the highest dose tested, had little inhibitory effect on 
FIX and FVIII binding (data not shown).
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Figure 2. ANXA5 membrane-
bound lattices inhibit the te-
nase complex formation on 
the surface of ionomycin-acti-
vated COS1 cells. A, Effects of 
pre-bound ANXA5 (0-100 nM) and 
ANXA1 (0-100 nM) on FIX (220 
nM)-FVIII (39 nM) interactions. 
The emitted signal of FVIII-Cy5 
(acceptor) is shown upon excita-
tion of the donor (FIX-Cy3) with 
the 532 nm laser. B, A concentra-
tion-dependent reduction of FIX-
Cy3 (220 nM) and FVIII-Cy3 (39 
nM) binding by pre-bound unlabe-
led ANXA5 (0-100 nM). The graph 
depicts the relative fluorescence 
(%) as compared with the MFI 
of membrane-bound FIX/FVIII in 
the absence of ANXA5. Data are 
mean±SD (n=3). 
Taken together, ANXA5 but not ANXA1 efficiently inhibits FIX-FVIII 
interactions suggesting that ANXA5 organization on cells exposing PS is 
responsible for ANXA5 anticoagulant properties. Additionally, pre-bound 
ANXA5 interferes in the tenase complex formation not only by competing 
with coagulation factors for PS-binding sites but also likely by reducing the 
lateral mobility of membrane-bound FIX/FVIII. 
         
ANXA5 assembles into 2D lattices on artificial membranes  
Based on the suggestion that the formation of ANXA5 lattices on cell 
membranes could be relevant in ANXA5-based anticoagulation, we aimed to 
explore ANXA5 organization on PS-exposing cell surfaces. For that, we used 
a FRET experimental approach as labeled ANXA5 molecules are located in 
close proximity (less than 10 nm) on the cell membrane i.e. at a distance 
of one ANXA5 molecule (an average diameter 5 nm) [6] and thus could 
directly interact with each other [29]. 
ANXA5 clustering was first studied on the surface of phospholipid bilayers 
consisting of 20/20/60 mol% PS/PE/PC as a simplified model of the cell 
membrane. ANXA5 was labeled with A488, A546, A647 and purified to get the 
labeled proteins with 1:1 stoichiometry (Figure S3). Binding experiments 
performed by FCM showed similar Ca2+-dependent binding characteristics 
of labeled ANXA5 moieties (0-30 nM) (Figure S4). FCM FRET experiments 
were carried out with ANXA5-A546 and ANXA5-A647 as donor and acceptor, 
respectively. Addition of 2.5 mM calcium to a mixture of 5 μM multilamellar 
lipid vesicles (MLVs), 8 nM ANXA5-A546, 12 nM ANXA5-A647 and excitation 
of ANXA5-A546 by the 532 nm laser resulted in a strong fluorescent signal 
of ANXA5-A647 due to FRET (Figure S4). The average FRET efficiency was 
0.62±0.05. 
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Next, we investigated whether ANXA5 organization on membrane surfaces 
was based on multiple ANXA5 interactions. To determine these multiple 
interactions, we developed a two-step FRET assay (two FRET transmissions) 
with ANXA5-A488 (donor 1), ANXA5-A546 (acceptor 1=donor 2) and 
ANXA5-A647 (acceptor 2). The two-step reaction was performed with the 
combination of 2 nM ANXA5-A488, 6 nM ANXA5-A546 and 4 nM ANXA5-A647 
in the presence of 2.5 mM Ca2+ (20/20/60 mol% PS/PE/PC surface) (Figure 
S4). The existence of two energy transmissions after excitation at 488 nm 
(from ANXA5-A488 to ANXA5-A546 and from ANXA5-A546 to ANXA5-A647) 
indicates that ANXA5 organization on the surface of artificial membranes is 
based on multiple ANXA5 interactions. 
We further tested whether ANXA5 protein-protein interactions grow in a 
three-dimensional direction independent of anionic phospholipids. For that, 
ANXA5-A647 covalently coupled to amine pro-active beads was incubated 
with ANXA5-A546 in the presence of calcium (Figure S4). No FRET signal 
was observed, illustrating that ANXA5 does not form three-dimensional 
complexes independent of negatively charged phospholipids. Similar results 
were also obtained in the absence of calcium. Our results indicate that 
ANXA5 assembles into 2D tightly-packed lattices on the surface of artificial 
membranes.
Studying ANXA5 lattices on PS-exposing cell membranes 
The FRET assay was also applied to study ANXA5 interactions on physiological 
cell membranes. We performed confocaol FRET measurements to provide 
more information on ANXA5 clustering on the plasma membrane within a 
single cell (Figure 3A-B). FRET values corrected for spectral bleed through 
are represented as a “FRET index” image (in a pseudocolor scale) (Figure 
3B), which displays intensities of acceptor emission due to FRET in each 
pixel [26]. The mean FRET efficiency values of ANXA5 interactions were 
equal to 60.6±6.4. However, the distribution of FRET pixel intensities was 
quite heterogeneous, ranging from 35 (threshold values; i.e. no or very 
low FRET) to 210-220 (i.e. high FRET) as shown on the surface plot for a 
representative image (Figure 3C). In contrast to ANXA5, FRET efficiency 
values of ANXA1 interactions were considerably low (35.3±2.1, p<0.001), 
ranging from the threshold values to 90 (Figure 3D and Figure S5). ANXA5 
and ANXA1 bind to PS-binding sites on the cell surface as their binding 
was abolished in the presence of the Ca2+-chelating agent EDTA (10 mM) 
(Figure 3A-B and Figure S5). 
ANXA5 interactions were also examined on the surface of ionomycin-
activated platelets as platelets play a dominant role in coagulation. Ionomycin 
treatment induced PS exposure in nearly all cells [30] and resulted in binding 
of labeled ANXA5 to platelets. Figure 4B shows the fluorescent signal of 
platelets labeled with ANXA5-A546 (left dot plot) and ANXA5-A647 (middle 
dot plot) upon excitation with the 532 nm and 633 nm laser, respectively and 
a strong FRET signal generated on activated platelets by excitation with the 
532 nm laser (right dot plot). The average FRET efficiency was 0.59±0.05. 
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Figure 3. ANXA5 self-association on the membrane surface of ionomycin-ac-
tivated COS1 cells determined by confocal FRET measurements. A, Images are 
shown of ANXA5-A546 (10 nM; green) and ANXA5-A647 (10 nM; red) fluorescence 
intensities with the donor channel and acceptor channel setting, respectively. The un-
corrected FRET signal (yellow) illustrates the emitted signal of ANXA5-A647 upon ex-
citation with the 543 nm laser. DIC indicates differential interference contrast. B, The 
raw FRET signal was corrected for spectral bleed through (“FRET index” image). The 
“Colocalization diagram” indicates co-localization of labeled ANXA5 on the membrane 
of COS1 cells and the mean of FRET indices. Control experiments were performed in 
the presence of 10 mM EDTA (A and B, lower panels). C, Surface plot illustrates the 
distribution of FRET pixel intensities on the cell membrane. D, Mean FRET efficiency 
values (error bars, SD of 43-47 cells) of ANXA5 and ANXA1 interactions (p<0.001). 
Scale bar 20 µm.  
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The specificity of ANXA5 binding to platelets was tested by addition of 
excess unlabeled ANXA5. A five-fold increase of unlabeled ANXA5 (up to 
100 nM) interfered in the binding of labeled ANXA5 molecules (Figure S6). 
On the other hand, addition of unlabeled ANXA5 in equimolar amounts (i.e. 
20 nM) to the FRET positive platelets (i.e. membrane-bound ANXA5 lattices) 
reduced the FRET signal but did not affect the binding of labeled ANXA5 
moieties. Even increasing the concentration of unlabeled ANXA5 up to 100 
nM did not affect binding of labeled ANXA5 to activated platelets (Figure S6) 
supporting thereby the formation of organized structures on a membrane 
surface. We also studied ANXA5 interactions on the surface of monocytic 
THP-1 cells with an apoptotic and necrotic phenotype. To control viability, 
THP-1 cells were labeled with 7-AAD. A high FRET signal was generated on 
the surface of apoptotic cells (7-AAD negative) and necrotic cells (7-AAD 
positive) with an average FRET efficiency of 0.48±0.04 and 0.69±0.05, 
respectively (Figure 4C). Untreated cells (7-AAD negative) gave no FRET 
signal. Control FRET experiments were performed with labeled ANXA1 as 
ANXA1 binds to PS without forming a 2D network [23,24]. After incubation 
of ionomycin-activated platelets with ANXA1-A546 and ANXA1-A647 and 
calcium (2.5 mM), a FRET signal was not observed (Figure 5), even after 
increasing the concentration of ANXA1 up to 100 nM. Summarizing, FCM and 
confocal FRET measurements revealed oligomerization of labeled ANXA5 on 
the membrane of ionomycin-activated platelets and COS1 cells as well as 
on apoptotic and necrotic THP-1 cells. ANXA1 membrane-bound clusters 
appeared to be unstructured to allow high FRET signals. 
DISCUSSION 
The purpose of this study was to get more insight into the mechanism of 
ANXA5 anticoagulant properties, especially with respect to its organization 
on PS-exposing cell surfaces. We aimed to prove that ANXA5 lattices inhibit 
the assembly formation of coagulation factors not only by competing with 
coagulation factors for PS-binding sites but also by reducing their lateral 
mobility. To test this hypothesis, we used a FRET experimental approach 
visualizing interactions between FIX and FVIII of the intrinsic pathway 
of blood coagulation as well as ANXA5 interactions on PS-exposing cell 
surfaces. We here provided evidence that besides the shielding of PS, 
ANXA5 anticoagulant activity is also based on its lattice formation on PS-
exposing cells. 
ANXA5 is known to interfere in blood coagulation through displacement of 
coagulation factors from procoagulant surfaces and thus inhibiting of their 
complex formation. Hence, ANXA5 is involved in this process indirectly as 
ANXA5 does not interact with coagulations factors [6,31]. We attempted 
to understand a role of ANXA5 lattices in coagulation reactions examining 
the influence of ANXA5 lattices on the interactions between FIX and FVIII. 
These membrane-bound factors interact via the A3 subunit of FVIII and the 
FIX light chain [27,28] forming thereby a tenase complex. Our FRET data 
showed that FIX-FVIII interactions on the surface of ionomycin-activated cells 
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Figure 4. ANXA5 interactions on PS-exposing cell surfaces determined by 
FCM FRET. A, Binding of labeled ANXA5 (0-30 nM) to ionomycin-activated platelets. 
The results were plotted on a log10-scale y axis. AU means arbitrary units. B, Binding 
of ANXA5-A546 (8 nM, left dot plot) and ANXA5-A647 (12 nM, middle dot plot) to 
activated platelets upon excitation with the 532 nm and 633 nm laser, respectively. 
FRET signal (20 nM ANXA5) is shown by the emitted signal of the acceptor upon 
excitation of the donor with the 532 nm laser (right dot plot). Experiments (A and 
B) were carried out with 1.0-2.0 × 105 platelets in the presence of 2.5 mM Ca2+. C, 
Average FRET efficiencies of ANXA5 interactions on ionomycin-activated platelets, 
apoptotic and necrotic THP-1 cells (mean ± SD). Data are from at least three inde-
pendent experiments. 
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were affected in a different manner by membrane-bound arrays of ANXA5 
and ANXA1. An inhibitory effect of pre-bound ANXA5 was already shown 
at low concentrations (5 nM). However, the binding of FIX and FVIII was 
still observable under these conditions. Pre-assembled ANXA1, by contrast, 
interfered in the tenase complex formation only at high concentrations. It 
is important to note that ANXA5 binding to phospholipid vesicles results in 
a rigidification of the membrane even at the mitochondrial level [32,33]. 
The ternary complexes ANXA5-Ca2+-phospholipid are known to cause 
strong immobilization of the phospholipid headgroups creating regions of 
diminished fluidity and hence, restricting the lateral diffusion of membrane 
Figure 5. ANXA1 interactions on the surface of ionomycin-activated plate-
lets determined by FCM FRET. A, Binding of labeled ANXA1 (0-60 nM) to activated 
platelets in the presence of 2.5 mM Ca2+. The results were plotted on a log10-scale y 
axis. AU means arbitrary units. B, FRET was generated after addition of 2.5 mM Ca2+ 
to a mixture of activated platelets and labeled ANXA1 ((ANXA1-A546 20 nM+ANXA1-
A647 20 nM) – upper panel; (ANXA1
-
A546 30 nM+ANXA1-A647 30 nM) – lower 
panel). No FRET signal was observed after excitation of the donor with the 532 nm 
laser (right dot plots). Experiments were carried out with 1.0-2.0 × 105 cells obtained 
from different donors (n=3).
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proteins [34-36]. It has also been suggested that the rigidification of 
cellular membranes could be a physiological function of trimer-forming 
annexins (i.e. ANXA5, ANXA4 and B12) [35]. In our case, ANXA5 lattices, 
even at low concentrations, inhibited the interactions between FIX and FVIII 
likely by restricting the lateral mobility of PS-bound coagulation factors, 
but they did not completely block FIX/FVIII binding. ANXA1, which binds 
to PS without forming a 2D network, does not interact extensively with the 
lipid bilayer and does not immobilize the phospholipid headgroups [35]. As 
a result, in the presence of ANXA1 arrays, PS-bound FIX and FVIII were 
less restricted to interact with each other to form the tenase complex. 
Our data fit with the ideas of Andree and colleagues, who suggested that 
the ANXA5 anticoagulant effect could be explained by the reduced lateral 
transport of prothrombin and FXa in rigid sheets of ANXA5 but not only 
by competing with coagulation factors for PS-binding sites. Incomplete 
displacement of membrane-bound coagulation factors by ANXA5 as shown 
by Andree et al. [6] and in this study may be explained by the fact that 
ANXA5 forms open lattices. Atomic force microscopy experiments have 
revealed that protein-free spaces within ANXA5 lattices are large enough 
(~9 nм in diameter) to allow the binding of other proteins (e.g., ANXA1, 
ANXA2) [37,38]. In pathological situations such as in antiphospholipid 
syndrome, antiphospholipid antibody-mediated disruption of the ANXA5 
anticoagulant shield may increase the mobility of coagulation factors and 
enhance their interactions ultimately leading to thrombin formation and an 
increased risk to develop thrombosis. Studying of ANXA5 lattice formation 
could be therefore of clinical importance contributing to understanding of 
prothrombotic properties of antiphospholipid antibodies. 
To characterize ANXA5 organization on cell surfaces, we employed a FRET 
experimental approach, a well-known technique to study interactions of 
proteins within a distance of 2-10 nm. Ungethum and colleagues recently 
showed that ANXA5 trimerizes and assembles into 2D ordered lattices 
on the membrane of apoptotic Jurkat cells using a FCM FRET protocol 
and transmission electron microscopy analysis [16]. In our FCM FRET 
experiments, we observed oligomerization of labeled ANXA5 on model 
membranes and PS-exposing cells such as ionomycin-activated platelets 
and apoptotic THP-1 cells. As shown by two-step FRET measurements, the 
ANXA5 organization was based on multiple protein-protein interactions 
reflecting the tight packing of molecules. In fact, these experiments did not 
prove ANXA5 trimerization as the detection of FRET between three molecules 
(e.g., between A and B, and between B and C) does not necessarily mean 
the presence of a trimer [19]. However, the formation of ANXA5 organized 
structures was strongly supported by experiments in which addition of 
unlabeled ANXA5 to pre-bound labeled ANXA5 on the surface of ionomycin-
activated platelets resulted in an abolished FRET signal (i.e. ANXA5-ANXA5 
interactions) but not the binding of labeled ANXA5 molecules. In the light 
of results reported in the literature, these findings could be explained by 
integration of unlabeled ANXA5 within protein-free spaces of ANXA5 arrays 
resulting in more ordered crystal structure [35,37-39]. 
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Confocal FRET measurements showing oligomerization of labeled ANXA5 
on the cell membrane of ionomycin-activated COS1 cells further confirmed 
the FCM data. We additionally demonstrated that the distribution of FRET 
pixel intensities on the cell surface was quite heterogeneous, ranging from 
the threshold values (i.e. no or very low FRET) to high FRET efficiency 
values. It is interesting to note that “FRET index image” displays intensities 
of acceptor emission due to FRET in each pixel [26]. We suggest that 
each pixel in our setting is around 0,08 µm-square and thus represents 
approximately 3000 molecules ANXA5, based on the mean area per ANXA5 
molecule (25.5 nm²) [40]. Hence, clustering of ANXA5 molecules at specific 
domains of the plasma membrane with different PS content [41] could 
be an explanation for higher FRET efficiency values. Calcium-induced PS 
clustering [24,42] and aggregation of acidic phospholipids on apoptotic cell 
membranes [43,44] can indeed increase the local density of fluorescent 
ANXA5, subsequently leading to FRET. This phenomenon was an argument 
to doubt ANXA5 trimerization on a cellular membrane [45]. Ungethum 
et al., however, succeeded to prove that ANXA5 variant 2D1-6 lacking 
the ability to form trimers generates less FRET on apoptotic Jurkat cells 
compared with wild-type ANXA5 [16]. Another explanation for the FRET 
heterogeneity in our approach could be the fact that the apparent FRET 
is a mix of the FRET-yielding dimers, non-FRET dimers (donor-donor and 
acceptor-acceptor), non-oligomerized monomers and high-order oligomers 
[46,47]. Oligomers larger than dimers are known to result in higher FRET 
efficiency than dimers alone, as calculated for the mGATI transporter 
constructs [47]. The possibility of ANXA5 to self-assembly into large lattices 
is also supported by FRAP (Fluorescence Recovery After Photobleaching) 
experiments, which demonstrate very weak mobility of ANXA5 molecules 
upon binding to ionomycin-treated N1E-115 cells [48]. 
In contrast to ANXA5, ANXA1 generated no FRET upon binding to ionomycin-
activated platelets as shown by FCM FRET experiments. Confocal FRET 
measurements, however, were sensitive enough to detect small patches of 
ANXA1 on the surface of ionomycin-activated COS-1 cells. ANXA1 appeared 
to form disordered clusters on the cell surfaces, which is in good agreement 
with previously reported findings [23,24,48]. Altogether, our results clearly 
showed differences in the organization of ANXA5 and ANXA1 on PS-exposing 
cells as well as the importance of ANXA5 lattices in inhibition of the tenase 
complex formation.    
Several limitations to this study need to be acknowledged. At first, in our 
approach the 22 lysine residues present in ANXA5 molecules were labeled 
randomly, depending on their availability. Due to the random positioning of 
the fluorophores and consequently varied distances between the dye pairs, 
a proper critical distance calculation on basis of the FRET efficiency is not 
possible. Another limitation of the study concerns the functional experiments 
(i.e. FXa or thrombin formation) we should perform to strength the conclusion 
about ANXA5-induced inhibition of assembly of the tenase complex. We did 
not present these data since results of functional experiments to prove the 
influence of ANXA5 on the prothrombinase, tenase and tissue factor-FVIIa 
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complexes on both artificial membranes and cell surfaces have already been 
published by many researches [5-7]. Lastly, we used ionomycin-treated 
cells as stimulation with ionomycin induces PS exposure in nearly all cells 
[30]. It should be interesting to investigate the effect of other cell activators 
in our FRET approach. 
To summarize, we conclude that ANXA5 lattice formation on cell surfaces 
exposing negatively charged phospholipids is also responsible for ANXA5 
anticoagulant properties. This lattice does not fully block binding of 
coagulation factors but inhibits the tenase complex formation (i.e. FIX-
FVIII interactions) by reducing the lateral mobility of coagulation factors. 
Our results as well as our FRET approach might be helpful in further 
understanding of thrombotic disorders where ANXA5 is involved.
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SUPPLEMENT 
Flow cytometric FRET measurements
An average FRET efficiency was calculated by quenching of the donor       
(E (quenching)) using the following formula [1]: 
                 
              
           
 
          
where Idon,acc is the average fluorescence intensity of the donor and 
acceptor labeled sample, measured in the donor channel and Idon is the 
average fluorescence intensity of the donor only labeled sample, measured 
in the same channel.
The energy transfer efficiencies (E) of FIX-FVIII interactions were corrected 
for the labeling ratios (LR = LD/LA) of donor (LD) and acceptor (LA) according 
the following equations [1,2]: 
      
     
       
 
 
       
      
  
      
 
 
   
 
                
where LRnorm = 1 and Enorm -  the normalized energy transfer efficiencies. 
Two-step FRET experiments:        
The energy transfer efficiencies (E) of the first and the second step were 
determined by quenching of the donor 1 and donor 2, respectively. The 
two-step FRET relay efficiency is as follows: Erelay = Efirst step x Esecond step 
[3].
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Figure S1. FIX-FVIII interactions on the surface of ionomycin-activated 
COS1 cells. The acceptor-sensitized emission FRET on activated COS1 cells labeled 
with the FRET-pair (FIX-Cy3 and FVIII-Cy5) (A), the donor-only (FIX-Cy3) (B) and the 
acceptor-only (FVIII-Cy5) (C) is shown. B, donor spectral bleed through is observed 
in the FRET channel after excitation with the donor laser (543 nm), whereas there 
is no crosstalk in the acceptor channel by excitation with the laser of acceptor (633 
nm). C, acceptor spectral bleed through detected in the FRET channel after excitation 
with the donor laser is low. 
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Figure S2. Membrane-bound arrays of ANXA5 and ANXA1 affect FIX-FVIII 
interactions on the surface of ionomycin-activated COS1 cells.   
A, Binding of ANXA5 and ANXA1 to activated COS1 cells. ANXA5-A546 and ANXA1-
A546 were excited by the 532 nm laser. Data are mean±SD (n=3). B, Dot plots 
illustrate abolished FIX-FVIII interactions by 20 nM of pre-bound unlabeled ANXA5 
(a) and 100 nM of pre-bound unlabeled ANXA1 (d). ANXA5 at 100 nM completely 
interfered in the binding of coagulation factors (b). The emitted signal of FVIII-Cy5 
(acceptor) is shown upon excitation of the donor (FIX-Cy3) with the 532 nm laser. 
Figure S3. Stoichiometry of labeled ANXA5 after purification by FPLC. The 
dye to protein ratios were determined by SELDI-TOF MS and visualized by a gel 
view. Unlabeled ANXA5 showed a band at approximately of 36 kDa. The changes 
in molecular weight (MW) correspond to the number of fluorescent dye molecules 
covalently coupled to one ANXA5 molecule.
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Figure S4. ANXA5 interactions on the surface of artificial membranes.   
A, Binding of labeled ANXA5 (0-30 nM) to MLVs (5 µM). ANXA5-A488, ANXA5-A546 
and ANXA5-A647 were excited by the 488 nm, 532 nm and 633 nm laser, respec-
tively. The results were plotted on a log10-scale y axis. B, Binding of ANXA5-A546 
(8 nM, left dot plot) and ANXA5-A647 (12 nM, middle dot plot) upon excitation with 
the 532 nm and 633 nm laser, respectively. FRET was generated after addition of 
Ca2+ to a mixture of 5 µM MLVs and 20 nM labeled ANXA5. FRET signal is shown 
by the emitted signal of the acceptor (ANXA5-A647) upon excitation of the donor 
(ANXA5-A546) with the 532 nm laser (right dot plot). C, ANXA5 interactions are 
two-dimensional but not three-dimensional. ANXA5-A647 (22 nM) coupled to amine 
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beads was excited by the 532 nm laser (a, b) or 532 nm and 633 nm laser together 
(c, d). The signal of ANXA5-A647 coated beads is shown in the Alexa 647 channel 
(c). Addition of ANXA5-A546 (20 nM) to ANXA5-A647 coated beads did not result in 
a positive signal in the Alexa 546 channel (b, d) and no FRET signal was observed 
(b). D, Multiple ANXA5 interactions on a phospholipid bilayer measured by two-step 
FRET. The black curves show the MFI of the two-step FRET (ANXA5-A488+ANXA5-
A546+ANXA5-A647). The grey curves illustrate the MFI of the following steps: 
ANXA5-A488, (ANXA5-A488+ANXA5-A546) and (ANXA5-A546+ANXA5-A647) in the 
Alexa 488, 546 and 647 channel, respectively. In the two-step FRET, there is a small 
decrease in MFI of Alexa 488 (left plot) and Alexa 546 (middle plot) and an increase 
in MFI of Alexa 647 (right plot). All experiments (A-D) were performed with 5 µM 
MLVs in the presence of 2.5 mM Ca2+.
Figure S5. ANXA1 interactions on the surface of ionomycin-activated COS1 
cells determined by confocal FRET measurements. A, Images are shown of 
ANXA1-A546 (20 nM; green) and ANXA1-A647 (20 nM; red) fluorescence intensities 
with the donor channel and acceptor channel setting, respectively. The uncorrected 
FRET signal (yellow) illustrates the emitted signal of ANXA1-A647 upon excitation 
with the laser of the donor (543 nm). Control experiments were performed in the 
presence of 10 mM EDTA (bottom panel). B, The FRET signal was corrected for 
spectral bleed through (“FRET index” image). The “Colocalization diagram” shows 
co-localization of labeled ANXA1 on the membrane of COS1 cells and the mean of 
FRET indices. Scale bar 20 µm. 
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Figure S6. Effects of unlabeled ANXA5 on the binding (A) and 2D network 
(B) of labeled ANXA5. A, Unlabeled ANXA5 at 20 nM and 100 nM concentrations 
interfere in the binding of ANXA5-A546 (20 nM) to ionomycin-activated platelets. 
ANXA5-A546 was excited by the 532 nm laser. B, Addition of unlabeled ANXA5 
(20 nM) to the membrane-bound ANXA5 lattices affected the FRET signal (left dot 
plot). Increasing the concentration of unlabeled ANXA5 up to 100 nM resulted in 
abolished FRET signal but not the binding of labeled ANXA5 (middle dot plot). The 
emitted signal of the acceptor (ANXA5-A647) is shown upon excitation of the donor 
(ANXA5-A546) with the 532 nm laser. Results are representative of at least four 
independent experiments with platelets obtained from different donors. Experiments 
were performed with 1.0-2.0 × 105 ionomycin-activated platelets and 2.5 mM Ca2+. 
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Annexin A5 (ANXA5), a Ca2+- and phospholipid-binding protein of the 
annexin family, has strong anticoagulant and antithrombotic properties as 
well as antiinflammatory features, both in vitro and in vivo [1-5]. Its exact 
physiological function, however, has not been fully understood. Circulating 
ANXA5 levels are low in healthy individuals (0 to 5 ng/mL) [6]. Elevated 
plasma ANXA5 levels reported in patients with acute myocardial infarction, 
severe trauma [7,8] and sickle cell disease [9] are shown to reflect the 
severity of cell damage. Reduced plasma ANXA5 levels are associated with 
the presence and extent of atherosclerotic plaques [10] as well as recurrent 
pregnancy loss [11]. 
The contribution of genetic variations to the variability of plasma ANXA5 
levels is poorly understood. Gonzalez-Conejero and colleagues reported that 
the single nucleotide polymorphism (SNP) rs11575945, which is located one 
nucleotide upstream of the ATG initiation codon in exon 2 of the ANXA5 gene, 
protects against both a first myocardial infarction and a new thrombotic event 
during 36 months follow-up [12,13]. The authors suggested a protective role 
of elevated plasma ANXA5 levels in the occurrence of arterial thrombosis. 
However, Marilyn Kozak questioned increased translation efficiency by the 
minor rs11575945T-allele, demonstrating its small contribution to initiation 
of translation [14,15], and van Heerde and colleagues showed normal 
levels of circulating ANXA5 in T-allele carriers [16]. Recently, Bogdanova et 
al. [17] described the M2 haplotype, a combination of minor alleles of four 
promoter SNPs (rs112782763, rs28717001, rs28651243, rs113588187). 
The M2 haplotype is related to reduction of ANXA5 gene promoter activity 
in vitro [17] as well as ANXA5 mRNA levels in placenta ex vivo [18,19]. 
The presence of this haplotype is associated with thrombotic obstetric 
complications [17,20,21] and deep venous thrombosis [22].
Here we investigated whether ANXA5 genetic variations influence plasma 
levels of ANXA5. To take into account all genetic information, a 496-bp 
promoter region and exon 2 of the ANXA5 gene were sequenced in healthy 
individuals. Subsequently, haplotypes were inferred, and the association of 
common haplotypes with circulating ANXA5 levels was investigated. 
The study population included 137 healthy individuals: 58 blood donors 
attending the Sanquin Blood bank, region South East, Nijmegen and 79 
individuals recruited by Radboudumc. In accordance with the Declaration 
of Helsinki, written informed consent was obtained from each participant. 
Plasma samples were obtained by centrifugation of 3.2% citrated blood 
at 4200g for 10 minutes. Circulating ANXA5 levels were determined by 
a Zymutest ANXA5 ELISA (Hyphen Biomed) following manufacturer’s 
instructions. Genomic DNA was isolated from peripheral leukocytes. A 496-
bp fragment of the ANXA5 promoter (261 base pairs upstream and 235 base 
pairs downstream of the first transcription start point) was amplified by 
polymerase chain reaction using two oligonucleotide primers as described 
[17]. Exon 2 with flanking regions (130-bp fragment) was amplified as 
previously described [23]. Purified amplicons were sequenced using the 
BigDye Terminator
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v3.1 Cycle Sequencing Kit (Applied Biosystems) and analyzed on the ABI 
3730 PRISM DNA Analyzer (Applied Biosystems). For statistical analyses, 
we used only complete data of 131 subjects. Hardy-Weinberg equilibrium 
for each SNP was evaluated by a chi-square test. Haploview software was 
used to estimate the degree of linkage disequilibrium (r2 values) between 
all SNP pairs and to determine haplotypes (H) [24]. Haplotypes were 
assigned manually to all individuals. Skewed distributed ANXA5 levels 
were 10log-transformed prior to statistical analyses. Differences between 
the log-transformed values were tested by t-test. All values reported were 
reconverted to geometric means with the appropriate 95% confidence 
interval (CI). Two-sided P-values <0.05 were considered statistically 
significant. Sequence analysis of a 496-bp fragment of the ANXA5 promoter 
in 67 male (mean 41.5±10.0 years, ±SD) and 64 female (mean 41.8±9.6 
years, ±SD) healthy subjects confirmed the presence of four SNPs (SNP2 
rs112782763, SNP3 rs28717001, SNP4 rs28651243, SNP5 rs113588187) 
previously reported by Bogdanova et al. [17]. Additionally, two other 
genetic variants (SNP1 rs62319820, SNP6 rs1050606) were detected. All 
participants were also examined for the presence of SNP7 rs11575945 
in exon 2. The genotype distributions of all seven SNPs were in Hardy-
Weinberg equilibrium. Haploview analysis showed a high degree of linkage 
disequilibrium between all variants except for SNP1 and SNP6. SNP3 and 
SNP4 as well as SNP2, SNP5 and SNP7 were completely linked (r2=1). 
Because of the tight linkage, only four common haplotypes (frequency 
>1%) were present (Table 1). 
Hx indicates all haplotypes except for the one given; CI, confidence 
interval.*P<0.05 as compared with non-carriers.
Table 2. Association of ANXA5 haplotypes with plasma ANXA5 levels. 
Haplotype Number (%)n=131
Geometric mean ANXA5 
(95% CI),ng/mL
Haplotype 1
H1H1 31 (23.7) 0.94 (0.82-1.07)
H1Hx 71 (54.2) 0.93 (0.84-1.02)
HxHx 29 (22.1) 0.77 (0.61-0.96)
Haplotype 2
H2H2 10 (7.6) 0.52 (0.44-0.62)*
H2Hx 56 (42.7) 0.85 (0.76-0.94)*
HxHx 65 (49.6) 1.01 (0.91-1.13)
Haplotype 3
H3H3 1 (0.8) 0.60
H3Hx 27 (20.6) 0.82 (0.67-1.02)
HxHx 103 (78.6) 0.92 (0.84-1.00)
Haplotype 4
H4H4 1 (0.8) 1.56
H4Hx 21 (16.0) 1.40 (1.14-1.72)*
HxHx 109 (83.2) 0.81 (0.76-0.88)
ANXA5 polymorphisms & plasma levels 
67
Plasma ANXA5 levels did not differ between male and female subjects 
(mean 0.88 ng/mL, 95% CI: 0.79-0.98 versus mean 0.90 ng/mL, 95% CI: 
0.80-1.01). ANXA5 levels were not influenced by age (linear regression; 
P=0.32). Haplotypes H1 and H2, the two major haplotypes, included 
Bogdanova’s  haplotype N [17]. Interestingly, haplotype H2 was associated 
with decreased plasma ANXA5 levels (Table 2). Homozygous H2 carriers 
had lower ANXA5 levels (mean 0.52 ng/mL, 95% CI: 0.44-0.62) than 
heterozygous H2 carriers (mean 0.85 ng/mL, 95% CI: 0.76-0.94) and 
non-H2 subjects (mean 1.01 ng/mL, 95% CI: 0.91-1.13). Since H1 and H2 
were only discriminated by SNP6, it is suggestive that the G-allele of this 
SNP is responsible for the decreased ANXA5 levels. Indeed, homozygous GG 
carriers had slightly lower ANXA5 levels (mean 0.76 ng/mL, 95% CI: 0.60-
0.96) than TG heterozygotes (mean 0.92 ng/mL, 95% CI: 0.84-1.02) and 
TT carriers (mean 0.94 ng/mL, 95% CI: 0.82-1.07) (P>0.05) (Table S1). 
However, the rs1050606G-allele was also present in haplotypes H3 and H4, 
which were not associated with decreased ANXA5 levels. The contribution 
of the G allele to a reduction of plasma ANXA5 needs to be further studied 
since the rs1050606G-allele is recently identified as a potential novel risk 
factor for recurrent pregnancy loss in the Japanese population [21]. 
Figure 1. Association of individual ANXA5 SNPs with plasma ANXA5 levels.  
Due to complete linkage between SNP2 rs112782763, SNP5 rs113588187 and SNP7 
rs11575945 as well as between SNP3 rs28717001 and SNP4 rs28651243, only the 
results for SNP2 genotypes and SNP3 genotypes, respectively, are shown. The results 
were plotted on a log10-scale y axis. Horizontal lines represent means. The means of 
log-transformed ANXA5 levels for different groups were compared by t-test.  
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Another important result was the association of haplotype H4 with increased 
levels of ANXA5. H4 heterozygotes had significantly higher circulating ANXA5 
levels than non-H4 carriers (mean 1.40 ng/mL, 95% CI: 1.14-1.72 versus 
mean 0.81 ng/mL, 95% CI: 0.76-0.88, respectively, P<0.001). Haplotype 
H4 is an extension of the M1 haplotype [17]. The possession of the minor 
T-allele of SNP1 rs62319820, which was unique for haplotype H4, seemed 
to be a major contributor to higher plasma ANXA5 levels (Figure 1, Table 
S1). Our results contradict findings of Bogdanova et al. who demonstrated 
reduced ANXA5 promoter activity for the M1 haplotype [17]. The absence of 
the rs62319820T-allele in their luciferase reporter constructs could be one 
of the reasons for this contradiction. 
Haplotype H3 was the third major haplotype in our population. Circulating 
ANXA5 levels in H3 heterozygotes (mean 0.82 ng/mL, 95% CI: 0.67-1.02) 
tended to be lower compared with those in non-H3 carriers (mean 0.92 
ng/mL, 95% CI: 0.84-1.00) (P=0.27). In line with our previous finding 
[16], the minor rs11575945T-allele (SNP7) did not significantly influence 
ANXA5 levels (Figure 1, Table S1). Haplotype H3 is an extension of the M2 
haplotype. Although the presence of the M2 allele of ANXA5 was found to be 
associated with decreased ANXA5 mRNA levels in placenta ex vivo [18,19], 
no correlation was observed with protein levels in the same samples [19]. 
In the present study, we showed no clear evidence for decreased plasma 
ANXA5 levels in H3 carriers. However, since the M2 haplotype of ANXA5 is 
associated with placental thrombosis [17,20,21] as well as deep venous 
thrombosis [22], slightly lower plasma ANXA5 levels found in H3 carriers 
need more attention and further investigation in larger studies.  
In conclusion, we reported that ANXA5 haplotypes may determine the 
variability of plasma ANXA5 levels in healthy subjects. More research is 
warranted to confirm our findings. Clarifying the relevance of the variability 
of circulating ANXA5 levels may be of clinical importance.
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Table S1. Plasma ANXA5 levels in different genotype groups. 
Polymorphism                   Genotype
                            Number 
(n=131)
Geometric mean ANXA5  
(95% CI), (ng/mL)
SNP1 rs62319820 CC 109 0.81 (0.76-0.88)
CT 21 1.40 (1.14-1.72)*
TT 1 1.56
SNP2 rs112782763 GG 103 0.92 (0.84-0.99)
GA 27 0.82 (0.67-1.02)
AA 1 0.6
SNP3 rs28717001 AA 84 0.85 (0.78-0.93)
AC 41 0.91 (0.79-1.05)
CC 6 1.57 (0.73-3.38)
SNP4 rs28651243 TT 84 0.84 (0.77-0.92)
TC 41 0.91 (0.79-1.05)
CC 6 1.57 (0.73-3.38)
SNP5 rs113588187 GG 103 0.92 (0.84-0.99)
GA 27 0.82 (0.67-1.02)
AA 1 0.6
SNP6 rs1050606 TT 31 0.94 (0.82-1.07)
TG 72 0.92 (0.84-1.02)
GG 28 0.76 (0.60-0.96)
SNP7 rs11575945 CC 103 0.92 (0.84-0.99)
CT 27 0.82 (0.67-1.02)
TT 1 0.6
CI means confidence interval.       
*P<0.001 as compared with the wild-type.
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ABSTRACT
Objective: Annexin A5 (ANXA5) has been suggested to possess 
antiatherogenic properties. We investigated whether ANXA5 genetic 
variations and plasma ANXA5 levels were associated with carotid 
atherosclerosis and contributed to cardiovascular disease (CVD) risk in 
patients with familial hypercholesterolemia (FH).     
Methods: We sequenced the promoter region and exon 2 of ANXA5 in 284 FH 
patients from the ASAP (Atorvastatin versus Simvastatin on Atherosclerosis 
Progression) trial. Common haplotypes (H) were constructed based on 
seven single nucleotide polymorphisms (SNPs). We studied whether plasma 
ANXA5 levels or ANXA5 haplotypes were associated with the extent of 
atherosclerosis (evaluated by carotid intima-media thickness (IMT). The 
association between ANXA5 haplotypes and the risk for CVD events was 
investigated in 1730 FH patients from the GIRaFH (Genetic Identification of 
Risk factors in Familial Hypercholesterolemia) study.    
Results: In ASAP, individuals carrying the ANXA5 haplotype H2 exhibited 
lower plasma ANXA5 levels, whereas H4 carriers had increased levels of 
circulating ANXA5 compared to non-carriers. Plasma ANXA5 levels were not 
associated with carotid IMT. None of the four ANXA5 haplotypes  correlated 
with the age-related IMT progression (ASAP study) or contributed to CVD 
risk (GIRaFH cohort).         
Conclusions: Both ANXA5 haplotypes and plasma ANXA5 levels were not 
associated with carotid IMT progression or CVD risk in FH patients.  
ANXA5 in familial hypercholesterolemia
75
INTRODUCTION 
Annexin A5 (ANXA5), a calcium-dependent phospholipid-binding protein, 
is highly expressed by endothelial cells [1] and present in atherosclerotic 
plaques, especially at sites with high prothrombotic potential [2;3]. ANXA5 
is considered to have antithrombotic capacities, by virtue of its scavenging 
effect on anionic phospholipids and downregulation of the surface 
expression of tissue factor [4-7]. Since atherosclerotic vessel walls contain 
apoptotic and activated cells that expose negatively charged phospholipids 
[8;9], ANXA5 may form an antithrombotic shield on these cell surfaces, 
thereby restricting their tendency to induce thrombus formation. Apart from 
its antithrombotic property, ANXA5 has also been shown to exert potent 
anti-inflammatory activities, which are attributed to downregulation of 
interferon-gamma (IFN-γ)-mediated inflammatory cellular responses [10]. 
In addition, ANXA5 inhibits phospholipase A2 activity, an enzyme essential 
for the generation of pro-inflammatory mediators [11;12]. Concomitantly, 
it has been shown that ANXA5 binds to oxidized low-density lipoprotein 
(oxLDL) thereby preventing the ox-LDL induced procoagulant and pro-
inflammatory effects [13]. In proatherogenic ApoE-/- mouse models, it has 
been demonstrated that ANXA5 administration reduces local inflammation 
and vascular remodeling as well as improves vascular function, confirming 
the notion that ANXA5 has antiatherogenic effects [14;15]. 
Additionally to the biochemical properties of ANXA5, attention is paid to a 
number of single nucleotide polymorphisms (SNPs) in ANXA5 but so far, 
little is known about their relative contribution to cardiovascular disease 
(CVD) risk. The minor T-allele of rs1131239, which is located in the Kozak 
sequence (i.e., one nucleotide upstream of the ATG initiation codon) in exon 
2 of ANXA5, is associated with a decreased risk of myocardial infarction 
under the age of 45 [16] and a lower risk of a new thrombotic event during 
36 months follow-up [17]. Increased plasma ANXA5 levels in rs1131239T-
allele carriers were found to be protective in the occurrence of arterial 
thrombosis. Subsequent studies, however, were unable to replicate these 
findings [18;19]. Moreover, ANXA5 intronic SNPs rs4833229 and rs6830321 
are    associated with increased restenosis risk in patients undergoing 
percutaneous coronary intervention for atherosclerosis [15]. Recently, 
Bogdanova and colleagues described the three ANXA5 promoter haplotypes 
(N, M1 and M2) and found that the ANXA5 M2 haplotype consisting of 
the minor alleles of four SNPs (rs112782763, rs28717001, rs28651243, 
rs113588187) reduces ANXA5 promoter activity in a luciferase reporter gene 
assay [20]. While the ANXA5 M2 haplotype has been linked to thrombotic 
obstetric complications [20-22], its contribution to CVD risk remains to be 
determined. More recently, we demonstrated that plasma ANXA5 levels in 
healthy individuals are affected by genetic variants in ANXA5. Haplotype H2 
was associated with significantly decreased plasma ANXA5 levels whereas 
haplotype H4 was associated with increased plasma ANXA5 levels [23]. Our 
defined haplotypes H3 and H4 are extensions of the M2 and M1 haplotypes, 
and haplotypes H1 and H2 include the wild-type haplotype N described 
by Bogdanova et al. The clinical relevance of plasma ANXA5 levels on 
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atherosclerotic CVD burden is yet unclear. Hypothetically, higher plasma 
ANXA5 levels are expected to have a protective role, whereas lower ANXA5 
levels are likely to be associated with progression of atherosclerosis (i.e., 
an increased plaque formation and an increased CVD risk). In this context, 
it has been shown that circulating ANXA5 levels correlate inversely with the 
severity of angiographically determined coronary stenosis and the extent of 
atherosclerotic plaque formation [24]. 
In this study, we set out to test the hypothesis that plasma ANXA5 levels 
and ANXA5 genetic variations are associated with carotid atherosclerosis 
and contribute to CVD risk in patients with familial hypercholesterolemia 
(FH), an autosomal dominant disease characterized by high plasma levels 
of low-density lipoprotein cholesterol (LDL-C) and an increased CVD risk. 
MATERIALS AND METHODS
ASAP trial        
ASAP (Atorvastatin versus Simvastatin on Atherosclerosis Progression) 
was a randomized, double-blind, two-center (Amsterdam and Nijmegen) 
study [25]. A total of 325 FH patients aged 30-70 years participated in the 
ASAP study. Eligibility of the patients was based on plasma LDL-C levels 
(>5.5 mmol/L) and the absence of significant clinical, hematological and 
biochemical abnormalities. Exclusion criteria were coronary heart disease 
within previous 3 months, hypertension, secondary hyperlipidemia, 
diabetes and other endocrine diseases [25]. The Ethics Committees of 
both trial centers approved the study. In the present study, we used only 
data collected after an 8-week placebo run-in period before starting any 
intervention with statins. Carotid IMT measurements were performed as 
described [25]. Briefly, ultrasound examinations were performed using a 
Biosound Phase-2 real time scanner (BiosoundEsaote, USA) equipped with 
a 10 MHz transducer. Three 10 mm segments were scanned bilaterally: the 
distal portion of the common carotid artery (CCA), the carotid bifurcation 
(BUL) and the proximal portion of the internal carotid artery (ICA). Both 
near and far walls were evaluated. Mean carotid IMT was calculated as 
averaged over anterior and posterior walls in the CCA, BUL and the posterior 
wall of the ICA, bilaterally (i.e. the mean from available 10 sites). Of the 
325 participants, genomic DNA of 299 patients was available for sequencing 
in this study.
GIRaFH cohort         
GIRaFH (Genetic Identification of Risk factors in Familial Hypercholesterole-
mia) was a retrospective, multicenter (27 Dutch lipid clinics) study including 
2400 unrelated heterozygous FH patients of Caucasian origin as previously 
described [26]. The mean follow-up period was 5 years. The primary out-
come of the study was the combination of cardiovascular mortality and CVD 
as described [26]. Genomic DNA of 1994 FH patients was available for ge-
notyping in the present study. The Ethics Institutional Review Board of each 
participating hospital approved the study.
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Genetic analysis                      
In the ASAP trial, a 496-bp fragment of the ANXA5 promoter (261 base 
pairs upstream and 235 base pairs downstream of the first transcription 
start point) was amplified by polymerase chain reaction (PCR) using two 
oligonucleotide primers: forward 5’CCGAGCCCTGGACAGCTCCCCA-3’ and 
reverse 5’-GCCCCGCGACCACGCTCTCCTCT-3’ as described [20]. Exon 2 with 
flanking regions (130-bp fragment) was amplified as previously described 
[27]. Purified amplicons were sequenced using the BigDye Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems) and analyzed on the ABI 3730 
PRISM DNA Analyzer (Applied Biosystems). We evaluated six SNPs within 
the ANXA5 promoter (rs62319820, rs112782763, rs28717001, rs28651243, 
rs113588187, rs1050606) and rs1131239 located in the Kozak sequence 
(exon 2) to reconstruct the four known haplotypes as described [23]. 
Successful sequencing of the promoter region and exon 2 was possible in 
284 (95.0%) and 298 (99.7%) patients, respectively.             
In the GIRaFH study, we genotyped four ANXA5 SNPs (rs62319820, 
rs113588187, rs1050606, rs1131239) to reconstruct the four common 
ANXA5 haplotypes. Genotyping was carried out using predesigned or custom 
TaqMan primers with FAM or VIC as fluorophores (Applied Biosystems, USA). 
SNP genotyping success rates were 93.5% (1864 patients) for rs62319820, 
94.6% (1886 patients) for rs113588187, 92.8% (1850 patients) for 
rs1050606 and 95.9% for rs1131239 (1912 patients). 
Biochemical measurements      
Total cholesterol, (calculated) LDL-C, high-density lipoprotein cholesterol 
(HDL-C) and triglycerides were determined by standard methods as 
previously described [25;26]. High-sensitivity C-reactive protein (hs-CRP) 
was measured in citrated plasma by a commercially available enzyme-
immunoassay (Dako, Denmark) as described [28]. Plasma ANXA5 levels 
were measured in 141 participants from the ASAP study using a commercially 
available Zymutest ANXA5 ELISA (Hyphen Biomed). The intra- and inter-
assay coefficients of variation (CV) for ANXA5 measurements were 3.1% 
and 3.8% respectively.  
Statistical analyses       
The means of continuous variables of different groups were compared by 
unpaired t-test or one-way ANOVA as appropriate; the χ2 test was used 
for categorical variables. Hardy-Weinberg equilibrium for each SNP was 
evaluated by the χ2 test. Haploview software (Broad Institute, Cambridge, 
MA, USA) was used to estimate the degree of linkage disequilibrium (LD; r2 
values) between all SNP pairs and to determine haplotypes (H). Haplotypes 
were assigned manually to the subjects with complete genetic data as 
described [23]. Only common haplotypes (frequency >1%) were used for 
statistical analyses. In the present study, we included 284 FH patients from 
the ASAP study as well as 1730 FH patients from the GIRaFH cohort in whom 
common haplotypes were constructed. Power calculations were performed 
to determine the minimal odds ratio detectable with a power >80% (Quanto 
version 1.2.4 software). 
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In the ASAP study, the age-related IMT progression in different ANXA5 
haplotype groups was estimated by a linear regression analysis (SAS version 
6.12 software). The interaction term (haplotype group x age) was entered 
in the regression models to account for different IMT progression rates with 
age between ANXA5 haplotype groups. The variable gender associated 
with IMT in a univariable regression model was included in the multiple 
regression model. The regression coefficient β represents IMT increase 
with age (millimeters per year, mm/year). Comparison of the regression 
slopes between groups was performed by testing of the interaction terms. 
In the single SNP analyses, the slopes of the major allele carriers were 
taken as the reference. In the haplotype model, we performed one-way 
ANOVA for each haplotype to address the difference in regression slopes 
within the haplotype group. To control for the familywise error rate over 
the 4 haplotypes, the level of significance for each interaction test was set 
at 0.05/4=0.0125 (Bonferroni correction for multiple testing). When the 
p-value of the interaction test was less than 0.0125, further analysis with 
t-test was warranted to assess the difference between two specific slopes 
(e.g. carriers and non-carriers). 
The distribution of plasma ANXA5 levels was normalized by ln-transformation 
and used in all analyses. A one-way ANOVA followed by the Bonferroni Post 
Hoc test was performed to assess differences in plasma ANXA5 levels within 
haplotype groups. The Bonferroni threshold for correction for multiple 
testing was estimated at 0.05/4=0.0125, taking into account the number of 
haplotypes (four). All values reported were reconverted to geometric means 
with the appropriate 95% confidence interval (CI). The association of plasma 
ANXA5 levels with carotid IMT was tested by a linear regression analysis 
and Pearson correlation. To test the relationship between circulating ANXA5 
levels and total cholesterol, triglycerides, HDL-C, LDL-C and hs-CRP, we 
calculated Pearson’s correlation coefficients. Skewed distributed variables 
(triglycerides and hs-CRP) were also ln-transformed prior to analysis. 
In the GIRaFH study, the contribution of ANXA5 variations to CVD risk was 
examined by Cox proportional hazards regression. The follow-up period 
started at birth and ended at the first occurrence of established fatal or 
non-fatal CVD event. Patients without CVD were censored at the date of the 
last lipid clinic visit or at the date of death attributable to other causes than 
CVD. In all analyses, we included year of birth, sex and smoking in the Cox 
regression models.  
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RESULTS 
Patient characteristics of the ASAP study     
Clinical characteristics of 284 FH patients participating in the ASAP study 
are shown in Table 1. Baseline characteristics of the study group were 
comparable to those of the total ASAP cohort (data not shown) [25]. The 
population consisted of Caucasian individuals with the mean age of 48.4 
years; sixty percent of the subjects were female. Twenty-nine percent of 
the patients had a history of CVD, and 60.6% individuals were smokers 
(former and current). 
Table 1. Baseline characteristics of FH patients                                                            
from the ASAP study. 
Characteristics n=284
Age, years 48.4 ± 10.4
Gender, male/female, n (%) 114 (40.1)/170 (59.9)
History of CVD, n (%) 82 (28.9)
Smoking, n (%)†  172 (60.6)
Body mass index, kg/m2 25.7 ± 3.5
Total cholesterol, mmol/L 10.13 ± 1.99
HDL-C, mmol/L 1.16 ± 0.31
LDL-C, mmol/L 8.17 ± 1.96
Triglycerides, mmol/L 1.64 (1.12-2.28)
Hs-CRP, mg/L 2.2 (0.8-4.6)
Carotid IMT, mm* 0.93 ± 0.22
CCA-IMT, mm* 0.87 ± 0.17
         
Values are presented as means±SD or n (%). Triglycerides and hs-CRP are given as 
median  (interquartile range).       
†Previous and current smokers.      
*Data of 282 patients are shown.      
CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; IMT, 
intima-media thickness; CCA-IMT, common carotid artery intima-media thickness; 
mm, millimeter.
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Effect of plasma ANXA5 levels on progression of atherosclerosis 
in ASAP         
 We investigated the association between plasma ANXA5 levels and carotid 
IMT in a subset of subjects (n=141) randomly selected from the ASAP co-
hort. Plasma ANXA5 levels did not differ significantly between male (n=50) 
and female (n=91) subjects (geometric mean 13.17 µg/L, 95% CI: 11.01-
15.75 versus 12.81 µg/L, 95% CI: 10.98-14.94, p=0.82) and were not 
influenced by age (linear regression: β=-0.009, p=0.10). Plasma ANXA5 le-
vels did not correlate with cholesterol (total, HDL, LDL) levels, triglycerides 
levels and an inflammation marker hs-CRP (Table S1). No association was 
found between plasma ANXA5 and carotid IMT (linear regression: β=-0.01, 
p=0.8). 
ANXA5 SNPs and haplotypes in ASAP      
Table S2 shows the minor allele frequencies and the genotype frequencies 
of the seven SNPs in ANXA5 in the ASAP cohort. All SNPs were in Hardy-
Weinberg equilibrium. Haploview analysis showed a high degree of linkage 
disequilibrium between all SNPs except for SNP1 and SNP6 (Figure S1). 
SNP3 and SNP4 as well as SNP2 and SNP5 were completely linked (r2=1). 
SNP7 was tightly linked to SNP2 and SNP5 (r2=0.85). Based on the seven 
polymorphisms, the four previously reported common haplotypes were 
constructed (Table 2). Haplotype H1, the most frequent haplotype (51%), 
was composed of the major alleles of all seven polymorphisms. Haplotype 
H2 was discriminated from haplotype H1 by rs1050606 (SNP6). Haplotype 
H3 was the third major haplotype (9.9%) and consisted of the major allele 
of rs62319820 and the minor alleles of the other polymorphisms. Haplotype 
H4 compiled the minor alleles of rs62319820, rs28717001, rs28651243, 
rs1050606 and the major alleles of the three other SNPs. Besides the 
common haplotypes, three rare haplotypes (H5, H6, H7; frequency <1%) 
were identified in nine patients (Table 2). They were excluded for further 
analyses.
ANXA5 haplotypes and plasma ANXA5 levels   
Among the ASAP participants, a one-way ANOVA corrected for multiple testing 
revealed significant differences in plasma ANXA5 levels within haplotypes 
H2 and H4 (Table 3). Haplotype H2 was associated with decreased plasma 
ANXA5 levels. Post Hoc analysis indicated that homozygous H2 carriers had 
lower ANXA5 levels (mean 6.20 µg/L, 95% CI: 4.24-9.05) compared to 
heterozygous subjects (mean 13.33 µg/L, 95% CI: 11.13-15.94, p<0.001) 
and non-H2 subjects (mean 14.25 µg/L, 95% CI: 12.18-16.69, p<0.001). 
There were no differences in plasma ANXA5 levels between H2 heterozygotes 
and non-H2 individuals (p=0.568). 
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Furthermore, non-H4 individuals (mean 10.98 µg/L, 95% CI: 9.73-12.39) 
had a 2-fold lower circulating ANXA5 levels compared to homozygous 
H4 carriers (mean 29.67 µg/L, 95% CI: 15.53-44.44, p=0.007) and 
heterozygous H4 subjects (mean 24.48 µg/L, 95% CI: 19.99-30.02, 
p<0.001). Plasma ANXA5 levels were not different between homozygotes 
for H4 and heterozygotes for H4 (p=0.615).   
With respect to the relationship of carotid IMT with lower plasma ANXA5 
levels in H2 carriers as well as with higher plasma ANXA5 levels in H4 
carriers, additional analyses did not reveal any statistical evidence for such 
association which might also be explained by the low number of cases in 
these subgroup analyses.   
          
         
Table 3. Association of ANXA5 haplotypes with plasma ANXA5 levels in FH 
patients from the ASAP study. 
Haplotype Number n=141
Geometric mean    
ANXA5 (95% CI), µg/L
Overall p-
value
Haplotype 1 0.875
H1H1 36 13.42 (10.90-16.53)
H1Hx 69 13.00 (11.19-15.09)
Non-H1 36 12.33 (9.07-16.78)
Haplotype 2 0.0005
H2H2 12 6.20 (4.24-9.05)
H2Hx 56 13.33 (11.13-15.94)
Non-H2 73 14.25 (12.18-16.69)
Haplotype 3 0.018
H3Hx 30 9.89 (7.48-13.09)
Non-H3 111 13.90 (12.24-15.77)
Haplotype 4 <0.0001
H4H4 3 29.67 (15.53-44.44)
H4Hx 25 24.48 (19.99-30.02)
Non-H4 113 10.98 (9.73-12.39)
Hx indicates all haplotypes except for the one given; CI, confidence interval.  
Differences were assessed by one-way ANOVA; the threshold for Bonferroni 
correction for multiple testing: 0.05/4 haplotype groups=0.0125
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ANXA5 haplotypes and progression of atherosclerosis in ASAP 
A linear regression analysis approach was applied to study the association 
between ANXA5 variations and age-related carotid IMT (i.e., the average 
of available IMT values measured in three carotid segments). None of 
the ANXA5 SNPs was associated with the age-related increase in carotid 
IMT (Table S3). Of the four haplotypes studied the ANXA5 haplotype H3 
tended to be associated with more rapid carotid IMT increase with age.
Heterozygous haplotype H3 carriers tended to have a larger arterial wall 
thickening over time compared with non-H3 subjects, in both the unadjusted 
model (β=0.0129 mm/year versus β=0.0072 mm/year, p=0.053) and after 
adjustment for gender (β=0.0135 mm/year versus β=0.0076 mm/year, 
p=0.044) (Table 4). However, this association did not reach Bonferroni-
corrected statistical significance level. Other ANXA5 haplotypes did not 
demonstrate any association with the age-related IMT progression (Table 
4).
Table 4. Association of ANXA5 haplotypes with the age-related carotid IMT 
progression in FH patients from the ASAP trial.
Unadjusted model Adjusted model*
Haplotype b (SE) Overall p-value b 
 (SE) Overall p-value
Haplotype H1 0.27 0.30
H1H1 (n=77) 0.0062 (0.0024) 0.0066 (0.0023)
H1Hx (n=128) 0.0077 (0.0017) 0.0083 (0.0017)
Non-H1 (n=68) 0.0111 (0.0021) 0.0113 (0.0021)
Haplotype H2 0.89 0.93
H2H2 (n=27) 0.0100 (0.0038) 0.0100 (0.0037)
H2Hx (n=107) 0.0081 (0.0019) 0.0084 (0.0018)
Non-H2(n=139) 0.0081 (0.0017) 0.0087 (0.0016)
Haplotype H3 0.053 0.044
H3Hx (n=54) 0.0129 (0.0026) 0.0135 (0.0026)
Non-H3 (n=219) 0.0072 (0.0013) 0.0076 (0.0013)
Haplotype H4 0.48 0.55
H4H4 (n=4) 0.0153 (0.0067) 0.0153 (0.0066)
H4Hx (n=41) 0.0067 (0.0027) 0.0075 (0.0026)
Non-H4 (n=228) 0.0084 (0.0013) 0.0088 (0.0013)
Results of the linear regression analysis (n=273) are shown. β indicates regression 
coefficient; β represents IMT increase with age (mm/year).*Adjusted for gender. 
Hx means all haplotypes except for the one given; IMT, intima-media thickness; SE, 
standard error.  
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ANXA5 haplotypes and the risk of cardiovascular events      
To confirm the results from the ASAP study, we investigated the contribution 
of ANXA5 variations to the risk of cardiovascular events in an independent 
cohort of 1730 FH patients from the GIRaFH study. Four ANXA5 SNPs 
covering the four common ANXA5 haplotypes were genotyped. All SNPs 
were in Hardy-Weinberg equilibrium (Table S4). Neither individual SNPs 
nor the common haplotypes were associated with CVD risk (Table 5 
and Table S5). No significant associations were found either with only 
homozygous wild type carriers (i.e., H1H1) as a reference category (data 
not shown). Subgroup analysis showed no significant associations between 
ANXA5 variations and the history of myocardial infarction, angina pectoris, 
stroke/TIA or cardiac death (data not shown). 
Table 5. Association of ANXA5 haplotypes with CVD risk in FH patients from 
the GIRaFH study.
Haplotype Number of sub-jects, n=1730
CVD+ (n=548)
n (%) HR (95% CI)
* p-value
Haplotype H1
Non-H1 482 150 (27.4) 1.0
H1Hx 883 278 (50.7) 0.9 (0.7-1.1) 0.5
H1H1 365 120 (21.9) 1.0 (0.8-1.3) 1.0
Haplotype H2
Non-H2 777 257 (46.9) 1.0
H2Hx 727 217 (39.6) 0.8 (0.7-1.0) 0.08
H2H2 226 74 (13.5) 1.0 (0.8-1.3) 0.9
Haplotype H3
Non-H3 1358 424 (77.4) 1.0
H3Hx 349 119 (21.7) 1.2 (1.0-1.5) 0.1
H3H3 23 5 (0.9) 0.8 (0.3-1.9) 0.6
Haplotype H4
Non-H4 1463 465 (84.8) 1.0
H4Hx 261 82 (15.0) 1.0 (0.8-1.3) 0.7
H4H4 6 1 (0.2) NA
CVD+, patients with cardiovascular disease; Hx, all haplotypes except for the one 
given; HR, hazard ratio; CI, confidence interval; NA, not applicable. HRs were 
calculated with HxHx (i.e., non-H1, non-H2, non-H3 and non-H4) as a reference 
category (HR=1.0).*Adjusted for sex, year of birth and smoking.
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DISCUSSION 
We investigated whether ANXA5 gene variants and plasma ANXA5 levels 
were associated with atherosclerosis progression or CVD risk in FH patients. 
In our study, plasma ANXA5 levels were not associated with IMT. ANXA5 
haplotypes were associated with plasma ANXA5 levels, but did not correlate 
with carotid IMT parameters in the ASAP study or CVD risk in the GIRaFH 
cohort. Our data, therefore, showed a lack of association of ANXA5 protein 
levels as well as ANXA5 haplotypes with carotid IMT progression or the risk 
of cardiovascular events in FH patients. 
A possible role of ANXA5 in the pathophysiology of atherosclerosis has been 
postulated based on the observations that ANXA5 has anti-atherogenic 
and anti-inflammatory properties and is found in high concentrations in 
atherosclerotic plaques. Of note, it has been shown that the uptake of labeled 
recombinant ANXA5 by atherosclerotic plaques correlates with the extent 
of apoptosis [29]. In this regard, reduced plasma ANXA5 levels in patients 
with severe coronary stenosis have been proposed to reflect the presence 
and extent of CVD [24]. Moreover, in systemic lupus erythematosus (SLE) 
patients, antiphospholipid antibody-mediated reduced binding of ANXA5 
to endothelial cells was found to be associated with IMT and it has been 
suggested to be an important mechanism in SLE-related CVD [3]. These 
observations prompted us to investigate whether ANXA5 plasma levels and 
ANXA5 gene variants are associated with atherosclerosis progression in a 
high risk population of FH patients. The FH patient population was chosen 
because of its homogeneity, characterized by elevated LDL-C levels and 
an increased risk of premature CVD [30]. We hypothesized that ANXA5 
variants associated with circulating plasma ANXA5 levels would predict 
clinical features of atherosclerosis and CVD risk in FH patients. 
The four promoter polymorphisms (rs112782763, rs28717001, rs28651243, 
rs113588187) evaluated in this study are known functional SNPs [20]. The 
rs112782763, which is located 19 nucleotides upstream from the transcription 
start site 1 (tsp1) in the gGCCc sequence, affects the zinc finger binding 
of the MTF-1 (metal-regulatory) transcription factor [31]. The substitution 
rs28717001 changes the tsp1 itself. The third polymorphism rs28651243 
located 27 nucleotides downstream from the tsp1 disrupts a SP1 (specificity 
protein 1 transcription factor) consensus. The rs113588187 destroys a 
BamHI restriction site in the close proximity of an AP-4 (motif B)/MED-1 
consensus, which in turn is essential for the full ANXA5 promoter activity 
[20;32]. The ANXA5 M2 haplotype (including our haplotype H3) comprising 
the four mentioned above promoter SNPs is related to a reduced ANXA5 
promoter activity in vitro [20] and reduced mRNA levels in placental tissues 
[33]. Altogether, it is thought that through reduced ANXA5 expression on 
the surface of placental trophoblasts and inefficient phospholipid shielding, 
this haplotype contributes to a prothrombotic placental environment [20]. 
In addition, SNP rs1131239 located in the ANXA5 Kozak sequence was 
chosen since the minor rs1131239T-allele has previously been reported to 
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be associated with a protective role in the risk for myocardial infarction 
[16;17]. Furthermore, we also evaluated the rs62319820, because its 
minor T-allele is known to be a major contributor to higher plasma ANXA5 
levels in healthy controls [23]. 
We initially found a trend towards a larger arterial wall thickening over 
time in heterozygous H3 patients compared to non-H3 carriers in the ASAP 
study, suggesting a possible clinical relevance of ANXA5 H3 in susceptibility 
to cardiovascular events. Remarkably, such a larger arterial wall thickness 
progression observed in ANXA5 H3 carriers (13.5 µm/year after adjusting 
for sex) should contribute to a higher incidence of cardiovascular events, 
resulting in an increased CVD risk in these individuals. Unfortunately, no 
such effect was found while studying the CVD risk in a large population of FH 
patients from the GIRAFH study, which was designed to substantiate genetic 
risk factors in FH patients. Power calculations showed that the GIRaFH study 
had a ~85% power (α=0.05) to detect a clinically relevant odds ratio of 1.5 
for ANXA5 H3 (haplotype frequency of 0.10; an assumed prevalence of the 
disease of 30%). Since replication in a larger study including patients with 
a similar disease phenotype failed, we have to consider our initial finding, 
a trend for an association of ANXA5 H3 with IMT in the ASAP study, as a 
false-positive result or as a type I error.  
Evidence for an association between ANXA5 genetic variants and carotid 
IMT or CVD risk in atherosclerosis is scarce. Recently, it has been shown a 
moderate association between ANXA5 intronic SNPs rs4833229, rs6830321 
and the risk on restenosis in patients undergoing percutaneous coronary 
intervention for atherosclerosis (odds ratio 1.29, pallelic=0.011 and odds 
ratio 1.35, pallelic=0.003, respectively) [15]. A possible explanation for 
the discrepancy with this study could be explained by the pathophysiology 
underlying FH. Since atherosclerosis is a multifactorial disease, the 
contribution of genetic variations to CVD risk should be considered in 
the context of a chronic inflammatory disease of the arterial wall. It is 
known that elevated plasma LDL-C levels in FH patients maintain a 
chronic inflammatory environment within the arterial wall. The effects of 
LDL-C on the inflammatory reactions in atherosclerosis appear to be more 
dominant than the small effects of endogenous ANXA5. Our observation 
that plasma ANXA5 levels were not associated with cholesterol levels or an 
inflammation marker may support the minor impact of endogenous ANXA5 
on inflammation in atherosclerosis. Of note, as our study was restricted to 
FH patients, the role of ANXA5 genetic variations in atherosclerosis should 
be examined in other patient populations in order to understand its true 
physiological impact. 
In conclusion, the data obtained from two independent cohorts of FH 
patients indicate that both common genetic variants in ANXA5 and plasma 
ANXA5 levels are not associated with carotid IMT parameters or CVD risk.  
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SUPPLEMENTAL DATA
Figure S1.  HAPLOVIEW LD plot of the seven SNPs within the promoter and 
5’-untranslated region of the ANXA5 gene. The LD coefficients r2 (x100) between 
all SNP pairs are shown in squares. The darker the gray color is, the higher the de-
gree of LD. The black color (r2=1) indicates complete linkage.
         
Table S1. Correlations of plasma ANXA5 levels with cholesterol,  
triglycerides, hsCRP levels and carotid IMT
ANXA5, µg/L
Variable Number r p-value
Total cholesterol, mmol/L 145 0.05 0.5
Triglycerides, mmol/L 145 0.03 0.7
HDL-C, mmol/L 145 0.06 0.9
LDL-C, mmol/L 144 0.03 0.7
Hs-CRP, mg/L 143 0.02 0.8
Carotid IMT, mm 145 -0.03 0.8
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein  
cholesterol; hs-CRP. high-sensitivity C-reactive protein; IMT, intima-media               
thickness. r, Pearson correlation coefficient. Plasma ANXA5, triglycerides and   
hs-CRP levels were ln-transformed prior to analyses.
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Table S2. Frequency distribution of ANXA5 SNPs in FH patients from 
the ASAP trial and expected frequencies according to Hardy-Weinberg        
Equilibrium (n=284)
Polymorphism MAF Observed genotype
Expected 
genotype p-value
SNP1  rs62319820 0.09 0.16
CC 239 237
CT 41 45
TT 4 2
SNP2 rs112782763 0.11 0.46
GG 226 227
GA 56 54
AA 2 3
SNP3  rs28717001 0.19 0.61
AA 186 185
AC 86 88
CC 12 11
SNP4 rs28651243 0.19 0.61
TT 186 185
TC 86 88
CC 12 11
SNP5 rs113588187 0.11 0.46
GG 226 227
GA 56 54
AA 2 3
SNP6 rs1050606 0.49 0.29
TT 79 75
TG 133 141
GG 72 68
SNP7 rs1131239 0.10 0.19
CC 226 228
CT 57 53
TT 1 3
MAF, minor allele frequency.
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Table S3. Association of individual ANXA5 SNPs with age-related carotid 
IMT in FH patients from the ASAP trial
Unadjusted model Adjusted model*
SNP/genotype β p-value β p-value
SNP1 rs62319820
CC (n=237) 0.0087 Ref. 0.0093 Ref.
CT+TT (n=45) 0.0084 0.93 0.0091 0.94
SNP2 rs112782763† 
GG (n=226) 0.0076 Ref. 0.0081 Ref.
GA (n=56) 0.0130 0.059 0.0136 0.05
SNP3 rs28717001‡
AA (n=184) 0.0074 Ref. 0.0078 Ref.
AC+CC (n=98) 0.0105 0.17 0.0111 0.13
SNP6 rs1050606
TT (n=78) 0.0066 Ref. 0.0070 Ref.
TG+GG (n=204) 0.0093 0.31 0.0098 0.28
SNP7 rs1131239
CC (n=225) 0.0076 Ref. 0.0081 Ref.
CT (n=57) 0.0126 0.07 0.0132 0.06
Results of the linear regression analysis (n=282) are shown.     
β indicates regression coefficient; β represents IMT increase with age (mm/year)
The slopes of the major allele carriers were taken as the reference.  
*Adjusted for gender and study center.      
†The same results for SNP5 rs113588187 due to complete linkage   
‡The same results for SNP4 rs28651243 due to complete linkage    
IMT means intima-media thickness; Ref., reference. 
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Table S4. Frequency distribution of ANXA5 SNPs in FH patients from the 
GIRaFH study and expected frequencies according to Hardy-Weinberg 
Equilibrium
Polymorphism Observed         genotype
Expected 
genotype p-value
rs62319820 n=1864 0.99
CC 1534 1534
CT 314 314
TT 16 16
rs113588187 n=1886 0.81
GG 1478 1477
GA 382 384
AA 26 25
rs1050606 n=1850 0.77
TT 415 418
TG 929 923
GG 506 509
rs1131239 n=1912 0.88
CC 1494 1495
CT 393 392
TT 25 26
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Table S5. Association of ANXA5 polymorphisms with CVD risk in FH pa-
tients from the GIRaFH study.
Polymorphism                                 CVD- n (%) CVD+ n (%) HR (95% CI)* p-value
rs62319820 n=1279 n= 585
CC 1047 (81.9) 487 (83.2) 1.0
CT 218 (17.0) 96 (16.4) 1.0 (0.8-1.2) 0.7
TT 14 (1.1) 2 (0.3) 0.3 (0.04-2.0) 0.2
rs113588187 n= 1295 n=591
GG 1019 (78.7) 459 (77.7) 1.0
GA 256 (19.8) 126 (21.3) 1.1 (0.9-1.4) 0.2
AA 20 (1.5) 6 (1.0) 0.8 (0.4-1.9) 0.7
rs1050606 n=1269 n=581
TT 282 (22.2) 133 (22.9) 1.0
TG 635 (50.0) 294 (50.6) 0.9 (0.8-1.2) 0.6
GG 352 (27.7) 154 (26.5) 1.0 (0.8-1.3) 1.0
rs1131239 n=1314 n=598
CC 1032 (78.5) 462 (77.3) 1.0
CT 262 (19.9) 131 (21.9) 1.2 (0.9-1.4) 0.2
TT 20 (1.5) 5 (0.8) 0.7 (0.3-1.6) 0.4
CVD+, patients with cardiovascular disease; CVD-, patients without cardiovascular 
disease;          
HR, hazard ratio; CI, confidence interval.      
HRs were calculated with the major allele as a reference category (HR=1.0). 
*Adjusted for sex, year of birth and smoking.
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ABSTRACT
Introduction: Annexin A5 (ANXA5) is a protein with antithrombotic properties 
present in vascular endothelium. It has been suggested that genetic variants 
in the Annexin A5 (ANXA5) gene affect ANXA5 expression, contributing to 
a local procoagulant state. Some studies showed associations of ANXA5 
single nucleotide polymorphisms (SNPs) or haplotypes with pregnancy-
related deep venous thrombosis (DVT) and myocardial infarction.  
Objectives: To investigate whether common variants in the ANXA5 promoter 
are associated with DVT risk in Dutch Caucasian individuals. 
Methods and Results: From the Amsterdam Case-control Thrombophilia 
(ACT) study, 148 patients with newly diagnosed DVT and 267 controls 
without previous VTE were included. We sequenced the promoter region 
of the ANXA5 gene and reconstructed four common haplotypes, based on 
six SNPs. Neither individual SNPs nor any of the common haplotypes were 
associated with an increased risk for DVT. Furthermore, the four ANXA5 
haplotypes were equally distributed among DVT patients and a second 
independent control group of 1705 individuals from the general population 
(Nijmegen Biomedical Study).  
Conclusions: Our data suggest that ANXA5 haplotypes do not contribute to 
DVT risk in the Dutch population.
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INTRODUCTION  
Venous thromboembolism (VTE) is a multifactorial disease with an incidence 
of 1-2 per 1000 per year in western countries [1]. Although several genetic 
risk factors for VTE such as factor V Leiden or prothrombin G20210A 
mutation have been identified, the risk of VTE is also increased in case 
of a positive family history of VTE, in whom known genetic risk factors 
have been ruled out [2]. This suggests that other as yet unknown genetic 
variants also predispose to VTE. 
Annexin A5 (ANXA5) is a natural anticoagulant protein highly expressed by 
vascular endothelium and placental trophoblasts [3-5]. The hypothesis of a 
possible role of ANXA5 in the pathogenesis of thrombotic disorders originates 
from its anticoagulant, antithrombotic and anti-inflammatory properties 
observed in vitro and in animal models in vivo [6-9]. In the presence of 
Ca2+-ions, ANXA5 binds and shields anionic phospholipids, which form 
the catalytic surface for coagulation reactions [10;11]. Reduced ANXA5 
expression on the surface of vascular cells and subsequently inefficient 
shielding of anionic phospholipids could contribute to the activation of blood 
coagulation and the creation of a prothrombotic environment within the 
blood vessel.
In the antiphospholipid syndrome, for example, a reduction of ANXA5 at 
the vascular wall is thought to be one of the several explanations for the 
occurrence of both arterial and venous thrombosis [12-14]. Reduced binding 
of ANXA5 to cardiolipin observed in patients with confirmed idiopathic venous 
thrombosis, supports the role of ANXA5 in thrombosis [15]. In patients with 
systemic lupus erythematosus, reduced binding of ANXA5 to endothelium 
has also been proposed as a mechanism underlying atherothrombosis 
[16]. In addition, ANXA5 down-regulates expression of the procoagulant 
tissue factor, which is a key player in VTE [9;17;18]. Furthermore, ANXA5 
is known to be an effective inhibitor of experimentally induced venous and 
arterial thrombosis in animal models [8;19].
If genetic variants within the ANXA5 gene affect ANXA5 expression on cell 
surfaces, these could also influence the risk of clinical outcomes such as 
arterial or venous thrombosis. Several studies have been performed to 
assess this. A genetic variant located in the Kozak sequence (g.-1C>T, 
rs1131239) of the ANXA5 gene was associated with higher plasma ANXA5 
levels [20]. This minor rs1131239T-allele was associated with a decreased 
risk of myocardial infarction in young patients [20] and a lower risk of 
developing a new coronary event during 36 months follow-up [21]. Other 
studies, however, were unable to reproduce these findings [22;23]. In 
the study that showed a decreased risk of myocardial infarction, venous 
thrombotic risk was also investigated but no significant association between 
the minor rs1131239T-allele and deep venous thrombosis (DVT) was 
found (OR for DVT 0.76, 95% CI 0.47-1.22) [20]. Similarly, in a Dutch 
population of 198 patients with autoimmune diseases, no association with 
venous or arterial thrombosis was found [24]. A haplotype comprising four 
ANXA5 promoter single nucleotide polymorphisms (SNPs) (rs112782763, 
rs28717001, rs28651243, rs113588187), collectively referred to as the M2 
haplotype, reduces ANXA5 promoter activity in a promoter construct assay 
in vitro [25], which could be translated to an increased DVT risk. Indeed, 
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the presence of the M2 allele was found to be a risk factor for DVT in 
pregnancy or the postpartum period [26] as well as in the general Southern 
Italian population [27]. 
In a previous study, we described four common ANXA5 haplotypes (H1, 
H2, H3 and H4) [28]. Of these, the haplotype H3 is an extension of the 
previously described M2 haplotype that reduces ANXA5 promoter activity 
in vitro [25] as well as correlates with lower plasma ANXA5 levels [28]. 
Interestingly, the minor rs1131239T-allele, which was associated with 
increased plasma ANXA5 levels and a decreased risk of myocardial infarction 
[20], is completely linked to SNPs comprising the M2 haplotype [28]. 
Given the conflicting results on the association of variants within the ANXA5 
gene upstream region with clinical outcomes in previous studies, we aimed 
to evaluate whether ANXA5 promoter SNPs and haplotypes influence the 
risk of DVT in the Dutch general population. For this study, we used a 
case-control study on risk factors for DVT, the Amsterdam Case-control 
Thrombophilia (ACT) study, and a second group of population controls 
(Nijmegen Biomedical Study, NBS). 
MATERIALS AND METHODS  
Study population
From the Amsterdam Case-control Thrombophilia Study (ACT) performed 
between September 1999 and May 2006 [29], we selected 437 unrelated 
individuals (154 cases and 283 controls) of Caucasian origin. Both cases 
and controls were from the Amsterdam region, the western part of the 
Netherlands. Cases were patients with newly diagnosed and objectively 
confirmed proximal DVT of the leg. Controls were patients without previous 
VTE, in whom DVT was suspected but ruled out. The diagnosis of DVT was 
based on the Wells score and D-dimer plasma level algorithm, followed 
by compression ultrasonography if indicated, as described [29;30]. 
A standardised questionnaire was used for all participants, to obtain 
information about known risk factors such as malignancy or treatment 
because of malignancy in the last 6 months; pregnancy or postpartum 
period; use of oral contraceptives or hormonal therapy; trauma within the 
last 60 days; being bedridden (for >3 days); paralysis or recent plaster 
immobilisation of the symptomatic leg; surgery within the last 4 weeks. 
Information was obtained prior to diagnosis of DVT, i.e. classification as 
case or control. Genomic DNA was isolated from peripheral leukocytes and 
was stored at +4°C. The Medical Ethical Committee of the Academic Medical 
Center in Amsterdam approved the study. 
The second control group consisted of individuals who had been included 
in the Nijmegen Biomedical Study (NBS), of which details were reported 
previously [31]. Briefly, the NBS is a population-based survey conducted 
by the Department for Health Evidence and the Department of Laboratory 
Medicine of the Radboudumc. 21,756 age- and sex-stratified randomly 
selected inhabitants of the municipality of Nijmegen in the eastern part 
of the Netherlands received an invitation to fill out a postal questionnaire 
on, e.g., lifestyle and medical history, and to donate blood samples. 
The response to the questionnaire was 43% (N=9350). 69% (N=6468) 
of the responders donated blood samples. Of the 1819 cancer free NBS 
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participants who served as controls in a genome-wide association study 
[32], we selected for this study 1705 controls of self-reported European 
descent who reported not to have had DVT or pulmonary embolism. 
Written informed consent was obtained from all ACT and NBS participants.
Genetic analysis 
In the ACT subjects, a 496-bp fragment of the ANXA5 promoter (261 base 
pairs upstream and 235 base pairs downstream of the first transcription 
start point) was amplified by polymerase chain reaction (PCR) using two 
oligonucleotide primers: forward 5’ CCGAGCCCTGGACAGCTCCCCA-3’ and 
reverse 5’-GCCCCGCGACCACGCTCTCCTCT-3’ [25]. PCR reactions were 
carried out in a final volume of 25 µl reaction mixture containing 2.5 µl 10x 
PCR Buffer (Qiagen), 5% DMSO (v/v), 1 M Betaine, 0.4 µM of each primer 
(forward and reverse), 0.08 mM of each deoxynucleotide triphosphate, 100 
150 ng genomic DNA and 1.25 U Taq DNA polymerase (Qiagen). Cycling 
conditions were: an initial denaturation step at 95°C for 3 minutes followed 
by denaturation at 95°C for 1 minute, annealing at 62°C for 1 minute and 
elongation at 72°C for 1 minute (30 cycles in total). PCRs were performed 
in a T3 Thermal Cycler (Biometra, Germany). Sequence analysis was 
performed by direct sequencing using the Big Dye Terminator ABI Prism 
Kit, version 1.1 (Applied Biosystems, Foster City, CA). Products of sequence 
reactions were analysed on a Genetic Analyzer 3730 (Applied Biosystems, 
Foster City, CA). Sequencing chromatograms were examined by the use of 
the Sequencer package (GeneCodes Co, Ann Arbor, MI). 
NBS controls were genotyped using the Illumina HumanHapCNV370-Duo 
BeadChip as described [32]. For this study, we extracted 4 SNPs in ANXA5 
(rs62319820, rs113588187, rs1050606 and rs1131239) from genome-
wide imputed SNP data using the “Genome of the Netherlands” (GoNL) 
data as reference.
Statistical analysis
Hardy-Weinberg equilibrium for each SNP was tested using the χ2 test. 
HAPLOVIEW software (Broad Institute, Cambridge, MA, USA) was used to 
estimate the degree of linkage disequilibrium (LD; r2 values) between all 
SNP pairs and to determine haplotypes (H) [33]. In the ACT participants, 
haplotypes were constructed using six promoter SNPs (rs62319820, 
rs112782763, rs28717001, rs28651243, rs113588187, rs1050606). As 
the minor rs1131239T-allele is completely linked to rs112782763 and 
rs113588187, haplotypes were equal to previously described elsewhere 
[28]. To reconstruct the four known ANXA5 haplotypes in the NBS controls, 
we used three haplotype-tagging SNPs (rs62319820, rs113588187, 
rs1131239) and SNP rs1050606, of which the major T-allele is specific for 
haplotype H1. Haplotypes were assigned manually to all individuals. 
The association of ANXA5 SNPs and haplotypes with DVT risk was examined 
using the χ2 test.  Odds ratios (ORs) with 95% confidence intervals (CI) were 
calculated as an estimate of the relative risk indicating the risk for DVT in a 
category of exposure (e.g., haplotype Hx carriers) relative to the reference 
category (e.g., non-haplotype Hx). ORs for DVT adjusted for age, sex, and 
presence of provoking risk factors were calculated using logistic regression. 
Statistical analyses were performed using SPSS version 20.0 software. Two-
sided probability values of <0.05 were considered statistically significant. 
Chapter 5
102
RESULTS 
Clinical characteristics of DVT patients and controls from the ACT 
study
In total, 148 DVT patients and 267 controls were included in the analyses, 
as sequencing of the ANXA5 promoter was not successful in 6 patients 
and 16 controls. The characteristics of the study participants are presented 
in Table 1. The mean age was comparable between both groups, and 
patients were more often male than controls (p=0.046). Body mass index 
was similar in cases and controls (26.0 and 27.2 kg/m2 respectively). Thirty 
DVT patients (20.3%) had a prior history of VTE. In 77 patients (52%), risk 
factors for DVT were identified. Factor V Leiden was found in 23.1% of cases 
and in 5.8% of controls and the prothrombin G20210A mutation - in 4.1% 
cases and 2.9% controls.
Table 1. Characteristics of the study population.
Case 
(n=148)
ACT controls 
(n=267)
NBS controls 
(n=1705)
Age, years 59.1 (16.0) 58.5 (16.7) 60.7 (10.3)
Male sex, n (%) 76 (51.4) 110 (41.2) 833 (48.9)
Provoking risk factors for VTE, n 
(%)† 77 (52.0) 107 (40.1) N.A.
Factor V Leiden, n (%)* 34 (23.1) 14 (5.8) 90 (5.4)
Prothrombin G20210A mutation, 
n (%)¥ 6 (4.1) 7 (2.9) 9 (0.54)
Previous VTE, n (%) 30 (20.3) N.A. N.A.
Continuous variables are presented as mean (standard deviation), categorical data 
as count (%).
VTE, venous thromboembolism; NA, not applicable
† malignancy or treatment because of malignancy in the last 6 months; pregnancy 
or postpartum period; use of oral contraceptives or hormonal therapy; trauma 
within the last 60 days; being bedridden (for > 3 days); paralysis or recent plaster 
immobilisation of the symptomatic leg; surgery within the last 4 weeks
*Data from 147 cases and 242 ACT controls (including 1 homozygous case and 1 
homozygous control) and 1678 NBS controls (including 1 homozygous)
¥ Data from 147 cases and 241 ACT controls (including 1 homozygous control) and 
1676 NBS controls. 
ANXA5 SNPs and haplotypes in the ACT study
Sequencing of the ANXA5 promoter showed the presence of six common 
polymorphisms (Figure 1), i.e. SNP1 (rs62319820, g.-628C>T), SNP2 
(rs112782763, g.-467G>A), SNP3 (rs28717001, g.-448A>C), SNP4 
(rs28651243, g.-422T>C), SNP5 (rs113588187, g.-373G>A) and SNP6 
(rs1050606, g.-302T>G) that have previously been reported [25;28;34]. 
We also identified three rare variants. SNP7 (g.-622G>C) located six 
nucleotides downstream of SNP1 was found in three controls and one
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Figure 1. ANXA5 polymorphisms and haplotypes. (A) rs numbers and risk 
allele frequencies in patients and controls. Nucleotide numbering from the ATG 
initiation codon; SNP, single nucleotide polymorphism; dbSNP indicates NCBI database 
for SNPs http://www.ncbi.nlm.nih.gov/snp); risk alleles in bold and underlined; N.A., 
not applicable; N.R., not reported. Genotype frequencies were in Hardy Weinberg 
equilibrium both in ACT controls (SNPs 1-6) and in NBS controls (SNPs 1,5,6 and 
10). (B) HAPLOVIEW Linkage Disequilibrium plot of the six SNPs within the ANXA5 
promoter in the ACT study. The LD coefficients r2 (x100) between all SNP pairs are 
shown in squares. The black colour (r2=1) indicates complete linkage. (C) Calling of 
haplotypes according to previous studies (25;28). 
patient in a heterozygous form as well as in one patient in a homozygous 
form (MAF in controls: 0.006; MAF in patients: 0.01). SNP8 (g.-585G>A) 
and SNP9 (g.-506G>A) upstream of SNP2 were present in two controls in a 
heterozygous form (MAF: 0.004). These rare polymorphisms were excluded 
from further analyses. 
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The genotype frequencies of the common ANXA5 SNPs were in Hardy-
Weinberg equilibrium both in DVT patients and in controls (Table S1). We 
examined an association between separate SNPs and DVT risk (Table S2). 
None of the six polymorphisms was significantly associated with DVT. 
Haploview analysis revealed a high degree of linkage disequilibrium between 
all SNPs except for SNP1 and SNP6. SNP2 and SNP5 as well as SNP3 and SNP4 
were completely linked (r2=1) (Figure 1). Only four common haplotypes 
(frequency > 1%) were present, which was similar to our previous study in 
a different Dutch population [28].  
Table 2 shows the association between ANXA5 haplotypes and DVT. Carriers 
of only major alleles for all SNPs (haplotypes H1, H1H1+H1Hx) appeared to 
have a slightly increased risk for DVT compared to non-H1 carriers, in both 
the unadjusted model (OR 1.5, 95% CI: 0.9-2.3) and after adjusting for 
age, sex and the presence of provoking risk factors (OR 1.4, 95% CI: 0.9-
2.2), but the risk estimates did not reach statistical significance. The H2, H3 
and H4 ANXA5 haplotypes were not associated with DVT. Additionally, when 
homozygous carriers of H1 (H1H1) were used as the reference category 
instead of HxHx, the haplotypes H2, H3 and H4 were not associated with DVT 
(data not shown). Furthermore, we compared H3 carriers (encompassing 
the M2 haplotype, 27 cases and 59 controls) to carriers of only H1 and/
or H2 (i.e., H1H1, H1H2, H2H2 genotypes; N/N in previous studies, 99 
cases and 171 controls) and no association between H3 and DVT was found 
(OR 0.79, 95% CI 0.47 - 1.33). We also examined DVT risk for men and 
women separately. In men, haplotype H2-carriers (H2H2+H2Hx) appeared 
to have a slightly decreased risk of DVT compared to non-H2 carriers (OR 
0.6, 95% CI: 0.3-1.1). Women carrying haplotype H3 tended to have a 
reduced risk for DVT (OR 0.5, 95% CI: 0.3-1.2). Again, these estimates did 
not reach statistical significance. Finally, subgroup analysis in 71 patients 
with unprovoked DVT did not also detect any association between ANXA5 
haplotypes and DVT (data not shown).
ANXA5 SNPs and haplotypes in population controls
To verify if the prevalence of ANXA5 haplotypes in the selected hospital 
controls is representative of the population prevalence, we included an 
independent control group from the general population. Of the 1705 NBS 
controls, 48.9% was male and the mean age was 60.7 years (Table 1). The 
prevalence of Factor V Leiden in NBS controls (5.4%) was similar to that 
in ACT controls (5.8%), whereas carriership of the prothrombin G20210A 
mutation was less prevalent in NBS controls (0.54%) compared to ACT 
controls (2.9%).
Four ANXA5 SNPs covering the four common ANXA5 haplotypes were 
evaluated. The genotype distributions of all SNPs were in Hardy-Weinberg 
equilibrium (Table S3). The common ANXA5 haplotypes were constructed 
in 1704 NBS controls as one control person presented with the rare ANXA5 
haplotype. Finally, all ANXA5 haplotypes were similarly distributed among 
DVT patients and NBS controls (Table 2) as well as among subgroups of 
men or women (data not shown). 
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Table 2. Association of ANXA5 haplotypes with DVT.
Haplotype Patients n=148, n (%)
ACT Controls 
n=267, n (%)
OR for DVT 
(95% CI)
NBS Controls* 
n=1704, n 
(%)
OR for DVT 
(95% CI)
H1 (CGATGT)
Non-H1 39 (26.4) 92 (34.5) 1 436 (25.6) 1
H1Hx 77(52.0) 119 (44.6) 1.5 (1.0 – 2.4) 875 (51.3) 1.0 (0.7 – 1.5)
H1H1 32 (21.6) 56 (21.0) 1.3 (0.8 – 1.4) 393 (23.1) 0.9 (0.6 – 1.5)
H1H1+H1Hx 109 (73.6) 175 (65.5) 1.5(0.9 – 2.3) 1268 (74.4) 1.0 (0.7 – 1.4)
Frequency H1 0.48 0.43 0.49
H2 (CGATGG)
Non-H2 66 (44.6) 112 (41.9) 1 775 (45.5) 1
H2Hx 61 (41.2) 116 (43.4) 0.9 (0.6 – 1.4) 752 (44.1) 1.0 (0.7 – 1.4)
H2H2 21 (14.2) 38 (14.2) 0.9 (0.5 – 1.7) 177 (10.4) 1.4 (0.8 – 2.3)
H2H2+H2Hx 82 (55.4) 154 (57.7) 0.9 (0.6 – 1.4) 929 (54.5) 1.0 (0.7 – 1.5)
Frequency H2 0.35 0.36 0.33
H3 (CACCAG)
Non-H3 121 (81.8) 208 (77.9) 1 1352 (79.3) 1
H3Hx 26 (17.6) 55 (20.6) 0.8 (0.5 – 1.4) 331 (19.4) 0.9 (0.6 – 1.4)
H3H3 1 (0.7) 4 (1.5) 0.4 (0.04 – 3.9) 21 (1.2) 0.5 (0.07 – 4.0)
H3H3+H3Hx 27 (18.2) 59 (22.1) 0.8 (0.5 – 1.3) 352 (20.7) 0.9 (0.6 – 1.3)
Frequency H3 0.09 0.12 0.11
H4 (TGCCGG)
Non-H4 125 (84.5) 221 (82.8) 1 1445 (84.8) 1
H4Hx 22 (14.9) 45 (16.9) 0.9 (0.5 – 1.5) 251 (14.7) 1.0 (0.6 – 1.6)
H4H4 1 (0.7) 1 (0.4) 1.8 (0.1 – 28.5) 8 (0.5) 1.4 (0.2 – 11.6)
H4H4+H4Hx 23 (15.5) 46 (17.2) 0.9 (0.5 – 1.5) 259 (15.2) 1.0 (0.6 – 1.6)
Frequency H4 0.08 0.09 0.08
* One person carrying the rare haplotype was excluded from analysis.
All haplotypes but the one given (e.g. non-H1, non-H2, non-H3 or non-H4) were 
used as the reference category (OR = 1).      
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DISCUSSION 
In this study, neither individual SNPs nor any of the four haplotypes within 
the ANXA5 gene upstream region (including the H3 haplotype which is an 
extension of the M2 haplotype) were associated with an increased risk of 
DVT. 
How do our findings relate to previous studies? First, there is a discrepancy 
in calling of haplotypes. Previous studies reported the M2 haplotype 
(comprising SNPs 2, 3, 4 and 5). We previously reported four other 
haplotypes (H1, H2, H3 and H4), of which H3 is an extension of the M2 
haplotype (additionally including SNP6 and SNP7, rs1131239 g.-1C>T 
[28]). The studies that found an association between ANXA5 haplotypes 
and DVT compared M2 carriers to non-M2 carriers [26;27]. According to our 
results, the non-M2 carriers include haplotypes H1 and H2 [28]. We found 
no association between haplotype H3 (the extension of the M2 haplotype) 
and DVT, neither when comparing H3 carriers to non-H3 carriers, nor when 
comparing H3-carriers to only H1 and/or H2 carriers (N/N in previous 
studies). It should be noted that the haplotypes H1 and H2 are associated 
with different plasma ANXA5 levels in healthy controls [28].  Although this 
suggests that H1 and H2 should not be combined as one reference category, 
data regarding the relevance of plasma ANXA5 levels in DVT patients are 
lacking. Nevertheless, this differentiation of haplotypes within the non-M2 
control group could be of clinical importance. For example in other disease 
states, such as in recurrent pregnancy loss, plasma ANXA5 levels are known 
to be related to clinical features [35]. This subject therefore requires further 
investigation. 
Second, one of the previous studies reporting an association of the ANXA5 
M2 haplotype with VTE was limited to pregnant women and to women in the 
postpartum period [26]. As only four of our patients had a DVT related to 
pregnancy, we could not investigate a possible association between ANXA5 
H3 and pregnancy-related thrombotic complications. 
Third, the discrepancy with the Italian studies may be explained by differences 
between populations as we found a higher percentage of controls carrying 
ANXA5 H3 (22.1% in ACT controls and 20.7% in NBS controls versus 14.4% 
and 16.6%, reported as the M2 haplotype in the Italian studies) (26;27). In 
our previous report, we showed a similar percentage of H3 carriers (21.4%) 
among healthy Dutch controls [28]. A higher percentage of healthy control 
subjects carrying the rs1131239T-allele (23.1%) was also found in the 
Spanish study [20]. As the frequency of SNPs varies for different ethnic 
groups, our study population was limited to Caucasian individuals. 
It is possible that the lack of association we observed is due to a relatively 
small sample size of the ACT study. However, considering the genotype 
frequency of the H3 haplotype among controls of 22%, the study had a 
~85% power (α=0.05) to detect an OR of 2.0 or more for DVT. Furthermore, 
with the use of a large cohort of population controls, the study was powered 
(~80%, α=0.05) to detect a clinically relevant OR of 1.7 for ANXA5 H3 
(genotype frequency of 20.6%). 
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We are aware that with the current study design, we cannot rule out the 
possibility that other genetic variants in regulatory regions of the ANXA5 
gene or other genes may be associated with DVT. This study, however, 
addressed the conflicting results in the literature and therefore analyses 
were restricted to the common ANXA5 variants in light of the common 
disease – common variant hypothesis. In the search for new candidate 
genes that may be a risk factor for DVT, other strategies may be considered 
to be more suitable, thereby studying rare variants as opposed to common 
polymorphisms. In this respect, a next-generation DNA sequencing platform 
was applied for sequencing of the coding regions of 186 haemostatic/
proinflammatory genes, including the ANXA5 gene, in Italian patients 
with idiopathic DVT [36]. Interestingly, the intronic ANXA5 polymorphism 
rs2306416 (g.A>G), which is located 57-bp downstream from the ATG 
codon, belonged to the top-5 variants selected for replication but failed 
to show any association with DVT after replication. Other ANXA5 variants 
located in exons and exon-intron boundaries were not associated with DVT 
in an initial stage. This suggests that even with a different study design, 
investigating the coding regions of ANXA5 besides the ANXA5 promoter, no 
association between ANXA5 SNPs and thrombosis risk will be found. 
Despite the lack of association between ANXA5 genetic variants and DVT, 
previous studies have shown that ANXA5 genetic variants may play a role 
in the occurrence of obstetric complications such as miscarriage and intra-
uterine growth restriction [25;34;37]. Furthermore, placental ANXA5 was 
shown to be critical for maintaining murine placental integrity [38] and 
in humans, reduced plasma ANXA5 levels were associated with recurrent 
pregnancy loss [35]. These associations require further research. 
In conclusion, we could not demonstrate a meaningful association between 
ANXA5 genetic variants and DVT in the Dutch population. 
Addendum
The Amsterdam Case-control Thrombophilia Study was performed between 
September 1999 and May 2006 and DNA samples and clinical data of 
participants are stored at the Academic Medical Center, Amsterdam. 
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SUPPLEMENTAL DATA
Table S1. Frequency distribution of ANXA5 polymorphisms and expected 
frequencies according to Hardy-Weinberg Equilibrium in the ACT study (DVT 
patients (n=148) and controls (n=267)).
Polymorphism
DVT patients Controls
Observed Expected† Observed Expected†
n n n n
SNP1 -628 C>T (rs62319820)
CC 125 125 221 222
CT 22 22 45 43
TT 1 1 1 2
SNP2 -467 G>A (rs112782763)
GG 121 121 208 208
GA 26 25 55 56
AA 1 1 4 4
SNP3 -448 A>C (rs28717001)
AA 99 101 171 168
AC 46 43 82 87
CC 3 5 14 11
SNP4 -422 T>C (rs28651243)
TT 99 101 171 168
TC 46 43 82 87
CC 3 5 14 11
SNP5 -373 G>A (rs113588187)
GG 121 121 208 208
GA 26 25 55 56
AA 1 1 4 4
SNP6 -302 T>G (rs1050606)
TT 32 34 56 50.
TG 77 74 119 131
GG 39 41 92 86
†Expected frequencies of all ANXA5 SNPs were not statistically different from ob-
served frequencies (p-value > 0.05), both in controls and in cases. 
 
ANXA5 in deep venous thrombosis
111
Table S2. DVT risk for ANXA5 SNPs in the ACT study.
SNP Geno-
type
Patients (n = 
148) n (%)
Controls (n = 
267) n (%)
OR         
(95% CI)
SNP1 rs62319820 CC 125 (84.5) 221 (83.8) 1
CT 22 (14.9) 45 (16.9) 0.9 (0.5-1.5)
TT 1 (0.7) 1 (0.4) 1.8 (0.1-28.5)
CT + TT 23 (15.5) 46 (17.2) 0.9 (0.5-1.5)
SNP2 rs112782763 GG 121 (81.8) 208 (77.9) 1
GA 26 (17.6) 55 (20.6) 0.8 (0.5-1.4)
AA 1 (0.7) 4 (1.5) 0.4 (0.05-3.9)
GA + AA 27 (18.2) 59 (22.1) 0.8 (0.5-1.3)
SNP3 rs28717001 AA 99 (66.9) 171 (64.4) 1
AC 46 (31.1) 82 (30.7) 1.0 (0.6-1.5)
CC 3 (2.0) 14 (5.2) 0.4 (0.1-1.3)
AC + CC 49 (33.1) 96 (36.0) 0.9 (0.6-1.3)
SNP4 rs28651243 TT 99 (66.9) 171 (64.4) 1
TC 46 (31.1) 82 (30.7) 1.0 (0.6-1.5)
CC 3 (2.0) 14 (5.2) 0.4 (0.1-1.3)
TC + CC 49 (33.1) 96 (36.0) 0.9 (0.6-1.3)
SNP5 rs113588187 GG 121 (81.8) 208 (77.9) 1
GA 26 (17.6) 55 (20.6) 0.8 (0.5-1.4)
AA 1 (0.7) 4 (1.5) 0.4 (0.05-3.9)
GA + AA 27 (18.2) 59 (22.1) 0.8 (0.5-1.3)
SNP6 rs1050606 TT 32 (21.6) 56 (21.0) 1
TG 77 (52.0) 119 (44.6) 1.1 (0.7-1.9)
GG 39 (26.4) 92 (34.5) 0.7 (0.4-1.3)
TG + GG 116 (78.4) 211 (79.0) 1.0 (0.6-1.6)
All odds ratios (OR) were calculated with major alleles-only as the reference cate-
gory (OR=1). DVT, deep venous thrombosis
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Table S3. Frequency distribution of ANXA5 SNPs and expected frequencies 
according to Hardy-Weinberg Equilibrium in NBS controls (n=1705).
Polymorphism Risk allele frequency
Observed 
genotype
Expected 
genotype p-value
SNP1  rs62319820 0.08 0.40
CC 1445 147.5
CT 252 247
TT 8 10.5
SNP5 rs113588187 0.11 0.88
GG 1353 1352
GA 331 332
AA 21 20
SNP6 rs1050606 0.51 0.26
TT 394 405.5
TG 875 852
GG 436 447.5
SNP7 rs1131239 0.11 0.95
CC 1350 1350
CT 334 335
TT 21 21
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Chapter 6
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized 
by the persistent presence of antiphospholipid antibodies (aPLs) in plasma 
of patients with a history of vascular thrombosis and/or pregnancy morbidity 
[1,2]. Many pathogenic mechanisms have been described in APS, and in 
several of these mechanisms Annexin A5 (ANXA5) is suggested to play an 
important role [3]. ANXA5 is a Ca2+- and phospholipid-binding protein highly 
expressed by vascular endothelium and placental syncytiotrophoblasts 
[4,5]. The protein exhibits strong anticoagulant properties in vitro and 
antithrombotic activities in animal models due to shielding of anionic 
phospholipids that normally catalyze the clotting cascade [6,7]. It has been 
shown that aPLs could reduce the quantity of ANXA5 on cell surfaces [8]. As 
a result of the aPL-mediated reduction of ANXA5 expression, an acceleration 
of coagulation on cultured trophoblasts and endothelial cells has been 
demonstrated, which may be a potential mechanism for thrombotic events 
and pregnancy loss in APS [8,9].
In addition to the “immunologic” model of APS, Bogdanova and colleagues 
recently introduced the “genetic” model to explain obstetric complications in 
APS [10]. This latter model suggests that genetic variations in ANXA5 could 
affect ANXA5 expression in placentas and thus the protective potential of 
ANXA5 against placental thrombosis. It has been proposed that carriage 
of the ANXA5 M2 haplotype might predispose to obstetric complications as 
well as to the development of aPLs [10]. The M2 haplotype, comprising 
minor alleles of four promoter polymorphisms (rs112782763, rs28717001, 
rs28651243, rs113588187), has been linked to decreased ANXA5 mRNA 
levels in placental tissues [11,12]. Several studies have shown an association 
of this haplotype with recurrent pregnancy loss and deep venous thrombosis 
[11,13,14]. Previously, we reported the four common haplotypes (H1 to 
H4) within the ANXA5 gene upstream region and showed haplotype specific 
differences in plasma ANXA5 levels [15]. The major difference of our 
haplotypes with haplotypes described by Bogdanova et al. is that their wild-
type N haplotype represents two haplotypes H1 and H2 associated with 
different plasma ANXA5 levels [15]. Furthermore, our H3 haplotype is an 
extension of the M2 haplotype [15].
The contribution of genetic variations in ANXA5 to thrombotic risk or 
pregnancy morbidity in APS patients is poorly understood. In a well-defined 
cohort of patients with systemic lupus erythematosus (SLE), lupus-like 
disease (LLD) and primary APS [2,16], we sequenced the ANXA5 promoter 
region and genotyped rs1131239 located in the ANXA5 Kozak sequence 
to reconstruct the four common haplotypes [15]. An association of ANXA5 
haplotypes with thrombosis or pregnancy morbidity was investigated. 
The study population consisting of 176 Caucasian patients (159 women/ 17 
men) was recruited within the lupus clinic of the University Medical Centre 
Utrecht, the Netherlands. The clinical and immunological characteristics of 
the patients were described in detail previously [2,16]. Sixty patients (56 
women/ 4 men; mean age 37.9±10.6 years; ±SD) met the Sapporo criteria 
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of APS [17]: 6 had primary APS; in 43 APS was associated with SLE and 
in 11 - with LLD. Of the 116 patients without APS (103 women/ 13 men; 
mean age 34.2±9.7 years; ±SD), 111 had SLE and 5 had LLD. Patients 
with SLE fulfilled the criteria of the American College of Rheumatology 
for the classification of SLE [18]. Among 60 APS patients, 46 persons 
had a history of thrombosis (in 22 arterial and in 31 venous). Sixty five 
of 159 female patients had been pregnant and 24 women with APS met 
the Sapporo criteria for pregnancy morbidity [17]. Serological detection 
of anticardiolipin antibodies (aCL), antibodies against β2-glycoprotein I 
and anti-ANXA5 antibodies was performed by ELISA assays as described 
[2,16]. Lupus anticoagulant (LAC) was measured by a PPT-LA and a diluted 
RVVT assay [2,16]. Plasma ANXA5 levels were determined by a “sandwich-
ELISA” assay. Genomic DNA was extracted from peripheral mononuclear 
cells [16]. A 496-bp fragment of the ANXA5 promoter was amplified by 
polymerase chain reaction. Purified amplicons were sequenced (BigDye 
Terminator v3.1 Cycle Sequencing Kit and ABI 3730 PRISM DNA Analyzer, 
Applied Biosystems). Single nucleotide polymorphism (SNP) rs1131239 
was detected by restriction fragment length polymorphism [16]. 
The control group included population controls from the Nijmegen Biomedical 
study (NBS) [19]. For this study, we used the subset of 1819 individuals 
(900 men/ 919 women; mean age 62.0±10.3 years; ±SD) who served as 
controls in a genome-wide association study (GWAS) [20]. Of 919 female 
controls, 759 women had been pregnant. Informed written consent was 
obtained from all NBS controls. NBS participants were genotyped using the 
Illumina HumanHap CNV370-Duo BeadChip [20]. To reconstruct ANXA5 
haplotypes, the four ANXA5 SNPs (rs62319820, rs113588187, rs1050606 
and rs1131239) were extracted from genome-wide imputed SNP data using 
the Genome of the Netherlands as reference [21]. 
Categorical variables were compared by χ2 test and continuous variables 
- by unpaired t-test. The Hardy-Weinberg equilibrium for each SNP was 
tested by χ2 test. The association of ANXA5 haplotypes with thrombosis 
or pregnancy morbidity was examined by contingency tables. Odds ratios 
(ORs) with 95% confidence intervals (CI) were calculated. Age and sex 
were included in the multivariate regression model. Two-sided p-values 
<0.05 were considered statistically significant. 
Table 1 shows the individual SNPs and the four common ANXA5 haplotypes. 
In controls, the genotypic distributions of the four SNPs were in Hardy-
Weinberg equilibrium. One control person carrying a rare haplotype was 
excluded from further analyses. The three ANXA5 haplotypes (i.e., H1, H2 
and H4) were distributed similarly between groups of patients and between 
patients and controls (Table 1 and Table S1). The frequency of ANXA5 H3 
was a slightly higher in APS patients compared to NBS controls (p=0.053). 
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In patients with APS, none of the four ANXA5 haplotypes was associated with 
thrombosis (either arterial or venous) both in an unadjusted model (Table 
2) and after correction for age and sex (data not shown). Nor were ANXA5 
haplotypes associated with arterial and venous thrombosis separately. By 
selecting NBS controls without a history of thrombosis (i.e., myocardial 
infarction, deep venous thrombosis, pulmonary embolism, stroke) 
(n=1512), no significant differences were found either in the distribution of 
haplotypes between APS patients and controls (data not shown). 
We further investigated an association of ANXA5 haplotypes with obstetric 
APS (Table 2). Haplotype H1 and H2 were not associated with pregnancy 
morbidity, whereas carriers of ANXA5 H3 (i.e., H3H3+H3Hx genotypes) had 
an increased risk compared to NBS controls (41.7% versus 21.2%; OR 2.6, 
95% CI: 1.2-6.1, p=0.02). After adjustment for age, the risk for ANXA5 H3 
carriers remained increased (OR 2.8, 95% CI: 1.1-7.1, p=0.03). Haplotype 
H4 was non-significantly underrepresented in patients with obstetric APS 
compared to controls (4.2% versus 14.6%; p=0.2) (Table 2). Additional 
analyses performed after selection of female controls without a history of 
pregnancy loss (n=579) showed the same results. Only ANXA5 H3 haplotype 
was associated with pregnancy morbidity, both in the unadjusted model 
(OR 2.8, 95% CI: 1.2-6.4, p=0.01) and after correction for age (OR 2.7, 
95% CI: 1.1-6.7, p=0.03).       
None of the ANXA5 haplotypes was associated with the risk of developing 
anti-β2-glycoprotein I antibodies (IgG or IgM class) (Table S2). Moreover, 
no differences were found in the distribution of ANXA5 haplotypes between 
aPL-positive (LAC, aCL) and aPL-negative patients (data not shown). In 
obstetric APS patients, ANXA5 H3 was not associated with the risk of aPL 
development either. The prevalence of triple aPL positivity (LAC, aCL and 
anti-β2-glycoprotein I) was even slightly higher in non-H3 patients (6 from 
14 women; 42.9%) compared to heterozygous H3 carriers (3 from 10 
women; 30.0%) (p=0.5). In the total population, ANXA5 haplotypes were 
not associated with plasma ANXA5 levels (Table S3). 
An important result of this study was a possible association of ANXA5 H3 with 
obstetric manifestations in APS patients. According to the National Center 
for Biotechnology Information database for SNPs, the percentage of subjects 
carrying the rs112782763A-allele and rs113588187A-allele, which are both 
specific for H3 haplotype, is around 20% in the European population. We 
found an approximately 2-fold higher prevalence of H3 carriers in obstetric 
APS patients compared to that in the European population and in Dutch 
population controls (NBS study). Although overrepresentation of ANXA5 
H3 in obstetric APS is in agreement with preliminary data published by 
Bogdanova et al. [10], we had no evidence to confirm the suggestion made 
by Bogdanova et al. [10] that carriage of the H3 haplotype could be related 
to an increased production of aPLs. 
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The main limitation of this study was the small sample size of the study 
population. Larger case-control studies should be used to validate our 
results regarding the possible impact of ANXA5 haplotypes on thrombotic 
risk and pregnancy morbidity in APS patients. Additionally, a reason for 
cautious interpretation of our results could be the inflammatory condition 
induced by SLE. Therefore, a study should be confined to patients with 
primary APS.     
In summary, our results indicate that ANXA5 haplotypes do not contribute 
to thrombotic risk in APS patients. ANXA5 H3 may be associated with an 
increased risk of pregnancy morbidity but not with an increased production 
of aPLs. Further investigations are warranted to assess the link between 
ANXA5 H3 and obstetric APS as a better understanding of mechanisms 
involved in pregnancy-related complications may open new pathways for a 
personalized medicine approach.     
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SUPPLEMENTAL DATA
Table S1. The distribution of ANXA5 haplotypes in patients and controls.
Haplotype
             
APS, n=60  
n (%)
SLE+LLD 
without 
APS, n=116, 
n (%)
                             NBS con-
trols, 
n=1818,      
n (%)
p-value1 p-value2
Haplotype H1 0.4 0.6
H1H1 12 (20.0) 23 (19.8) 422 (23.2)
H1Hx 29 (48.3) 66 (56.9) 929 (51.1)
Non-H1 19 (31.7) 27 (23.3) 467 (25.7)
Haplotype H2 0.8 0.8
H2H2 6 (10.0) 12 (10.3) 191 (10.5)
H2Hx 29 (48.3) 50 (43.1) 796 (43.8)
Non-H2 25 (41.7) 54 (46.6) 831 (45.7)
Haplotype H3 0.2 0.053
H3H3 0 1 (0.9) 23 (1.3)
H3Hx 19 (31.7) 24 (20.7) 356 (19.6)
Non-H3 41 (68.3) 91 (78.4) 1439 (79.2)
Haplotype H4 0.3 0.7
H4H4 0 0 9 (0.5)
H4Hx 7 (11.7) 20 (17.2) 264 (14.5)
Non-H4 53 (88.3) 96 (82.8) 1545 (85.0)
APS, antiphospholipid syndrome; LLD, lupus-like disease; SLE, systemic lupus ery-
thematosus; NBS, Nijmegen Biomedical Study.     
1 Differences and significances in the distribution of ANXA5 haplotypes between 
APS patients and SLE+LLD patients without APS.      
2 Differences and significances in the distribution of ANXA5 haplotypes between 
APS patients and NBS controls.       
P-values are based on χ2 statistics. 
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ANXA5 in antiphospholipid syndrome
Table S3. Association of ANXA5 haplotypes with plasma ANXA5 levels.
Haplotype Number (%)n=176
Geometric mean ANXA5 
(95% CI), µg/L
Haplotype H1
H1H1 35 (19.9) 6.30 (4.71-8.33)
H1Hx 95 (54.0) 7.03 (6.17-8.08)
Non-H1 46 (26.1) 7.69 (6.30-9.49)
Haplotype H2
H2H2 18 (10.2) 8.76 (6.11-12.68)
H2Hx 79 (44.9) 6.75 (5.75-8.00)
Non-H2 79 (44.9) 7.03 (5.99-8.17)
Haplotype H3
H3H3 1 (0.6) 8.17
H3Hx 43 (24.4) 7.17 (6.05-8.50)
Non-H3 132 (75.0) 7.03 (6.17-8.00)
Haplotype H4
H4Hx 27 (15.3) 7.75 (5.93-10.07)
Non-H4 149 (84.7) 6.94 (6.17-7.77)
Results are based on ln-transformed plasma ANXA5 levels. All values reported were 
reconverted to geometric means with the appropriate 95% confidence intervals.  
Hx indicates all haplotypes except for the one given; CI, confidence interval.  
No differences were found.
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Chapter 7
GENERAL DISCUSSION
Thesis objective 
Annexin A5 (ANXA5), a calcium-dependent phospholipid-binding protein, 
exerts strong anticoagulant and antithrombotic properties as well as anti-
inflammatory features. Due to its high affinity binding to phosphatidylserine 
(PS), ANXA5 is widely used as an imaging probe to visualize apoptosis 
non-invasively in animal models and in patients [1-3]. Besides its excellent 
imaging capacities, ANXA5 is also a therapeutic agent. The native ANXA5 as 
well as fusion proteins based on the structure of the native ANXA5 molecule 
have powerful antithrombotic capacities in animal thrombosis models [4-8]. 
More importantly, the inhibitory effects of ANXA5 are not associated with a 
bleeding tendency as compared to other anticoagulant therapies. However, 
full understanding of ANXA5-mediated anticoagulant effects is needed 
before this therapy can be applied to humans. One of the objectives of this 
thesis was to extend our knowledge about the mode of action of ANXA5-
based anticoagulation on negatively charged phospholipids-exposing cell 
surfaces (chapter 2). 
The history of ANXA5 started about 36 years ago from its isolation from 
placental tissues. Through the years, we learned a lot about exogenous 
ANXA5. The physiological significance of endogenous ANXA5, however, is 
still not completely understood. So far, only two annexins were related to 
a clinical phenotype, later termed as “annexinopathy.” By the identification 
of abnormalities in ANXA5 expression in the antiphospholipid syndrome [9] 
and by the description of the M2 promoter haplotype within the ANXA5 
gene, associated with lower ANXA5 mRNA levels in placentas and placental 
thrombotic complications in some studies [10-13], we have made a little step 
towards understanding of biological role of endogenous ANXA5 in humans. 
With respect to the second objective of this thesis we investigated whether 
ANXA5 genetic variations contribute to pathogenesis of thrombosis- (deep 
venous thrombosis, antiphospholipid syndrome) or inflammation-related 
diseases (atherosclerosis in familial hypercholesterolemia patients) in order 
to get more insight into the biological significance of endogenous ANXA5 
in humans as well as to identify possible new biomarkers and their clinical 
implications (chapters 3, 4, 5 and 6). 
ANXA5 lattices in ANXA5-mediated anticoagulation
In the 1980s, Chris Reutelingsperger and colleagues isolated ANXA5, earlier 
called a VAC (vascular anticoagulant protein), from human umbilical cord 
arteries and from the intima of bovine aorta, and demonstrated strong 
anticoagulant capacities of ANXA5 in vitro [14;15]. Thereafter, it has been 
shown that ANXA5 is a potent inhibitor of thrombus formation in vivo in 
a venous thrombosis model as well as in an arterial thrombosis model 
[4;5;16].
The anticoagulant properties of ANXA5 have been extensively studied on 
the surface of artificial and cellular membranes [15;17;18]. Its high affinity 
for negatively charged phospholipids, especially PS (dissociation constant 
[Kd] <0.2 nM), forms the basis for ANXA5 inhibitory activities [19;20]. 
ANXA5 binds with higher affinity to PS as compared to most coagulation 
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factors [20]. In this respect, ANXA5 interferes in blood coagulation through 
displacement of coagulation factors from procoagulant surfaces and thus 
inhibiting their complex formation. 
Andree and colleagues introduced the idea that the ANXA5 anticoagulant 
mechanism is more complex than just displacement of coagulation factors 
from PS-exposing surfaces. They showed the incomplete displacement of 
FXa, FVa and prothrombin from the phospholipid surface by ANXA5 and 
proposed that the rigid ANXA5 clusters may reduce the lateral mobility of 
membrane-bound coagulation factors preventing thereby their complex 
formation [21]. Now it is known that membrane-bound ANXA5 molecules 
do not exist as monomers but assemble into trimers and ordered arrays of 
trimers [22-25]. However, the exact role of the 2D ordered arrays of ANXA5 
in PS-depending coagulation reactions is still a subject of investigation. 
In chapter 2, we provided new insights into the role of ANXA5 lattices 
in ANXA5-mediated anticoagulant effects. We studied the interactions 
between labeled FVIII and FIX on PS-exposing cell surfaces applying a flow 
cytometric and microscopic FRET experimental approach, which is a well-
known technique to study protein-protein interactions within a distance of 
2-10 nm [26;27]. Our results indicate that pre-bound ANXA5 arrays (i.e., 
2D ordered lattices) reduce but do not fully block the binding of coagulation 
factors to activated cells. That means that FIX and FVIII are able to bind 
to available PS molecules on the cell surface and that available anionic 
phospholipids could be located within the protein-free spaces of ANXA5 
lattices. It is well established that on the surface of artificial membranes, 
ANXA5 assembles into open lattices containing large protein-free spaces 
(~9 nm in diameter) [22;28;29]. We believe that ANXA5 molecules may 
also form open arrays on cell surfaces and that coagulation factors or 
other proteins could be integrated within ANXA5 2D lattices. The second 
interesting aspect of our results concerns the reduced lateral mobility of PS-
bound coagulation factors by ANXA5 arrays. We clearly showed that ANXA5, 
assembled into 2D ordered lattices, inhibits FIX-FVIII interactions (i.e., the 
tenase complex formation) already at low concentrations (5 nM), whereas 
ANXA1, which does not form 2D lattices, only reduced FIX-FVIII interactions 
under the same conditions. It should be noted that the binding of trimer-
forming annexins (i.e., ANXA5, ANXA4 and ANXB12) to a phospholipid 
surface causes the rigidification of a cellular membrane and consequently 
creates the regions of diminished fluidity within the membrane [30;31]. In 
this regard, membrane-bound coagulation factors FIX and FVIII seemed 
to be restricted by rigid sheets of pre-bound ANXA5 to interact with each 
other and hence to form the tenase complex. However, our suggestion 
about reduced lateral diffusion of coagulation factors in the presence of 
ANXA5 lattices was not confirmed by other methods. FRAP (Fluorescence 
Recovery After Photobleaching) experiments, which were applied to study 
the mobility of FIX and FVIII on membrane surfaces, appeared to be not 
suitable most likely due to a high diffusion rate of coagulation factors on 
PS-exposing membranes (unpublished results). Fluorescence correlation 
spectroscopy (FCS) experiments would be very interesting in order to 
determine the mobility-related parameters of coagulation factors and to 
prove our suggestions. 
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This study was one of the first attempts towards understanding the role 
of ANXA5 organization on cell surfaces in ANXA5-mediated anticoagulant 
effects. Our work demonstrated that ANXA5 lattices inhibit tenase complex 
formation not only by shielding of PS but also presumably by reducing the 
lateral mobility of PS-bound coagulation factors. In pathological situations 
such as antiphospholipid antibody syndrome (APS), antiphospholipid 
antibodies could disrupt the ANXA5 anticoagulant shield on vascular 
endothelium or placental syncytiotrophoblasts [32;33] that may increase 
the mobility of coagulation factors and enhance their interactions ultimately 
leading to thrombin formation and an increased thrombotic risk. It is known 
that antiphospholipid antibodies belong to a heterogeneous population of 
autoantibodies meaning that only part of these autoantibodies may cause 
thrombosis through interaction with endogenous ANXA5 and through 
disruption of ANXA5 lattices. As an example, a monoclonal antiphospholipid 
antibody CIC15, which is responsible for pregnancy loss in mice, do not 
disrupt the ANXA5 2D ordered organization (AFM experiments) and do not 
inhibit ANXA5 anticoagulant properties [28]. Moreover, it is still a subject 
of debate whether antiphospholipid antibodies may promote thrombosis 
through displacing of ANXA5 from procoagulant cell surfaces and thus 
through reducing of ANXA5 concentrations on damaged cells [32;34-
37]. We applied our flow cytometric FRET approach to examine whether 
antiphospholipid antibodies interfere in the binding of ANXA5 to PS-
exposing cells and/or in ANXA5 2D lattices. Our preliminary data clearly 
showed that the 4F3 monoclonal anti-ß2GPI antibody (provided by Prof. 
de Groot, University Medical Centre, Utrecht), directed against domain I 
of ß2GPI, disturbs ANXA5 lattice formation on the surface of ionomycin-
activated platelets but do not affect the binding of ANXA5 to activated 
platelets (unpublished results). On the other hand, monoclonal WAC2a 
anti-ANXA5 antibodies, which are directed against the phospholipid-binding 
sites of ANXA5 [38], reduced the binding of ANXA5 to activated platelets in 
a concentration-dependent manner but did not disturb pre-bound ANXA5 
lattices on PS-exposing cell surfaces (unpublished results). Whether our 
FRET approach may contribute to understanding of prothrombotic properties 
of antiphospholipid antibodies requires further investigation. However, we 
believe that the knowledge provided herein could motivate future research 
and could be of clinical importance. 
Endogenous ANXA5 and disease
The idea that ANXA5, the most abundant member of the annexin family, 
could contribute to the pathophysiology of human diseases is not new. It 
comes from the wide distribution of ANXA5 in human tissues, especially 
its high expression in placental syncytiotrophoblasts and vascular 
endothelium. The contribution of ANXA5 to human diseases is also based on 
ANXA5 anticoagulant, antithrombotic, anti-inflammatory and anti-apoptotic 
capacities. The first evidence for an antithrombotic role of endogenous 
ANXA5 in human morbidity was demonstrated by Jacob H. Rand, who linked 
the antiphospholipid antibody-mediated reduction of ANXA5 expression on 
the surface of endothelial cells and placental trophoblasts (”immunologic” 
model) to vascular thrombosis and pregnancy loss in patients suffering from 
antiphospholipid syndrome [9;39]. Later, Bogdanova et al. presented genetic 
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evidence for the association of reduced ANXA5 expression through carriage 
of the ANXA5 M2 haplotype with recurrent pregnancy loss (defined as 2 
or more consecutive pregnancy losses <20 weeks of gestation) (“genetic” 
model) [10]. Here we provided data linking genetic variations in ANXA5 
with inflammation-related and thrombosis-related disease conditions.   
ANXA5 genetic variations in atherosclerosis
Atherosclerosis is a chronic inflammatory disease of the vascular wall 
consisting of two different distinct pathologic processes - conventional 
atherogenesis (i.e., the development of atheromatous plaques) at early 
stages and atherothrombosis (trigged by a disruption of the atherosclerotic 
plaques) at advanced stages of the disease [40-42]. Atherothrombosis 
is formed on an underlying vulnerable atherosclerotic lesion, which 
is characterized by an increased degree of inflammation and a high 
prothrombotic potential [43]. A rupture of the plaque’s fibrous cap can 
trigger thrombus formation and subsequently acute obstruction of the blood 
vessels, manifesting as myocardial infarction or stroke [41]. 
ANXA5 has been found abundantly within human atherosclerotic plaques 
especially at the sites with high prothrombotic potential [44;45]. It has been 
suggested that endogenous ANXA5 can prevent plaque rupture by shielding 
damaged and/or activated cells and can inhibit propagation of thrombus 
formation [46-48]. However, little is known about the true effects of 
endogenous ANXA5 within atherosclerotic lesions. In contrast, recombinant 
ANXA5 has favorable effects in prevention of atherosclerosis in both in vitro 
and in vivo models. In proatherogenic ApoE-/- mouse models, administration 
of ANXA5 reduces plaque inflammation of advanced atherosclerotic lesions 
and vascular remodeling as well as improves endothelial function [49-51]. 
Furthermore, recombinant ANXA5 has been shown to inhibit uptake of 
oxidized LDL by macrophages, an important step in foam cell formation 
and acceleration of atherosclerosis [52]. Besides these effects, ANXA5 
also reduces pro-inflammatory effects of oxidized LDL, such as induction 
of matrix metalloproteinase-9 or synthesis of leukotriene B4, which are 
both involved in plaque instability and plaque rupture [52;53]. Based on 
these findings, it has been suggested that recombinant ANXA5 could play 
a protective role in both atherogenesis and atherosclerotic plaque rupture 
[53]. 
In this regard, we hypothesized that ANXA5 variations affecting ANXA5 
expression levels within the arterial wall or in plasma could be associated 
with clinical features such as carotid IMT (intima-media thickness, a 
surrogate marker of atherosclerosis) and/or cardiovascular disease (CVD) 
risk. Reduced ANXA5 expression, for instance, may result in inefficient 
shielding of exposed procoagulant surfaces in the plaque and consequently 
in activation of coagulation. The hypercoagulability appears to have a 
protective effect against vascular injury within early atherosclerotic vessels 
on the one hand and to contribute to the formation of intraplaque thrombi 
and plaque instability in the advanced stages of the disease on the other 
hand [42;54]. Moreover, because of an extensive cross-talk between 
coagulation and inflammation [55], a prothrombotic environment may also 
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contribute to the maintenance of a persistent inflammatory state within the 
arterial wall, which in turn leads to more rapid progression of atherosclerosis 
and an increased risk of cardiovascular events. In this regard, two ANXA5 
common haplotypes, namely H3 and H4, could be of particular interest: 
ANXA5 H3 (reported as M2 haplotype) is associated with reduced ANXA5 
mRNA expression in placental tissues and placental thrombosis in some 
studies [10-12;56] and ANXA5 H4 is associated with higher plasma ANXA5 
levels in controls (chapter 3). Whether ANXA5 haplotypes really influence 
ANXA5 expression within the arterial wall is still unknown.  
In chapter 4, we presented data obtained from two independent patient 
cohorts with familial hypercholesterolemia (FH). The combination of the 
ASAP (Atorvastatin versus Simvastatin on Atherosclerosis Progression) 
trial and the GIRaFH (Genetic Identification of Risk factors in Familial 
Hypercholesterolemia) cohort allowed us to investigate the contribution 
of genetic variants in ANXA5 and plasma ANXA5 levels to carotid IMT 
progression and CVD risk. However, our results provided no evidence to 
support our above mentioned hypothesis. We did not find any significant 
associations of ANXA5 SNPs/haplotypes with carotid IMT and CVD risk. 
Plasma ANXA5 levels, which were partially determined by variations in 
ANXA5, did not correlate with carotid IMT parameters either. The result of 
this study is in contrast to the results of Ewing et al., who demonstrated a 
moderate association between two ANXA5 intronic SNPs (rs4833229 and 
rs6830321) and the risk on restenosis in patients undergoing percutaneous 
coronary intervention for atherosclerosis [50]. The discrepancy with the 
study of Ewing et al. could be particularly explained by the pathophysiology 
of FH. Atherosclerosis is a complex and multifactorial disease. Although some 
studies succeeded to find genes and biomarkers related to atherosclerosis, 
there may be more studies that failed to find any association between 
genes and atherosclerosis or CVD risk. Furthermore, it is well established 
that FH patients are characterized by very high plasma LDL-C levels, which 
maintain a chronic inflammatory environment within the arterial wall and 
lead in turn to accelerated progression of intima-media thickness and a 
greatly increased risk for premature coronary artery disease [57]. Effects 
of elevated LDL-C levels in FH patients on the inflammatory reactions in the 
arterial wall should be more dominant than effects of endogenous ANXA5. 
Actually, we still do not know the real effects of endogenous ANXA5 in 
human atherosclerotic plaques. A protective role of endogenous ANXA5 
in atherosclerosis development in double knock-out (ApoE-/- and ANXA5 
-/-) mouse models is currently under investigation. Moreover, it has been 
demonstrated that the antiphospholipid antibody-mediated reduced binding 
of ANXA5 to endothelial cells is associated with atherosclerotic changes and 
supposed to be a mechanism for atherothrombosis in patients with systemic 
lupus erythematosus (SLE) [44]. As SLE patients are known to have an 
accelerated, early atherosclerosis, it should be interesting to investigate the 
role of ANXA5 genetic variations in this patient population.           
Taken together, although exogenous ANXA5 functions as a potent 
antiatherogenic and antiatherothrombotic agent, the physiological 
significance of endogenous ANXA5 in atherosclerosis have to be proven.  
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ANXA5 genetic variations in thrombosis-related pathologies 
Thrombosis, the formation of a clot within a blood vessel, may occur in 
arteries (i.e., arterial thrombosis), leading to myocardial infarction 
or stroke as well as in the deep veins (i.e., deep venous thrombosis, 
DVT), most often in the large veins of the legs and can be associated with 
pulmonary embolism (PE; i.e., a blood clot in the lungs) [58;59]. DVT and 
PE are collectively termed as venous thromboembolism (VTE). Thrombosis, 
which occurs in placenta (i.e., placental thrombosis), is responsible for 
some pregnancy complications such as pregnancy loss and preeclampsia.    
ANXA5 is linked to thrombotic disease through the antiphospholipid 
syndrome (APS). In 1997, Rand et al. demonstrated that the antiphospholipid 
antibody-induced reduction of ANXA5 on the surface of endothelial cells 
and trophoblasts lead to acceleration of blood coagulation [39]. It has 
been suggested that ANXA5 may have an antithrombotic role in vivo and 
that underexpression of ANXA5 on cell surfaces may account for vascular 
thrombosis and pregnancy loss in APS (“immunologic” model). The ANXA5 
resistance assay [60] presented later confirmed that patients with the APS-
associated vascular thrombosis [60] and pregnancy morbidity [61] had 
reduced ANXA5 anticoagulant activity. 
Hypothetically, genetic variations within the ANXA5 gene could also affect 
expression of ANXA5 on cell surfaces contributing thereby to a local 
procoagulant state (“genetic” model). With the description of the ANXA5 M2 
promoter haplotype, which appears to regulate the transcription of ANXA5, 
several studies have been performed to investigate an association between 
the M2 haplotype and DVT risk. Grandone and colleagues demonstrated 
that carriers of the ANXA5 M2 haplotype had a 3.4-fold increased risk 
of pregnancy-related venous thrombosis in a study of 83 cases and 195 
controls (13). The same authors showed that the M2 haplotype is associated 
with thrombotic risk (OR 2.2, 95% CI: 1.3-3.7) in the general population 
from Southern Italy (231 cases and 382 controls) [62]. In chapter 5, 
we evaluated these findings and clearly demonstrated that ANXA5 SNPs/
haplotypes do not contribute to DVT risk in the Dutch general population 
(148 cases, 267 hospital controls and 1705 population controls). Our finding 
is in line with a recent Norwegian study in which no associations were found 
between genetic variations in ANXA5 (i.e., the M1, M2 haplotypes and six 
tag-SNPs) and the risk of pregnancy-related venous thrombosis (313 cases 
and 353 controls) [63]. It should be noted that there is the discrepancy in 
calling of haplotypes. The wild type N haplotype of Bogdanova et al. [10], 
which is used as the reference category in many studies, actually includes 
two haplotypes: H1 (really wild type haplotype) and H2 (associated with 
lower plasma ANXA5 levels) (chapter 3). Based on this aspect, Bogdanova’s 
N haplotype (the combination H1+H2) should not be used as one reference 
category.
A possible explanation for the discrepancy with previously published results 
of the Italian study of Grandone et al. could be differences in genotype/
haplotype frequencies in the controls. It is well established that genotype/
haplotype frequencies vary between ethnic or geographic groups. Based 
on more than 270.000 SNPs, Nelis et al. described the European genetic 
structure identifying four areas, namely: 1) Central and Western Europe, 2) 
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the Baltic countries, Poland and Western Russia, 3) Finland, and 4) Italy [64]. 
According to our results, a percentage of Dutch controls carrying the ANXA5 
H3 haplotype (22.1% in ACT controls, 20.7% in NBS controls (chapter 5) 
and 21.4% in healthy controls (chapter 3)) is considerably higher compared 
to that in Italian controls (reported as M2 haplotype; 14.4% and 16.6%) 
[13;62] and in Norwegian controls (reported as M2 haplotype; 15.1%) 
[63]. However, the haplotype frequency of ANXA5 H3 found in our studies 
is similar to that observed in European population-based controls from the 
dataset of 1000 Genomes Project (22.4%; Europe is represented by Utah 
residents with Northern and Western European ancestry) and therefore our 
result is in line with the findings of Nelis et al. With regard to the differences 
in haplotype frequencies between Dutch and Italian controls, they are also 
in accordance with the European genetic structure. Hence, the ANXA5 M2 
haplotype may represent a new thrombophilic risk factor for pregnancy-
related venous thrombosis in Italian patients if further studies confirm this 
result.
Another explanation for our inability to find any significant associations with 
DVT in this study could be the current study design. The question is whether 
DNA sequencing of the coding regions and exon-intron boundaries of ANXA5 
besides the sequencing of the ANXA5 promoter used in this study could be a 
right approach to find other genetic variations in ANXA5 predisposing to DVT. 
In this regard, in 2012 Lotta et al. implemented the next-generation DNA 
sequencing strategy for sequencing of the coding regions of 186 hemostatic/
proinflammatory genes, including the ANXA5 gene, in Italian patients with 
idiopathic DVT [65]. Although ANXA5 SNP rs2306416 (57-bp downstream 
from the ATG codon) belonged to the top-5 variants, this variation was not 
associated with DVT in the replication study. That means that even with a 
different study design, SNPs in the ANXA5 gene are presumably not related 
to venous thrombosis. 
In chapter 6, we evaluated patients with autoimmune disorders and we 
found no evidence for an association between ANXA5 haplotypes and 
thrombosis risk in a subset patients with antiphospholipid syndrome (APS) 
either. The four ANXA5 haplotypes were distributed similarly between 
APS patients (n=46) and a large group of population controls (n=1818). 
Taken together, in the Dutch population, genetic variations in ANXA5 do 
not contribute to the risk of thrombosis in the general population and in 
patients with APS. 
The hemostatic system also plays an important role in the pathogenesis of 
pregnancy complications, such as APS-associated pregnancy morbidity. 
ANXA5, which is abundantly present on the apical surfaces of placental 
syncytiotrophoblasts and shields anionic phospholipids externalized 
during trophoblast differentiation/fusion, has been suggested to play an 
antithrombotic role in the maintenance of blood fluidity in the placenta 
[66]. A reduction of the ANXA5 shield either antiphospholipid antibody-
mediated or through carriage of the ANXA5 M2 haplotype (“immunologic” 
model versus “genetic” model) was suggested to be responsible, at least in 
part, for the thrombophilic state at the syncytiotrophoblast surface and to 
explain some pregnancy complications [67-70]. It should be noted that the 
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association of the M2/ANXA5 allele with reduced placental ANXA5 mRNA 
levels was only demonstrated by Bogdanova et al. [11] but not observed by 
de Jong et al. [71]. Interestingly, the latter research group also found that 
the minor rs62319820T-allele, which is unique for the ANXA5 H4 haplotype 
(an extension of the M1 haplotype), was associated with increased placental 
ANXA5 mRNA expression [71]. In our previous report, we demonstrated 
that the rs62319820T-allele is a major contributor to higher plasma ANXA5 
levels in healthy controls (chapter 3). For that reason, the rs62319820T-
allele as a part of the M1 haplotype could not be associated with reduced 
ANXA5 promoter activity as published by Bogdanova et al. [10] and it would 
be relevant to revisit this finding. The clinical relevance of ANXA5 H4 (an 
extension of the M1 haplotype) is still unknown. In chapter 6, we investigated 
the contribution of the ANXA5 haplotypes to pregnancy morbidity associated 
with APS. According to the revised Sapporo clinical criteria for APS, the term 
obstetric APS is defined as a previous unexplained recurrent first trimester 
loss and/or mid-trimester and third-trimester intrauterine death and/or 
severe preeclampsia, placental abruption, or intrauterine growth restriction 
[72]. Here we demonstrated overrepresentation of ANXA5 H3 (an extension 
of the M2 haplotype) in obstetric APS women compared to female controls 
(24 cases and 759 controls; 41.7% versus 21.2%). This result is in line with 
the preliminary data of Bogdanova et al., showing enrichment of the M2 
haplotype (36.7%) in a small cohort of patients with obstetric APS (n=30) 
[69]. The ANXA5 H4 haplotypes associated with increased plasma ANXA5 
levels was non-significantly underrepresented in obstetric APS compared 
to controls. Although our results suggest that ANXA5 H3 is a risk factor for 
pregnancy morbidity associated with APS, replication in a larger patient 
cohort is needed to confirm these results. It would also be interesting 
to investigate whether ANXA4 H4 plays a protective role in pregnancy 
complications.                      
   
FUTURE PERSPECTIVES 
 
ANXA5 genetic variations as biomarker in human pathology 
The term biomarker has been defined by the National Institutes of Health 
Biomarkers Definitions Working Group as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic 
intervention” [73].
Should genetic variations in ANXA5, a subject of our interest, serve as 
biomarkers in human pathology? Although the biological role of endogenous 
ANXA5 remains to be proven, we have evidence from in vitro and in vivo 
studies to suggest that endogenous ANXA5 plays an antithrombotic role 
in placental environment as well as in the vasculature [39;60;66;67]. 
Furthermore, in 2007 genetic evidence was given for the association 
between the ANXA5 M2 promoter haplotype and recurrent pregnancy loss 
in German females [10]. It was suggested that the hypofunctional M2 allele 
may promote the procoagulant state in placental tissues and that the M2 
haplotype could represent a new hereditary factor for obstetric complications 
and recurrent pregnancy loss [12;74]. An association of the ANXA5 M2 
haplotype with recurrent pregnancy loss was further demonstrated in Italian 
136
Chapter 7
[12], Japanese [56] and Bulgarian women [75], but not in subjects from 
East China [76] and also not in a second cohort of Japanese women [77]. 
It should be noticed that some issues require further attention. First, the 
percentage of M2 haplotype carriers among German controls is considerably 
lower (8.2% in Munster fertile controls; 14.4% in Munich fertile controls; 
15.4% in PopGen population controls) [10;78] than the European population 
frequency based on the 1000 Genomes Project (22.4%; Europe is represented 
by Utah residents with Northern and Western European ancestry). According 
to Nelis et al. who described the European genetic structure [64], the 
frequency of the M2 haplotype in control subjects from Germany belonging 
to Central and Western Europe should be comparable with the European 
population frequency estimates. The second subject that needs attention in 
the German association studies is that there is a significant deviation from 
Hardy-Weinberg equilibrium in two control groups (Munich and Munster 
fertile controls), mainly due to an excess of M2 homozygotes [10;75;78]. 
Third, the association of the M2 haplotype with reduced placental ANXA5 
mRNA levels was only reported by Bogdanova et al. and was not confirmed 
in a recent study [71]. Furthermore, besides ANXA5, many other annexins 
are also present in placental tissues [79;80]. It should be kept in mind 
that changes in expression levels of one individual annexin could affect the 
expression of other members of the annexin family [81]. Imagine that the 
M2 haplotype (our H3 haplotype) really leads to downregulation of ANXA5 
expression levels in placenta, and then it would be interesting to investigate 
if it could be compensated by the upregulation of other individual annexins 
and what is a collective protective role of annexins present in placenta in 
pregnancy complications. We therefore think that further work is required 
to understand above mentioned issues and revisit some results from in 
vitro experiments before we can conclude that the ANXA5 M2 haplotype 
undoubtedly represents a factor predisposing to pregnancy complications 
and that it could be a biomarker for pregnancy failure. If more supportive 
evidence can be found for an association between the ANXA5 M2 haplotype 
and pregnancy loss, screening for carriage of ANXA5 M2 will help to identify 
a subgroup of women with an increased risk of pregnancy failure who might 
benefit from better management and personalized treatment. Consequently, 
based on disease mechanisms in women carrying ANXA5 M2 rather than 
the disease outcome, recombinant ANXA5 and related compounds may be 
applied as novel therapeutic approaches for the treatment of pregnancy 
loss and other pregnancy complications. We hope that an increased 
understanding of ANXA5-mediated anticoagulant effects provided in this 
thesis will be of clinical significance contributing to further improvements in 
the therapeutic regimens.       
Regarding the contribution of ANXA5 variations to the risk of thrombosis 
in the general population or cardiovascular events in a patient cohort with 
accelerated atherosclerosis (familial hypercholesterolemia), our work did 
not reveal any associations between variants in the ANXA5 gene upstream 
region and clinical parameters. That means that ANXA5 variations could not 
serve as a thrombosis risk marker.    
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CONCLUSION 
My PhD project was focused on two main aspects of ANXA5: 
I) to extend our knowledge about ANXA5-mediated anticoagulant effects on 
cell surfaces exposing negatively charged phospholipids, especially a role of 
ANXA5 lattices in PS-depending coagulation reactions; II) to shift our focus 
from exogenous ANXA5 to understanding of physiological significance of 
endogenous ANXA5 in inflammation- and thrombosis-related pathologies. 
We clearly showed that ANXA5 is assembled into ordered lattices on PS-
exposing cell surfaces and that ANXA5 lattices inhibit tenase complex 
formation not only by shielding of PS but also likely by reducing the lateral 
mobility of membrane-bound coagulation factors.
We described four common ANXA5 haplotypes in the ANXA5 gene upstream 
region, of which two haplotypes influence plasma ANXA5 levels in controls. In 
atherosclerosis, which is a chronic inflammatory disease of the vascular wall, 
ANXA5 variations and plasma ANXA5 levels are not associated with intima-
media thickness parameters (a marker of atherosclerosis) or cardiovascular 
disease risk in two cohorts of familial hypercholesterolemia patients. The 
ANXA5 polymorphisms did not contribute to deep venous thrombosis 
risk in the general population nor did they affect the risk of thrombosis 
(either arterial or venous) in a subset of patients with antiphospholipid 
syndrome. However, the ANXA5 H3 haplotype was associated with obstetric 
manifestations in women suffering from antiphospholipid syndrome, a 
finding that merits further investigation.     
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SUMMARY 
This thesis was focused on two main aspects: I) to extend our knowledge 
about ANXA5-mediated anticoagulant effects on cell surfaces exposing 
negatively charged phospholipids; II) to understand the physiological 
significance of endogenous ANXA5 in inflammation- and thrombosis-related 
human pathologies. 
ANXA5 lattices interfere in the tenase complex formation on PS-
exposing cells           
In chapter 2, we investigated the ANXA5 self-association on model mem-
branes as well as on PS-exposing cell surfaces and tried to understand the 
role of ANXA5 lattices in PS-depending coagulation reactions. A flow cyto-
metric and microscopic Fluorescence Resonance Energy Transfer (FRET) ap-
proach was used to visualize ANXA5 interactions. We clearly demonstrated 
that upon binding to ionomycin-activated platelets and ionomycin-stimula-
ted COS1 cells, ANXA5 showed a high FRET signal, an indicator of membra-
ne-bound structured arrays. We also showed that ANXA5 organization on 
the surface of artificial membranes is based on multiple ANXA5 interactions 
(a two-step FRET approach) and that these ANXA5-ANXA5 interactions do 
not grow in a three-dimensional direction independent of anionic phosp-
holipids (experiments with amine beads). Thereafter, we used the same 
FRET experimental approach to visualize interactions between FIX and FVIII 
of the intrinsic pathway of blood coagulation. FIX-FVIII interactions were 
inhibited by low concentrations (5 nM) of pre-bound ANXA5. By contrast, 
labeled ANXA1, which binds to PS without forming 2D lattices, only partly 
affected FIX-FVIII interactions. From these observations, we proposed that 
besides the shielding of negatively charged phospholipids, the organization 
of ANXA5 on PS-exposing cell surfaces is also relevant in ANXA5-based an-
ticoagulation. In the presence of ANXA5 arrays but not the ANXA1 clusters, 
PS-bound coagulation factors FIX and FVIII were restricted to interact with 
each other to form the tenase complex. Here, we provided evidence that 
pre-bound ANXA5 arrays interfere in the tenase complex formation (and 
possibly in the assembly formation of other coagulation factors) not only 
by shielding of PS molecules but presumably also by reducing the lateral 
mobility of PS-bound coagulation factors.          
Genetic variations in the ANXA5 gene and plasma ANXA5 levels  
In chapter 3, we described common haplotypes (H) within the ANXA5 
gene upstream region and their associations with plasma ANXA5 levels 
in Dutch healthy individuals. In comparison with three ANXA5 promoter 
haplotypes previously reported by Bogdanova et al. (9), we showed the 
presence of four common haplotypes H1-H4 (haplotype frequency >1%) 
within the ANXA5 gene upstream region. We additionally demonstrated that 
our haplotypes H1 and H2, the two major haplotypes, included Bogdanova’s 
wild-type haplotype N. Importantly, circulating ANXA5 levels were shown 
to be influenced by ANXA5 genetic variants. Here we provided evidence for 
the association of haplotype H2 with decreased plasma ANXA5 levels and 
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haplotype H4 (tagged by SNP rs62319820) – with increased plasma ANXA5 
levels.
Our finding regarding an association of ANXA5 haplotype H2 and haplotype 
H4 with lower and higher plasma ANXA5 levels, respectively, was further 
confirmed in the patient cohort with atherosclerosis (chapter 5). 
Unfortunately, plasma ANXA5 levels were not of clinical importance as no 
correlation was found with any of the used phenotypic or clinical outcome 
parameters (i.e., carotid IMT, cholesterol levels and an inflammation marker, 
hs-CRP). Furthermore, in patients with autoimmune disorders (chapter 6), 
plasma ANXA5 levels were not influenced by ANXA5 genetic variations nor 
were they associated with thrombosis or miscarriage.  
Relevance of ANXA5 genetic variations in (cardio)vascular disease In 
chapter 4, we investigated whether ANXA5, which possesses antiatherogenic 
properties, could serve as a biomarker in familial hypercholesterolemia (FH) 
patients with underlying atherosclerosis. The important characteristics of 
FH are elevated low-density lipoprotein cholesterol (LDL-C) levels and an 
increased risk of premature cardiovascular disease (CVD). We studied a 
possible relationship of ANXA5 genetic variations and/or plasma ANXA5 
levels with carotid IMT (intima-media thickness; a marker of atherosclerosis) 
in FH patients from the ASAP (Atorvastatin versus Simvastatin on 
Atherosclerosis Progression) trial. We additionally studied the contribution 
of ANXA5 genetic variations to CVD risk in a large group of FH patients 
participating in the GIRaFH (Genetic Identification of Risk factors in Familial 
Hypercholesterolemia) study. We demonstrated that ANXA5 SNPs and 
haplotypes H1-H4 did not contribute to the age-related IMT progression. 
Interestingly, ANXA5 haplotype H3 tended to be associated with more 
rapid carotid IMT increase with age, but this association did not reach the 
Bonferroni-corrected statistical significance level. Furthermore, ANXA5 
genetic variations were not associated with CVD risk. The data obtained 
from two independent cohorts of FH patients indicate that both common 
genetic variants in ANXA5 and plasma ANXA5 levels are not associated with 
carotid IMT parameters or CVD risk. That also means that ANXA5 could not 
serve as a biomarker in atherosclerosis, anyway, not in FH patients. 
In chapter 5, we evaluated whether ANXA5 promoter SNPs and/or 
haplotypes H1-H4 contribute to the risk of deep venous thrombosis (DVT) 
in the Dutch general population. We did not find any association between 
individual SNPs or common haplotypes H1-H4 and an increased risk for 
DVT. The genotype and haplotype groups were equally distributed among 
patients with newly diagnosed DVT and hospital controls without previous 
VTE (Amsterdam Case-control Thrombophilia (ACT) study) as well as 
among DVT patients and a large group of population controls (Nijmegen 
Biomedical Study). Our study was adequately powered to detect genotype- 
and/or haplotype-specific differences. Therefore, we concluded that ANXA5 
genetic variants do not contribute to DVT risk in the Dutch population.  
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There is plenty of evidence for the involvement of ANXA5 in the 
antiphospholipid syndrome (APS), an autoimmune disorder characterized 
by the persistent presence of antiphospholipid antibodies in plasma of 
patients with a history of vascular thrombosis and/or pregnancy morbidity. 
The contribution of genetic variations in ANXA5 to thrombotic risk or 
pregnancy morbidity in APS patients is still poorly understood. In chapter 
6, we demonstrated that ANXA5 haplotypes H1-H4 did not contribute to 
thrombotic risk in APS patients. However, ANXA5 H3 was overrepresented 
in women with obstetric APS, a subject that could be of clinical importance. 
None of the ANXA5 haplotypes was associated with an increased production 
of antiphospholipid antibodies or with plasma ANXA5 levels. Whether ANXA5 
H3 could represent a biomarker in pregnancy-related complications in APS, 
needs further investigation.  
In chapter 7, we discussed our results presented in chapters 2 to 6.    
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SAMENVATTING 
Dit proefschrift beschrijft de fysiologische betekenis van Annexine A5 
(ANXA5). ANXA5 is één van de meest voorkomende eiwitten binnen de 
annexine familie die in totaal uit 12 humane annexines bestaat. ANXA5 
komt veel voor in de placenta en in endotheelcellen. Evenals de andere 
eiwitten binnen de annexine familie bindt ANXA5 in aanwezigheid van Ca²+-
ionen aan een negatief geladen fosfolipidenoppervlak. Negatief geladen 
fosfolipidenoppervlakken bestaan uit negatief geladen fosfatidylserine 
(PS) moleculen en komen tot expressie bij cel activatie en celdood. We 
onderscheiden twee vormen van celdood;  apoptose, een geprogrammeerde 
vorm van celdood, en necrose, een ongereguleerde vorm. ANXA5 heeft 
van alle humane annexines de hoogste affiniteit voor negatief geladen 
fosfolipiden. ANXA5 bindt met hoge affiniteit aan PS-exposerende 
celoppervlakken en schermt hierdoor de negatief geladen fosfolipiden af. 
Vanwege deze uitstekende bindingscapaciteiten is ANXA5 zeer geschikt om 
celdood in diermodellen en in patiënten aan te tonen en daarnaast zorgt dit 
mechanisme ook voor de antistollende en anti-inflammatoire activiteiten 
van dit eiwit. In trombose diermodellen zorgen het natieve ANXA5 en ANX5-
bevattende fusie-eiwitten voor sterke antitrombotische effecten. Belangrijk 
is dat de ANXA5 anticoagulante effecten niet geassocieerd zijn met een 
verhoogde kans op bloedingscomplicaties. Dit is in tegenstelling tot andere 
antistollingsmiddelen die wel een verhoogde bloedingsneiging veroorzaken. 
Voordat ANXA5 klinisch toepasbaar zal zijn is het echter van groot belang 
de klinische betekenis van ANXA5 beter te begrijpen waaronder het exacte 
anticoagulante werkingsmechanisme van ANXA5.
Ongeveer 36 jaar geleden werd ANXA5 voor het eerst geïsoleerd uit 
placentaire weefsels. Door de jaren heen hebben we veel geleerd over 
exogeen ANXA5. De fysiologische betekenis van endogeen ANXA5 is echter 
nog niet volledig begrepen. Ook met betrekking tot de pathologie van 
annexines is nog veel werk te verzetten. De door Rand et al. geïntroduceerde 
term "annexinopathy” beschrijft slechts twee annexine (ANXA2 en ANXA5)-
gerelateerde ziektebeelden waarbij de afwijkingen in de expressie levels 
centraal staan. Zo is een toegenomen expressie van ANXA2 in leukocyten 
gelinkt aan bloedingscomplicaties bij acute promyelocyten leukemie. Bij 
patiënten lijdend aan het antifosfolipidensyndroom is de verminderde 
ANXA5 expressie in de placenta en endotheelcellen geassocieerd met 
vasculaire trombose en herhaalde miskramen. Met de recente beschrijving 
van het M2 haplotype binnen het ANXA5 gen, dat geassocieerd is met de 
lagere ANXA5 mRNA levels in placenta en placentaire trombose, hebben we 
een kleine stap gezet in het begrijpen van de (patho)fysiologische rol van 
endogeen ANXA5. 
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In dit proefschrift is de focus gericht op twee belangrijke aspecten: I) het 
vergroten van onze kennis over het werkingsmechanisme van ANXA5-
gebaseerde antistolling op PS bevattende celmembranen; II) het verkrijgen 
van meer inzicht in de biologische significantie van endogeen ANXA5.
ANXA5 lattices interfereren in de tenase complexvorming op PS-
exposerende celoppervlakken                   D 
De PS bevattende celmembraan is een sterke katalysator van de bloedstolling. 
De antistollende activiteiten van annexines zijn gebaseerd op het afschermen 
van deze stollingsbevorderende celoppervlakken. ANXA5 heeft van alle 
annexines de hoogste affiniteit voor negatief geladen fosfolipiden en in 
theorie ook de hoogste antistollende activiteit. In hoofdstuk 2 hebben 
we hiervoor een verklaring gezocht door de structurele organisatie van 
ANXA5 op model membranen en op PS bevattende celmembranen nader 
te onderzoeken. Hiervoor werd een flowcytometrische en confocale FRET 
(Fluorescence Resonance Energy Transfer) methode gebruikt om ANXA5 
interacties te visualiseren. Met deze aanpak werd duidelijk aangetoond 
dat ANXA5, na binding aan ionomycine-geactiveerde bloedplaatjes en 
ionomycine-gestimuleerde COS1 cellen, een hoog FRET signaal vertoonde 
wat een aanwijzing is voor membraangebonden gestructureerde arrays. 
We toonden ook aan dat de oppervlak-geassocieerde ANXA5 organisatie 
gebaseerd is op meervoudige ANXA5 interacties (two-step FRET) en dat deze 
ANXA5-ANXA5 interacties 2-dimensionaal zijn (d.w.z., één laagje dik). Deze 
interacties worden ook wel aangeduid als 2D-lattices. Verder gebruikten 
we dezelfde FRET gebaseerde experimentele aanpak om de interacties 
tussen FIX en FVIII van de intrinsieke route van de stollingscascade te 
visualiseren. FIX-FVIII interacties werden geremd door lage concentraties 
(5 nM) van pre-gebonden ANXA5. ANXA1, dat ook aan PS bindt maar geen 
2D lattices vormt, remde gedeeltelijk de FIX-FVIII interacties. Uit deze 
waarnemingen hebben we geconcludeerd dat, naast de afscherming van 
negatief geladen fosfolipiden, de organisatie van ANXA5 op PS-exposerende 
celoppervlakken ook relevant is voor de ANXA5-gebaseerde antistolling. 
Onze werkhypothese is dat de mobiliteit van PS-gebonden FIX en FVIII in 
aanwezigheid van ANXA5 arrays zodanig beperkt is dat er geen interacties 
tussen stollingsfactoren kunnen plaatsvinden en er geen tenase complex 
gevormd kan worden. Ondanks dat we de mobiliteit van de stollingsfactoren 
niet direct hebben kunnen meten hebben we gegronde redenen om aan te 
nemen dat ANXA5 arrays interfereren in de tenase complexvorming (en 
waarschijnlijk ook in de complexvorming van andere stollingsfactoren). 
Door deze waarnemingen kunnen we concluderen dat het afschermen 
van PS-moleculen en het verminderen van de laterale mobiliteit van PS-
gebonden stollingsfactoren belangrijke onderdelen zijn van de antistollende 
activiteit van ANXA5.
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Genetische variaties in het ANXA5 gen en ANXA5 plasmaspiegels  
Genetische variaties komen in alle genen van ons lichaam voor. Genetische 
variaties kunnen verantwoordelijk zijn voor het ontstaan van een bepaalde 
ziekte of bijdragen aan de pathofysiologie van een ziekte. In het ANXA5 gen 
zijn ook verschillende genetische variaties gevonden. In hoofdstuk 3 zijn 
single-nucleotide polymorfismen (SNPs) en veelvoorkomende haplotypen 
(d.w.z., een combinatie van genetische variaties; haplotype frequentie 
>1%) binnen het ANXA5 promoter gebied beschreven en is een associatie 
van genetische variaties met ANXA5 plasmaspiegels in gezonde personen 
bestudeerd. In vergelijking met de drie ANXA5 promoter haplotypes die 
eerder beschreven werden door Bogdanova et al., identificeerden wij vier 
veelvoorkomende haplotypen H1-H4 in het ANXA5 promoter gebied. Tevens 
bleek uit onze studie dat de haplotypen een effect hadden op de ANXA5 
plasmaspiegels. Zo is  haplotype H2 geassocieerd met lagere plasma ANXA5 
levels en haplotype H4 (tagged door SNP rs62319820) – met hogere ANXA5 
plasmaspiegels. We hebben bovendien aangetoond dat Bogdanova’s wilde-
type haplotype N uit twee haplotypen (H1 en H2) bestaat. 
Onze bevinding dat het ANXA5 haplotype H2 en H4 geassocieerd is met 
respectievelijk lagere en hogere ANXA5 plasmaspiegels werd verder 
bevestigd in de patiëntengroep met atherosclerose (hoofdstuk 5). Echter 
bleken de plasma ANXA5 levels niet van klinisch belang te zijn, omdat er 
geen enkele correlatie werd gevonden met de klinische uitkomstparameters, 
zoals de dikte van de vaatwand (IMT), bloed cholesterol spiegels en een 
ontsteking marker (hs-CRP)). Bovendien waren plasma ANXA5 levels niet 
geassocieerd met trombose of herhaalde miskramen bij patiënten met 
auto-immuunziekten (hoofdstuk 6).
De relevantie van ANXA5 haplotypes in (cardio)vasculaire 
ziektebeelden        
Atherosclerose (in de volksmond ook aderverkalking genoemd) is een 
ziektebeeld waarin zowel de ontsteking (ook wel aangeduid als inflammatie) 
als ook de stolling een rol spelen. ANXA5 heeft antistollende activiteiten en 
anti-inflammatoire eigenschappen. In hoofdstuk 4 hebben we onderzocht 
of ANXA5 genetische variaties (d.w.z., individuele SNPs en haplotypen H1-
H4) als biomarkers bij patiënten met atherosclerose zouden kunnen dienen. 
Dat hebben we gedaan bij patiënten met familiaire hypercholesterolemie 
(FH), een ziekte die zich gekenmerkt door de hoge LDL-cholesterol (“slecht 
cholesterol”) spiegels in het bloed en een verhoogd risico op vroegtijdige 
hart- en vaatziekten. Bij FH patiënten uit de ASAP trial (Atorvastatine versus 
Simvastatine op Atherosclerose Progressie) hebben we een associatie van 
ANXA5 genetische varianten en / of ANXA5 plasmaspiegels met IMT (d.w.z., 
de dikte van de vaatwand, een marker van atherosclerose) onderzocht. 
In een tweede grote groep van FH patiënten uit de GIRaFH (Genetische 
Identificatie van Risicofactoren bij Familiaire Hypercholesterolemie) studie 
bestudeerden we bovendien of de variaties in het ANXA5 gen bijdragen 
aan het risico op hart- en vaatziekten. Onze resultaten lieten zien dat 
haplotypen H1-H4 en de individuele SNPs niet geassocieerd zijn met de 
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IMT progressie (d.w.z., progressie van atherosclerose). Ook bleken de 
ANXA5 plasmaspiegels niet geassocieerd met de IMT parameters. Geen 
van de onderzochte genetische variaties leverden een bijdrage aan een 
verhoogd cardiovasculair risico. Uit de hierboven beschreven data kunnen 
we concluderen dat ANXA5 als biomarker geen voorspellende waarde heeft 
bij atherosclerose; in ieder geval niet bij de patiënten met FH. 
In hoofdstuk 5 hebben we een associatie tussen ANXA5 promoter SNPs 
/ veelvoorkomende haplotypen H1-H4 en het risico op diepe veneuze 
trombose (DVT) onderzocht in de Nederlandse bevolking. We hebben geen 
enkele associatie gevonden tussen individuele promoter SNPs of haplotypen 
H1-H4 en het DVT risico. De frequenties van genotypes en haplotypen waren 
gelijk verdeeld zowel tussen patiënten met nieuwe gediagnosticeerde DVT 
en ziekenhuis controles zonder voorafgaande veneuze trombo-embolie 
(Amsterdam Case-control Trombofilie (ACT) studie) als ook tussen DVT 
patiënten en een grote controlegroep uit de bevolking (Nijmegen Biomedische 
Studie, NBS). Onze studie had voldoende power (~80%) om genotype- 
en/of haplotype-specifieke verschillen te detecteren. Daarom hebben we 
geconcludeerd dat ANXA5 genetische varianten niet geassocieerd zijn met 
het DVT risico in de Nederlandse bevolking. 
Er is voldoende bewijs voor de betrokkenheid van ANXA5 in het 
antifosfolipidensyndroom (APS). APS is een auto-immuunziekte die wordt 
gekarakteriseerd door de persistente aanwezigheid van antifosfolipide 
antistoffen in plasma van patiënten met een voorgeschiedenis van vasculaire 
trombose en / of herhaalde miskramen. Of en in welke mate genetische 
variaties in ANXA5 het risico op trombose of zwangerschapscomplicaties bij 
APS patiënten verhogen is in hoofdstuk 6 onderzocht. Allereerst hebben we 
aangetoond dat ANXA5 haplotypen H1-H4 niet zonder meer geassocieerd 
zijn met een verhoogde kans op trombose bij deze patiënten. Wel hebben we 
laten zien dat ANXA5 H3 vaker voorkwam bij vrouwen met een obstetrisch 
APS ten opzichte van een grote controlegroep. ANXA5 haplotypen H1-H4 
waren niet geassocieerd met een verhoogde productie van antifosfolipide 
antistoffen noch met ANXA5 plasmaspiegels. Of de biomarker ANXA5 H3 bij 
vrouwen met een obstetrisch APS daadwerkelijk een veelbelovende marker 
voor zwangerschap gerelateerde complicaties is, zal in de toekomst verder 
uitgezocht moeten worden. 
In hoofdstuk 7 worden de conclusies van de verschillende hoofdstukken in 
perspectief geplaatst en uitgebreid bediscussieerd. Naar aanleiding van de 
bevindingen van dit proefschrift worden een aantal suggesties besproken 
voor vervolgonderzoek. 
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Ik begin met de woorden van Vladimir Majakovski (een Russische dichter) 
uit zijn werk “Een bijzonder avontuur” (1920):   
“Светить всегда, светить везде, Schijnen, altijd en overal,   
До дней последних донца,  tot de laatste dagen,    
Светить - и никаких гвоздей!  schijnen, en verder niemandal  
Вот лозунг мой и солнца!”  Dat is ons beider (van mij en van  
     de zon) Motto!
Je promotieonderzoek. Je werkt met een maximale inzet, toont je 
doorzettingsvermogen en je probeert om te gaan met tegenslag etc. Dat 
zijn de jaren vol inspiratie, creativiteit en bevlogenheid.   
Research is echt teamwork; “promoveren doe je niet alleen.” Bij mijn 
onderzoek waren veel mensen zowel binnen als buiten het Radboudumc 
betrokken. Zonder jullie hulp was dit proefschrift nooit tot stand gekomen. 
Mijn hartelijke dank hiervoor.  
Waander, in jouw proefschrift (1994) schreef je over je grenzeloze liefde 
voor Annexine A5. Anno 2015 straal je nog steeds die liefde uit voor dit 
onderwerp. Hartelijk bedankt dat jij jouw lievelingsonderwerp aan mij 
toevertrouwde. Afgelopen jaren zijn verschillende routes en zijwegen 
bewandeld om de significantie van endogeen Annexine A5 te begrijpen. Er 
zijn talloze uitermate verschillende experimenten gedaan op het Annexine 
A5 gebied. Met de negatieve resultaten was je niet echt ontevreden. Jij 
zag altijd de positieve kant van negatieve resultaten. Jouw oneindige 
enthousiasme werkte altijd bevrijdend. Uiteindelijk is het allemaal goed 
gekomen. Heel veel dank voor je vertrouwen in mij als persoon en je morele 
steun de afgelopen jaren.        
Joop, je hulp in de afrondingsfase heb ik erg op prijs gesteld. Bedankt 
voor het lezen en corrigeren van het manuscript.     
Gerard en Marian, ik wil jullie als leden van de manuscriptcommissie 
bedanken voor de zorgvuldige beoordeling van mijn proefschrift. 
Nancy, jij hebt mij ingewerkt op het Annexine A5 project toen ik nog met 
mijn afstudeerstage bezig was. Van jou heb ik veel technieken geleerd. 
Ook heb ik lang geprofiteerd van je aanwezigheid op het lab. Jij was 
echt aanwezig op het lab! Ik bewonder nog steeds je gedrevenheid en je 
daadkracht. Dank je wel dat je bereid bent om mijn paranimf te zijn.   
Mark, het is alweer drie jaar geleden dat je promoveerde. Nu ben ik aan 
de beurt. Heel veel dank voor het delen van je kennis, de inhoudelijke 
gesprekken, de praktische hulp op het lab, je morele steun, gewoon de 
gezelligheid en nog veel meer… Ik kon bij je terecht met allerlei vragen; 
je maakte tijd vrij om veel onderwerpen te bespreken. Je evenwichtige en 
rustgevende houding in moeilijke situaties stel ik ook erg op prijs. Ik ben 
blij dat je mijn paranimf wilt zijn. 
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Rob en Jeroen, van jullie heb ik heel veel geleerd over de flowcytometrie. 
Jullie inzet was onmisbaar voor het FRET project.    
Selene, veel dank voor het inwerken in moleculaire technieken, een 
luisterend oor en je betrokkenheid.          
Arnoud, je was altijd bereid om je biochemische kennis te delen. Jouw 
adviezen bij het opzetten en uitvoeren van experimenten hebben mij enorm 
geholpen.        
Lieve collega’s van de unit trombose en hemostase Clint, Bert, Robert, 
Trix, Bea, Myriam, Kitty, Wideke, Paul, Bas, Sabine, Ans, Marieke, 
Monique, Ans, Sandy, heel erg bedankt voor de gezellige en leerzame tijd 
op het lab. Grapjes maken en veel lachen hoorden er altijd bij!   
Nelly, ik kon altijd bij je terecht bij problemen met de statistiek. Met veel 
geduld kon je de moeilijkste materie uitleggen. Heel veel dank! 
Marieke, van jou heb ik veel geleerd over de haplotypes. Ik realiseer me 
dat ik geluk had en dat ik kon profiteren van het feit dat je er was. Dankzij 
jou is de basis gelegd voor vier publicaties. Hartelijk dank voor de zeer leer-
zame periode.                
Anton en het lab interne geneeskunde, mijn hartelijke dank voor de 
plezierige samenwerking aan het artherosclerose project. Zonder jullie hulp 
had ik het niet voor elkaar gekregen.      
Chris, je liefde voor Annexine A5 is echt grenzeloos! Bedankt voor je advie-
zen en suggesties bij het tot stand komen van het FRET artikel. Ik vond het 
zeer leerzaam (en ook erg spannend) om deze materie met je te bespreken. 
Saskia en Geesje, jullie opmerkingen en de kritische blik op de materie 
hebben erg geholpen bij het publiceren van twee artikelen. Bedankt!   
Flip, Ron en Bas, veel dank voor de inhoudelijke discussies rondom het 
antifosfolipidensyndroom.      
Mijn oud collega’s uit Rusland, ik wil jullie allemaal bedanken voor jul-
lie steun en interesse in mijn onderzoek. Tijdens mijn korte bezoekjes aan 
Izhevsk besproken we veel leuke wetenschappelijke onderwerpen. Dat 
gaan we zeker in de toekomst voortzetten. Jullie verjaardags- en nieuw-
jaarskaarten, terwijl ik al ruim 15 jaar weg ben uit Rusland, zijn onmisbaar 
voor mij. Hartelijk bedankt!        
Lieve familie Voronetskyi (Sasha (in memoriam), Dzhamal (in memo-
riam) en Marina), jullie liefde voor de wetenschap, vooral wiskunde heeft 
mij altijd erg aangesproken. Over de statistiek heb ik veel van jullie geleerd. 
Ook ben ik jullie dankbaar voor de morele steun. Dzamal, je schreef ooit 
in je brief “Жизнь без тягот и борьбы - это виртуальная, а не реальная 
жизнь. Так что дерзай, у тебя все будет хорошо.” Je hoeft niet bang te 
zijn om nieuwe uitdagingen in je leven aan te gaan. Alles is inderdaad goed 
gekomen. Bedankt!
Lieve pa (in memoriam) en ma, jullie hebben mij altijd gestimuleerd om 
door te leren en door te zetten. Zonder jullie zou ik nooit zo ver komen. 
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Pa, je droom is uitgekomen. Het proefschrift is nu klaar. Mijn zus Olga, 
je steunde me altijd in mijn minder goede tijden. Dat heeft mij enorm 
geholpen bij het afronden van mijn promotie. Dank je.   
Lieve Bennie en Felix, dankzij jullie liefde en onvoorwaardelijke steun heb 
ik het gered... Het proefschrift is af!!! 
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Larissa Emelianova werd op 19 januari 1968 geboren in Izhevsk, de 
hoofdstad van de autonome republiek Oedmoertië (Russisch: Удму́ртия) 
in de Russische Federatie. Ze heeft kindergeneeskunde gestudeerd aan 
de Medische Staatsacademie te Izhevsk (diploma cum laude). Na het 
voltooien van haar opleiding ging ze werken als kinderarts in het klinisch 
kinderziekenhuis te Izhevsk. Bovendien was ze verbonden aan de faculteit 
Pediatrie van de Medische Staatsacademie als docent kinderziekten. Ze deed 
onderzoek naar de chronische longaandoeningen bij kinderen, waaronder 
cystic fibrosis en bronchiale astma. In juni 1999 trouwde ze met Bennie 
Hiddink uit Baak (Gelderland). In december 1999 promoveerde ze op het 
proefschrift ‘De klinisch-metabolische bijzonderheden van bronchiale astma 
bij kinderen” en emigreerde naar Nederland.   
In Nederland heeft ze een nieuwe start gemaakt door het afronden van 
de opleiding “Biologie en Medisch Laboratoriumonderzoek” aan de Saxion 
Hogeschool te Deventer (diploma cum laude). Sinds eind 2006 werkte ze in 
verschillende functies bij het laboratorium hematologie (unit trombose en 
hemostase) van het Radboudumc: stagiaire, research analist en promovenda. 
In januari 2009 begon ze aan haar promotietraject onder begeleiding van 
prof. dr. T.M. de Witte, prof. dr. J.H. Jansen en dr. W.L. van Heerde. De 
resultaten van dit onderzoek staan beschreven in dit proefschrift. 
Van september 2013 tot maart 2014 heeft ze op vrijwillige basis gewerkt aan 
een tumor microparticles project bij prof. dr. L.W. Terstappen (Universiteit 
Twente, Enschede). Sinds april 2014 is de auteur van dit proefschrift 
werkzaam als datamanager trialbureau bij het Integraal Kankercentrum 
Nederland. Ze houdt zich bezig met het lokale datamanagement van 
hematologische en oncologische studies. 
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